{"3e656b573daa51b1346e42473b52225895ed3661": [["enzymatic A subunit catalyses the ADP-ribosylation of G~ which leads to deregulation of the adenylate cyclase system and eventually cholera and cholera-like disease.", [["ADP", "CHEMICAL", 34, 37], ["cholera", "DISEASE", 132, 139], ["cholera-like disease", "DISEASE", 144, 164], ["ADP", "CHEMICAL", 34, 37], ["adenylate", "CHEMICAL", 92, 101], ["ADP", "SIMPLE_CHEMICAL", 34, 37], ["adenylate cyclase", "GENE_OR_GENE_PRODUCT", 92, 109], ["adenylate cyclase", "PROTEIN", 92, 109], ["the adenylate cyclase system", "PROBLEM", 88, 116], ["cholera", "PROBLEM", 132, 139], ["cholera-like disease", "PROBLEM", 144, 164]]], ["The B pentamer is responsible for recognition of the pentamer-saccharide head group of ganglioside GM1, the receptor of CT and LT on the surface of the target epithelial cells of the intestinal system.", [["surface", "ANATOMY", 137, 144], ["epithelial cells", "ANATOMY", 159, 175], ["intestinal system", "ANATOMY", 183, 200], ["saccharide", "CHEMICAL", 62, 72], ["ganglioside", "CHEMICAL", 87, 98], ["B pentamer", "GENE_OR_GENE_PRODUCT", 4, 14], ["ganglioside GM1", "SIMPLE_CHEMICAL", 87, 102], ["surface", "CELLULAR_COMPONENT", 137, 144], ["epithelial cells", "CELL", 159, 175], ["intestinal", "ORGAN", 183, 193], ["system", "ANATOMICAL_SYSTEM", 194, 200], ["B pentamer", "PROTEIN", 4, 14], ["CT", "PROTEIN", 120, 122], ["LT", "PROTEIN", 127, 129], ["target epithelial cells", "CELL_TYPE", 152, 175], ["CT", "TEST", 120, 122], ["LT", "ANATOMY_MODIFIER", 127, 129], ["surface", "ANATOMY_MODIFIER", 137, 144], ["target epithelial cells", "OBSERVATION", 152, 175], ["intestinal system", "ANATOMY", 183, 200]]]], "9b6226155a6410fd5a5e0f70971c7fde7cd9731b": [["IntroductionCanine infectious respiratory disease (CIRD), otherwise known as kennel cough or infectious tracheobronchitis, is one of the most common infectious diseases in dogs and has a worldwide distribution .", [["respiratory", "ANATOMY", 30, 41], ["infectious respiratory disease", "DISEASE", 19, 49], ["CIRD", "DISEASE", 51, 55], ["kennel cough", "DISEASE", 77, 89], ["infectious tracheobronchitis", "DISEASE", 93, 121], ["infectious diseases", "DISEASE", 149, 168], ["dogs", "ORGANISM", 172, 176], ["dogs", "SPECIES", 172, 176], ["IntroductionCanine infectious respiratory disease", "PROBLEM", 0, 49], ["kennel cough", "PROBLEM", 77, 89], ["infectious tracheobronchitis", "PROBLEM", 93, 121], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["respiratory disease", "OBSERVATION", 30, 49], ["infectious", "OBSERVATION_MODIFIER", 93, 103], ["tracheobronchitis", "OBSERVATION", 104, 121], ["most common", "OBSERVATION_MODIFIER", 137, 148], ["infectious", "OBSERVATION", 149, 159], ["worldwide", "OBSERVATION_MODIFIER", 187, 196], ["distribution", "OBSERVATION_MODIFIER", 197, 209]]], ["CIRD describes an infection of the upper respiratory tract caused by single or multiple agents (Appel and Binn, 1987; Mochizuki et al., 2008) .", [["upper respiratory tract", "ANATOMY", 35, 58], ["CIRD", "DISEASE", 0, 4], ["infection of the upper respiratory tract", "DISEASE", 18, 58], ["upper respiratory", "ORGANISM_SUBDIVISION", 35, 52], ["tract", "ORGANISM_SUBDIVISION", 53, 58], ["an infection of the upper respiratory tract", "PROBLEM", 15, 58], ["infection", "OBSERVATION", 18, 27], ["upper", "ANATOMY_MODIFIER", 35, 40], ["respiratory tract", "ANATOMY", 41, 58]]], ["It has been postulated that the pathogenesis of CIRD is multi-factorial, since dogs experimentally infected with a single respiratory pathogen often showed only mild clinical signs, while severe clinical disease, such as that commonly documented in natural outbreaks, could not be reproduced (Karpas et al., 1968; Appel and Percy, 1970; Bemis et al., 1977) .IntroductionCIRD is characterised by an acute onset of mild to severe episodes of a paroxysmal dry cough and nasal discharge Mochizuki et al., 2008) .", [["nasal", "ANATOMY", 467, 472], ["CIRD", "DISEASE", 48, 52], ["respiratory pathogen", "DISEASE", 122, 142], ["IntroductionCIRD", "DISEASE", 358, 374], ["paroxysmal dry cough", "DISEASE", 442, 462], ["dogs", "ORGANISM", 79, 83], ["dogs", "SPECIES", 79, 83], ["a single respiratory pathogen", "PROBLEM", 113, 142], ["mild clinical signs", "PROBLEM", 161, 180], ["severe clinical disease", "PROBLEM", 188, 211], ["a paroxysmal dry cough", "PROBLEM", 440, 462], ["mild", "OBSERVATION_MODIFIER", 161, 165], ["acute", "OBSERVATION_MODIFIER", 398, 403], ["mild", "OBSERVATION_MODIFIER", 413, 417], ["severe", "OBSERVATION_MODIFIER", 421, 427], ["cough", "OBSERVATION", 457, 462], ["nasal", "ANATOMY", 467, 472]]], ["Due to the highly contagious nature of the disease, dogs living in crowded conditions, such as shelters and day care centres, are especially susceptible to infection (Appel and Binn, 1987; Buonavoglia and Martella, 2007) .", [["infection", "DISEASE", 156, 165], ["dogs", "ORGANISM", 52, 56], ["dogs", "SPECIES", 52, 56], ["the disease", "PROBLEM", 39, 50], ["infection", "PROBLEM", 156, 165], ["highly", "OBSERVATION_MODIFIER", 11, 17], ["contagious", "OBSERVATION_MODIFIER", 18, 28], ["disease", "OBSERVATION", 43, 50], ["infection", "OBSERVATION", 156, 165]]], ["Most dogs with CIRD recover spontaneously within days to weeks unless complicating factors occur, such as lower respiratory tract involvement or severe secondary infections .", [["lower respiratory tract", "ANATOMY", 106, 129], ["CIRD", "DISEASE", 15, 19], ["lower respiratory tract involvement", "DISEASE", 106, 141], ["infections", "DISEASE", 162, 172], ["dogs", "ORGANISM", 5, 9], ["tract", "ORGANISM_SUBDIVISION", 124, 129], ["dogs", "SPECIES", 5, 9], ["complicating factors", "PROBLEM", 70, 90], ["lower respiratory tract involvement", "PROBLEM", 106, 141], ["severe secondary infections", "PROBLEM", 145, 172], ["respiratory tract", "ANATOMY", 112, 129], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["secondary", "OBSERVATION_MODIFIER", 152, 161], ["infections", "OBSERVATION", 162, 172]]], ["However, CIRD can become enzootic in certain environments, because of the repeated introduction of novel infectious agents into dog populations (Mochizuki et al., 2008) .IntroductionA variety of viral and bacterial agents have been detected in dogs with CIRD.", [["CIRD", "CHEMICAL", 9, 13], ["CIRD", "DISEASE", 254, 258], ["dog", "ORGANISM", 128, 131], ["dogs", "ORGANISM", 244, 248], ["dogs", "SPECIES", 244, 248], ["enzootic", "PROBLEM", 25, 33], ["novel infectious agents", "TREATMENT", 99, 122], ["viral and bacterial agents", "TREATMENT", 195, 221], ["enzootic", "OBSERVATION_MODIFIER", 25, 33], ["viral", "OBSERVATION", 195, 200]]], ["Canine distemper virus (CDV), canine adenovirus type 2 (CAV-2), canine parainfluenza virus (CPIV), canine herpesvirus-1 (CHV) and Bordetella bronchiseptica are commonly reported pathogens in this disease complex (Erles et al., 2004; Buonavoglia and Martella, 2007) , but recent studies have reported the involvement of new viral agents (Priestnall and Smith, 2012) .", [["Canine distemper virus", "DISEASE", 0, 22], ["canine parainfluenza virus", "DISEASE", 64, 90], ["canine herpesvirus-1", "DISEASE", 99, 119], ["Bordetella bronchiseptica", "DISEASE", 130, 155], ["Canine distemper virus", "ORGANISM", 0, 22], ["CDV", "ORGANISM", 24, 27], ["canine adenovirus type 2", "ORGANISM", 30, 54], ["CAV-2", "ORGANISM", 56, 61], ["canine parainfluenza virus", "ORGANISM", 64, 90], ["CPIV", "ORGANISM", 92, 96], ["canine herpesvirus-1", "ORGANISM", 99, 119], ["CHV", "GENE_OR_GENE_PRODUCT", 121, 124], ["Bordetella bronchiseptica", "ORGANISM", 130, 155], ["Canine distemper virus", "SPECIES", 0, 22], ["canine", "SPECIES", 30, 36], ["canine parainfluenza virus", "SPECIES", 64, 90], ["canine herpesvirus-1", "SPECIES", 99, 119], ["Bordetella bronchiseptica", "SPECIES", 130, 155], ["Canine distemper virus", "SPECIES", 0, 22], ["CDV", "SPECIES", 24, 27], ["canine adenovirus type 2 (CAV-2", "SPECIES", 30, 61], ["canine parainfluenza virus", "SPECIES", 64, 90], ["CPIV", "SPECIES", 92, 96], ["canine herpesvirus-1", "SPECIES", 99, 119], ["CHV", "SPECIES", 121, 124], ["Bordetella bronchiseptica", "SPECIES", 130, 155], ["Canine distemper virus", "PROBLEM", 0, 22], ["CDV", "TEST", 24, 27], ["canine adenovirus type 2", "PROBLEM", 30, 54], ["CAV", "TEST", 56, 59], ["canine parainfluenza virus", "PROBLEM", 64, 90], ["canine herpesvirus", "PROBLEM", 99, 117], ["Bordetella bronchiseptica", "PROBLEM", 130, 155], ["this disease complex", "PROBLEM", 191, 211], ["Buonavoglia", "TEST", 233, 244], ["recent studies", "TEST", 271, 285], ["distemper virus", "OBSERVATION", 7, 22], ["parainfluenza virus", "OBSERVATION", 71, 90], ["new", "OBSERVATION_MODIFIER", 319, 322], ["viral", "OBSERVATION", 323, 328]]], ["Canine respiratory coronavirus (CRCoV) was first isolated in 2003 from the airways of dogs with acute respiratory signs (Erles et al., 2003) and is highly prevalent among dogs with clinical signs of respiratory disease in many different countries (Yachi and Mochizuki, 2006; Erles et al., 2004; Mochizuki et al., 2008; An et al., 2010a) .", [["airways", "ANATOMY", 75, 82], ["respiratory", "ANATOMY", 102, 113], ["respiratory", "ANATOMY", 199, 210], ["Canine respiratory coronavirus", "DISEASE", 0, 30], ["acute respiratory signs", "DISEASE", 96, 119], ["respiratory disease", "DISEASE", 199, 218], ["Canine respiratory coronavirus", "ORGANISM", 0, 30], ["CRCoV", "ORGANISM", 32, 37], ["airways", "MULTI-TISSUE_STRUCTURE", 75, 82], ["dogs", "ORGANISM", 86, 90], ["dogs", "ORGANISM", 171, 175], ["Canine respiratory coronavirus", "SPECIES", 0, 30], ["dogs", "SPECIES", 86, 90], ["dogs", "SPECIES", 171, 175], ["Canine respiratory coronavirus", "SPECIES", 0, 30], ["CRCoV", "SPECIES", 32, 37], ["Canine respiratory coronavirus", "PROBLEM", 0, 30], ["acute respiratory signs", "PROBLEM", 96, 119], ["respiratory disease", "PROBLEM", 199, 218], ["respiratory coronavirus", "OBSERVATION", 7, 30], ["airways", "ANATOMY", 75, 82], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["respiratory signs", "OBSERVATION", 102, 119], ["respiratory disease", "OBSERVATION", 199, 218]]], ["In 2004, canine influenza virus (CIV) was detected in racing Greyhounds in Florida, USA, and caused severe respiratory disease (Crawford et al., 2005) .Contents lists available at ScienceDirectThe Veterinary Journal j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / t v j l To date, the virus is endemic in many states of the USA (Payungporn et al., 2008; Barrell et al., 2010; Hayward et al., 2010; Holt et al., 2010; Seiler et al., 2010; Serra et al., 2011) , but so far there are no endemic areas outside the USA (Kruth et al., 2008; Knesl et al., 2009; De Benedictis et al., 2010; Piccirillo et al., 2010) .Contents lists available at ScienceDirectTo the authors' knowledge there are no published studies investigating the prevalence of CIRD-related pathogens in dogs in Germany.", [["respiratory", "ANATOMY", 107, 118], ["canine influenza virus (CIV)", "DISEASE", 9, 37], ["respiratory disease", "DISEASE", 107, 126], ["CIRD", "DISEASE", 769, 773], ["canine influenza virus", "ORGANISM", 9, 31], ["CIV", "ORGANISM", 33, 36], ["dogs", "ORGANISM", 795, 799], ["canine influenza virus", "SPECIES", 9, 31], ["dogs", "SPECIES", 795, 799], ["canine influenza virus", "SPECIES", 9, 31], ["CIV", "SPECIES", 33, 36], ["canine influenza virus", "PROBLEM", 9, 31], ["severe respiratory disease", "PROBLEM", 100, 126], ["a g e", "TEST", 240, 245], ["a t e", "TEST", 286, 291], ["the virus", "TEST", 311, 320], ["Holt et al.", "TEST", 428, 439], ["Seiler et al.", "TEST", 447, 460], ["Serra et al.", "TEST", 468, 480], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["respiratory disease", "OBSERVATION", 107, 126], ["no", "UNCERTAINTY", 511, 513]]], ["Furthermore, the prevalence of these infectious agents in healthy dogs has not previously been reported.", [["dogs", "ORGANISM", 66, 70], ["dogs", "SPECIES", 66, 70], ["infectious", "OBSERVATION", 37, 47]]], ["Therefore, the aim of our study was to investigate the prevalence of CPIV, CAV-2, CIV, CRCoV, CHV-1, CDV and B. bronchiseptica in dogs with acute respiratory disease, and to compare the data to findings in healthy dogs.Study protocolThe study was performed as a prospective investigation from July 2011 to July 2012.", [["respiratory", "ANATOMY", 146, 157], ["B. bronchiseptica", "DISEASE", 109, 126], ["acute respiratory disease", "DISEASE", 140, 165], ["CAV-2", "GENE_OR_GENE_PRODUCT", 75, 80], ["CIV", "GENE_OR_GENE_PRODUCT", 82, 85], ["CRCoV", "GENE_OR_GENE_PRODUCT", 87, 92], ["CHV-1", "ORGANISM", 94, 99], ["CDV", "ORGANISM", 101, 104], ["B. bronchiseptica", "ORGANISM", 109, 126], ["dogs", "ORGANISM", 130, 134], ["dogs", "ORGANISM", 214, 218], ["B. bronchiseptica", "SPECIES", 109, 126], ["dogs", "SPECIES", 130, 134], ["dogs", "SPECIES", 214, 218], ["CPIV", "SPECIES", 69, 73], ["CIV", "SPECIES", 82, 85], ["CRCoV", "SPECIES", 87, 92], ["CHV-1", "SPECIES", 94, 99], ["CDV", "SPECIES", 101, 104], ["B. bronchiseptica", "SPECIES", 109, 126], ["our study", "TEST", 22, 31], ["CPIV", "PROBLEM", 69, 73], ["CAV", "TEST", 75, 78], ["CIV", "PROBLEM", 82, 85], ["CHV", "TEST", 94, 97], ["CDV", "PROBLEM", 101, 104], ["B. bronchiseptica in dogs", "PROBLEM", 109, 134], ["acute respiratory disease", "PROBLEM", 140, 165], ["Study protocol", "TEST", 219, 233], ["The study", "TEST", 233, 242], ["a prospective investigation", "TEST", 260, 287], ["CAV", "ANATOMY", 75, 78], ["bronchiseptica", "OBSERVATION", 112, 126], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory disease", "OBSERVATION", 146, 165]]], ["The study protocol was approved by the Federal Institution for Animal Welfare (approval number 55.2-1-54-2532.3-33-12).AnimalsNasal and pharyngeal swabs were collected from 151 dogs at the Clinic of Small Animal Medicine, Ludwig Maximilian University of Munich (n = 90), a private practice in Stockstadt/Main (n = 3), an animal shelter in Beckstetten/Jengen (n = 29) and the research kennels at the Department of Nutrition and Dietetics, Ludwig Maximilian University of Munich (n = 29).", [["Nasal", "ANATOMY", 126, 131], ["pharyngeal swabs", "ANATOMY", 136, 152], ["Animals", "ORGANISM", 119, 126], ["Nasal", "MULTI-TISSUE_STRUCTURE", 126, 131], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 136, 152], ["dogs", "ORGANISM", 177, 181], ["dogs", "SPECIES", 177, 181], ["The study protocol", "TEST", 0, 18], ["AnimalsNasal", "TREATMENT", 119, 131], ["pharyngeal swabs", "TREATMENT", 136, 152], ["Nasal", "ANATOMY", 126, 131], ["pharyngeal swabs", "ANATOMY", 136, 152]]], ["Of the 61 dogs with clinical signs CIRD, 16 (26.2%) lived in an animal shelter at the time of sampling and 45 (73.8%) were privately owned.", [["CIRD", "DISEASE", 35, 39], ["dogs", "ORGANISM", 10, 14], ["dogs", "SPECIES", 10, 14], ["clinical signs CIRD", "TEST", 20, 39]]], ["All healthy dogs originated from an animal shelter (13/90; 14.4%), a research kennel (29/90; 32.2%), or private households (48/90; 53.3%).AnimalsSixty-one dogs with CIRD and 90 healthy dogs were included in the study.", [["CIRD", "DISEASE", 165, 169], ["dogs", "ORGANISM", 12, 16], ["dogs", "ORGANISM", 155, 159], ["dogs", "ORGANISM", 185, 189], ["dogs", "SPECIES", 12, 16], ["dogs", "SPECIES", 155, 159], ["dogs", "SPECIES", 185, 189], ["the study", "TEST", 207, 216]]], ["Inclusion criteria for dogs diagnosed with CIRD were history of acute onset of respiratory signs (<14 days), including nasal discharge, sneezing, cough and dyspnoea.", [["respiratory", "ANATOMY", 79, 90], ["nasal", "ANATOMY", 119, 124], ["CIRD", "DISEASE", 43, 47], ["respiratory signs", "DISEASE", 79, 96], ["sneezing", "DISEASE", 136, 144], ["cough", "DISEASE", 146, 151], ["dyspnoea", "DISEASE", 156, 164], ["dogs", "ORGANISM", 23, 27], ["nasal", "ORGANISM_SUBDIVISION", 119, 124], ["dogs", "SPECIES", 23, 27], ["dogs", "PROBLEM", 23, 27], ["respiratory signs", "PROBLEM", 79, 96], ["nasal discharge", "PROBLEM", 119, 134], ["sneezing", "PROBLEM", 136, 144], ["cough", "PROBLEM", 146, 151], ["dyspnoea", "PROBLEM", 156, 164], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["respiratory", "ANATOMY", 79, 90], ["signs", "OBSERVATION", 91, 96], ["nasal", "ANATOMY", 119, 124], ["sneezing", "OBSERVATION", 136, 144], ["cough", "OBSERVATION", 146, 151], ["dyspnoea", "OBSERVATION", 156, 164]]], ["Dogs were excluded if an underlying cardiac condition, neoplasia, pleural effusion, or functional or anatomic abnormalities of the respiratory tract were diagnosed, based on the results of history, physical examination, and, if necessary, radiographic and/or echocardiographic examination.", [["cardiac", "ANATOMY", 36, 43], ["neoplasia", "ANATOMY", 55, 64], ["pleural", "ANATOMY", 66, 73], ["respiratory tract", "ANATOMY", 131, 148], ["cardiac condition", "DISEASE", 36, 53], ["neoplasia", "DISEASE", 55, 64], ["pleural effusion", "DISEASE", 66, 82], ["abnormalities of the respiratory tract", "DISEASE", 110, 148], ["Dogs", "ORGANISM", 0, 4], ["cardiac", "ORGAN", 36, 43], ["neoplasia", "CANCER", 55, 64], ["pleural", "ORGAN", 66, 73], ["respiratory tract", "ORGANISM_SUBDIVISION", 131, 148], ["an underlying cardiac condition", "PROBLEM", 22, 53], ["neoplasia", "PROBLEM", 55, 64], ["pleural effusion", "PROBLEM", 66, 82], ["functional or anatomic abnormalities of the respiratory tract", "PROBLEM", 87, 148], ["physical examination", "TEST", 198, 218], ["radiographic and/or echocardiographic examination", "TEST", 239, 288], ["cardiac", "ANATOMY", 36, 43], ["condition", "OBSERVATION", 44, 53], ["neoplasia", "OBSERVATION", 55, 64], ["pleural", "ANATOMY", 66, 73], ["effusion", "OBSERVATION", 74, 82], ["respiratory tract", "ANATOMY", 131, 148]]], ["Healthy dogs were eligible for inclusion in the study if the physical examination was unremarkable, if they had not been vaccinated within 4 weeks before the sampling date and if they did not have a history of respiratory signs within the last 8 months.Sampling procedureTwo nasal and two pharyngeal swabs (sterile cotton swabs, Sarstedt AG) were collected from healthy dogs and from dogs with CIRD.", [["respiratory", "ANATOMY", 210, 221], ["nasal", "ANATOMY", 275, 280], ["pharyngeal swabs", "ANATOMY", 289, 305], ["swabs", "ANATOMY", 322, 327], ["respiratory signs", "DISEASE", 210, 227], ["CIRD", "DISEASE", 394, 398], ["dogs", "ORGANISM", 8, 12], ["nasal", "ORGAN", 275, 280], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 289, 305], ["dogs", "ORGANISM", 370, 374], ["dogs", "ORGANISM", 384, 388], ["dogs", "SPECIES", 8, 12], ["dogs", "SPECIES", 370, 374], ["dogs", "SPECIES", 384, 388], ["cotton", "SPECIES", 315, 321], ["the study", "TEST", 44, 53], ["the physical examination", "TEST", 57, 81], ["respiratory signs", "PROBLEM", 210, 227], ["Sampling procedure", "TREATMENT", 253, 271], ["Two nasal", "TREATMENT", 271, 280], ["two pharyngeal swabs", "TREATMENT", 285, 305], ["sterile cotton swabs", "TREATMENT", 307, 327], ["Sarstedt AG", "TREATMENT", 329, 340], ["CIRD", "TREATMENT", 394, 398], ["nasal", "ANATOMY", 275, 280], ["pharyngeal swabs", "ANATOMY", 289, 305]]], ["For nasal sampling, the swab was placed about 3 cm into one nostril; pharyngeal samples were collected by gently rolling the swab on the soft palate.", [["nasal", "ANATOMY", 4, 9], ["swab", "ANATOMY", 24, 28], ["nostril", "ANATOMY", 60, 67], ["pharyngeal samples", "ANATOMY", 69, 87], ["swab", "ANATOMY", 125, 129], ["soft palate", "ANATOMY", 137, 148], ["pharyngeal samples", "CANCER", 69, 87], ["palate", "ORGAN", 142, 148], ["nasal sampling", "TREATMENT", 4, 18], ["the swab", "TREATMENT", 20, 28], ["pharyngeal samples", "TEST", 69, 87], ["nasal", "ANATOMY", 4, 9], ["pharyngeal", "ANATOMY", 69, 79], ["soft palate", "ANATOMY", 137, 148]]], ["One pair of nasal and pharyngeal swabs was submitted to Vet Med Labor GmbH, Division of IDEXX Laboratories in Ludwigsburg, Germany, for molecular detection of viral pathogens; the other pair of swabs was stored at \u221220\u00b0C until real-time PCR analysis for B. bronchiseptica was performed at the PCR laboratory of the Clinic of Small Animal Medicine of the University of Munich.", [["nasal", "ANATOMY", 12, 17], ["pharyngeal swabs", "ANATOMY", 22, 38], ["swabs", "ANATOMY", 194, 199], ["viral pathogens", "DISEASE", 159, 174], ["nasal", "MULTI-TISSUE_STRUCTURE", 12, 17], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 22, 38], ["B. bronchiseptica", "ORGANISM", 253, 270], ["B. bronchiseptica", "SPECIES", 253, 270], ["B. bronchiseptica", "SPECIES", 253, 270], ["nasal and pharyngeal swabs", "PROBLEM", 12, 38], ["viral pathogens", "PROBLEM", 159, 174], ["swabs", "TEST", 194, 199], ["PCR analysis", "TEST", 236, 248], ["B. bronchiseptica", "PROBLEM", 253, 270], ["nasal", "ANATOMY", 12, 17], ["pharyngeal", "ANATOMY", 22, 32], ["viral pathogens", "OBSERVATION", 159, 174], ["Small", "OBSERVATION_MODIFIER", 324, 329]]], ["For virus detection, a combined analysis of the nasal and pharyngeal swab specimens from each dog was performed; for detection of B. bronchiseptica, nasal and pharyngeal swabs were analysed separately.", [["nasal", "ANATOMY", 48, 53], ["pharyngeal swab specimens", "ANATOMY", 58, 83], ["nasal", "ANATOMY", 149, 154], ["pharyngeal swabs", "ANATOMY", 159, 175], ["nasal", "ORGANISM_SUBDIVISION", 48, 53], ["pharyngeal swab specimens", "CANCER", 58, 83], ["dog", "ORGANISM", 94, 97], ["B. bronchiseptica", "ORGANISM", 130, 147], ["nasal", "ORGANISM_SUBDIVISION", 149, 154], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 159, 175], ["dog", "SPECIES", 94, 97], ["B. bronchiseptica", "SPECIES", 130, 147], ["B. bronchiseptica", "SPECIES", 130, 147], ["virus detection", "TEST", 4, 19], ["a combined analysis", "TEST", 21, 40], ["the nasal and pharyngeal swab specimens", "TEST", 44, 83], ["B. bronchiseptica", "PROBLEM", 130, 147], ["nasal and pharyngeal swabs", "TEST", 149, 175], ["nasal", "ANATOMY", 48, 53], ["pharyngeal", "ANATOMY", 58, 68], ["bronchiseptica", "OBSERVATION", 133, 147], ["nasal", "ANATOMY", 149, 154], ["pharyngeal swabs", "ANATOMY", 159, 175]]], ["It was not possible to take pharyngeal samples from three dogs, while nasal samples could not be taken from two dogs.Real-time PCR for detection of virusesPCR for viral RNA and DNA of CPIV, CAV-2, CIV, CRCoV, CHV-1, and CDV was performed at Vet Med Labor GmbH, Division of IDEXX Laboratories, Ludwigsburg, Germany.", [["pharyngeal samples", "ANATOMY", 28, 46], ["nasal samples", "ANATOMY", 70, 83], ["pharyngeal samples", "CANCER", 28, 46], ["dogs", "ORGANISM", 58, 62], ["nasal samples", "CANCER", 70, 83], ["dogs", "ORGANISM", 112, 116], ["virusesPCR", "GENE_OR_GENE_PRODUCT", 148, 158], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["CAV-2", "ORGANISM", 190, 195], ["CIV", "ORGANISM", 197, 200], ["CRCoV", "CELL", 202, 207], ["CHV-1", "ORGANISM", 209, 214], ["CDV", "ORGANISM", 220, 223], ["virusesPCR", "DNA", 148, 158], ["viral RNA", "RNA", 163, 172], ["dogs", "SPECIES", 58, 62], ["dogs", "SPECIES", 112, 116], ["CPIV", "SPECIES", 184, 188], ["CIV", "SPECIES", 197, 200], ["CRCoV", "SPECIES", 202, 207], ["CHV-1", "SPECIES", 209, 214], ["CDV", "SPECIES", 220, 223], ["pharyngeal samples", "TEST", 28, 46], ["nasal samples", "TREATMENT", 70, 83], ["virusesPCR", "TEST", 148, 158], ["viral RNA", "PROBLEM", 163, 172], ["CPIV", "TEST", 184, 188], ["CAV", "TEST", 190, 193], ["CIV", "TEST", 197, 200], ["CRCoV", "TEST", 202, 207], ["CHV", "TEST", 209, 212], ["CDV", "PROBLEM", 220, 223], ["not possible", "UNCERTAINTY", 7, 19], ["CAV", "ANATOMY", 190, 193]]], ["Isolation and purification of total nucleic acid were conducted using the QIAamp DNA Blood BioRobot MDx Kit on an automated platform (BioRobot Universal, Qiagen GmbH).", [["nucleic acid", "CHEMICAL", 36, 48], ["Isolation", "TREATMENT", 0, 9], ["total nucleic acid", "TREATMENT", 30, 48], ["the QIAamp DNA", "TREATMENT", 70, 84]]], ["Real-time PCR at IDEXX Vet Med Labor was performed using the LightCycler 480 system (Roche) with proprietary forward and reverse primers and hydrolysis probes.", [["proprietary forward and reverse primers", "DNA", 97, 136], ["proprietary forward", "TREATMENT", 97, 116], ["reverse primers", "TREATMENT", 121, 136], ["hydrolysis probes", "TREATMENT", 141, 158], ["reverse primers", "OBSERVATION", 121, 136]]], ["Target genes for viral pathogen detection were as follows: (1) canine parainfluenza virus: haemagglutinin-neuraminidase gene; (2) canine adenovirus type 2: hexon gene; (3) canine influenza virus: haemagglutinin gene; (4) canine respiratory coronavirus: haemagglutinin-esterase gene; (5) canine herpesvirus: DNA polymerase gene; and (6) canine distemper virus: phosphoprotein (P) gene.", [["canine", "ORGANISM", 63, 69], ["parainfluenza virus", "ORGANISM", 70, 89], ["haemagglutinin-neuraminidase", "GENE_OR_GENE_PRODUCT", 91, 119], ["canine adenovirus type 2", "ORGANISM", 130, 154], ["hexon", "GENE_OR_GENE_PRODUCT", 156, 161], ["canine influenza virus", "ORGANISM", 172, 194], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 196, 210], ["canine respiratory coronavirus", "ORGANISM", 221, 251], ["haemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 253, 276], ["canine herpesvirus", "ORGANISM", 287, 305], ["DNA", "CELLULAR_COMPONENT", 307, 310], ["canine distemper virus", "ORGANISM", 336, 358], ["phosphoprotein (P)", "GENE_OR_GENE_PRODUCT", 360, 378], ["Target genes", "DNA", 0, 12], ["haemagglutinin-neuraminidase gene", "DNA", 91, 124], ["hexon gene", "DNA", 156, 166], ["haemagglutinin gene", "DNA", 196, 215], ["canine respiratory coronavirus: haemagglutinin-esterase gene; (5) canine herpesvirus: DNA polymerase gene", "DNA", 221, 326], ["canine distemper virus: phosphoprotein (P) gene", "DNA", 336, 383], ["canine parainfluenza virus", "SPECIES", 63, 89], ["canine", "SPECIES", 130, 136], ["canine influenza virus", "SPECIES", 172, 194], ["canine respiratory coronavirus", "SPECIES", 221, 251], ["canine herpesvirus", "SPECIES", 287, 305], ["canine distemper virus", "SPECIES", 336, 358], ["canine parainfluenza virus", "SPECIES", 63, 89], ["canine influenza virus", "SPECIES", 172, 194], ["canine respiratory coronavirus", "SPECIES", 221, 251], ["canine herpesvirus", "SPECIES", 287, 305], ["canine distemper virus", "SPECIES", 336, 358], ["viral pathogen detection", "TEST", 17, 41], ["canine parainfluenza virus", "PROBLEM", 63, 89], ["haemagglutinin-neuraminidase gene", "TREATMENT", 91, 124], ["canine adenovirus type", "TREATMENT", 130, 152], ["hexon gene", "TREATMENT", 156, 166], ["canine influenza virus", "PROBLEM", 172, 194], ["haemagglutinin gene", "TREATMENT", 196, 215], ["canine respiratory coronavirus", "PROBLEM", 221, 251], ["haemagglutinin-esterase gene", "TREATMENT", 253, 281], ["DNA polymerase gene", "PROBLEM", 307, 326], ["phosphoprotein (P) gene", "TREATMENT", 360, 383], ["respiratory coronavirus", "ANATOMY", 228, 251]]], ["Molecular diagnostics were carried out with six quality controls, including PCR positive controls of known quantity, PCR negative controls, negative extraction controls, an internal positive control spiked into the lysis solution to monitor the nucleic acid extraction efficiency and the presence or absence of inhibitory substances, RNA quality control and an environmental contamination monitoring control.Real-time PCR for detection of Bordetella bronchisepticaDNA isolation was performed with the QIAamp DNA Micro Kit (Qiagen GmbH) and eluted in 30 \u03bcL elution buffer (Buffer AE).", [["nucleic acid", "CHEMICAL", 245, 257], ["Bordetella bronchisepticaDNA", "ORGANISM", 439, 467], ["Bordetella bronchisepticaDNA", "SPECIES", 439, 467], ["Molecular diagnostics", "TEST", 0, 21], ["PCR", "TEST", 76, 79], ["PCR", "TEST", 117, 120], ["an internal positive control", "TREATMENT", 170, 198], ["the lysis solution", "TREATMENT", 211, 229], ["the nucleic acid extraction efficiency", "PROBLEM", 241, 279], ["inhibitory substances", "TREATMENT", 311, 332], ["RNA quality control", "TREATMENT", 334, 353], ["an environmental contamination monitoring control", "TREATMENT", 358, 407], ["Bordetella bronchisepticaDNA isolation", "TREATMENT", 439, 477]]], ["PCR analysis was performed using a Applied Biosystems 7500 Real Time PCR System (Life Technologies GmbH) with 40 cycles, consisting of a denaturation step for 15 s at 95\u00b0C and a combined annealing and amplification step at 60\u00b0C for 60 s.", [["PCR analysis", "TEST", 0, 12], ["a Applied Biosystems", "TREATMENT", 33, 53], ["a denaturation step", "TREATMENT", 135, 154], ["a combined annealing and amplification step", "TREATMENT", 176, 219]]], ["The analysis used SYBR Green PCR Master Mix (QIAGEN GmbH) mixed with water, 5 pmol forward primer (5\u2032-CCCCCGCACATTTCCGAACTTC-3\u2032), 5 pmol reverse primer (5\u2032-AGGCTCCCA AGAGAGAAAGGCTT-3\u2032) and 3 \u03bcL of template in a total volume of 30 \u03bcL on a MicroAmp 96-well reaction plate (Life Technologies GmbH).", [["reverse primer", "DNA", 137, 151], ["The analysis", "TEST", 0, 12], ["SYBR Green PCR Master Mix (QIAGEN GmbH) mixed with water", "TREATMENT", 18, 74], ["5 pmol forward primer", "TREATMENT", 76, 97], ["CCCCCGCACATTTCCGAACTTC", "TEST", 102, 124], ["AGAGAGAAAGGCTT", "TEST", 166, 180], ["a total volume", "TEST", 209, 223], ["a MicroAmp", "TEST", 236, 246]]], ["A melting curve analysis was performed to confirm amplification of a single PCR product and the correct size was verified on a 2% agarose gel.Statistical analysisData were evaluated using PASW Statistics 18 (SPSS).", [["agarose", "SIMPLE_CHEMICAL", 130, 137], ["A melting curve analysis", "TEST", 0, 24], ["a single PCR product", "TREATMENT", 67, 87], ["a 2% agarose gel", "TREATMENT", 125, 141], ["Statistical analysisData", "TEST", 142, 166], ["size", "OBSERVATION_MODIFIER", 104, 108]]], ["Groups were compared with Fisher's exact tests and \u03c7 2 tests.", [["Fisher's exact tests", "TEST", 26, 46], ["\u03c7 2 tests", "TEST", 51, 60]]], ["Age comparisons between sick and healthy dogs were performed using t tests.", [["dogs", "ORGANISM", 41, 45], ["dogs", "SPECIES", 41, 45], ["t tests", "TEST", 67, 74]]], ["Prevalences of the pathogens were calculated with a confidence interval (CI) of 95%.Study populationSamples were collected from 61 dogs with CIRD and 90 clinically healthy dogs.Study populationAge was not documented for three sick dogs and one healthy dog.", [["CIRD", "DISEASE", 141, 145], ["dogs", "ORGANISM", 131, 135], ["dogs", "ORGANISM", 172, 176], ["dog", "ORGANISM", 252, 255], ["dogs", "SPECIES", 131, 135], ["dogs", "SPECIES", 172, 176], ["dogs", "SPECIES", 231, 235], ["dog", "SPECIES", 252, 255], ["the pathogens", "PROBLEM", 15, 28], ["CI", "TEST", 73, 75], ["Study populationSamples", "TEST", 84, 107], ["CIRD", "TREATMENT", 141, 145], ["Study population", "TEST", 177, 193]]], ["The median age of dogs with CIRD was 3.5 years (3 months-16 years) and the median age of healthy dogs was 3.3 years (3 months-13 years; P = 0.156).", [["CIRD", "DISEASE", 28, 32], ["dogs", "ORGANISM", 18, 22], ["dogs", "ORGANISM", 97, 101], ["dogs", "SPECIES", 18, 22], ["dogs", "SPECIES", 97, 101]]], ["In the sick dog group, 63.9% were male or castrated male; 36.1% were female or spayed female.", [["dog", "ORGANISM", 12, 15], ["dog", "SPECIES", 12, 15]]], ["The healthy dogs consisted of 40.0% male or castrated male and 60.0% female or spayed female dogs.", [["dogs", "ORGANISM", 12, 16], ["dogs", "ORGANISM", 93, 97], ["dogs", "SPECIES", 12, 16], ["dogs", "SPECIES", 93, 97]]], ["There was a significantly higher proportion of male intact dogs in the CIRD group than in the healthy group (P = 0.001).", [["CIRD", "DISEASE", 71, 75], ["dogs", "ORGANISM", 59, 63], ["CIRD", "CANCER", 71, 75], ["dogs", "SPECIES", 59, 63], ["intact", "OBSERVATION_MODIFIER", 52, 58], ["dogs", "OBSERVATION", 59, 63]]], ["Mixed breed was the most commonly recorded breed (39.3% of dogs with CIRD; 32.2% of healthy dogs).", [["CIRD", "DISEASE", 69, 73], ["dogs", "ORGANISM", 59, 63], ["dogs", "ORGANISM", 92, 96], ["dogs", "SPECIES", 59, 63], ["dogs", "SPECIES", 92, 96], ["CIRD", "TEST", 69, 73]]], ["The clinical signs documented in dogs in the CIRD group included cough (86.7%), nasal discharge (62.2%), sneezing (26.7%) and dyspnoea (6.7%).Study populationInformation about vaccination status was available for 98.4% of dogs with CIRD and 96.7% of healthy dogs.", [["nasal", "ANATOMY", 80, 85], ["CIRD", "DISEASE", 45, 49], ["cough", "DISEASE", 65, 70], ["sneezing", "DISEASE", 105, 113], ["dyspnoea", "DISEASE", 126, 134], ["CIRD", "DISEASE", 232, 236], ["dogs", "ORGANISM", 33, 37], ["CIRD", "CANCER", 45, 49], ["nasal", "ORGANISM_SUBDIVISION", 80, 85], ["dogs", "ORGANISM", 222, 226], ["dogs", "ORGANISM", 258, 262], ["dogs", "SPECIES", 33, 37], ["dogs", "SPECIES", 222, 226], ["dogs", "SPECIES", 258, 262], ["The clinical signs", "TEST", 0, 18], ["cough", "PROBLEM", 65, 70], ["nasal discharge", "TEST", 80, 95], ["sneezing", "PROBLEM", 105, 113], ["dyspnoea", "PROBLEM", 126, 134], ["CIRD", "TREATMENT", 232, 236], ["nasal", "ANATOMY", 80, 85]]], ["A vaccine containing CPIV had been administered SC in 43.3% of dogs with CIRD and 54.0% of healthy dogs (P = 0.241).", [["CPIV", "CHEMICAL", 21, 25], ["CIRD", "DISEASE", 73, 77], ["CPIV", "CANCER", 21, 25], ["dogs", "ORGANISM", 63, 67], ["dogs", "ORGANISM", 99, 103], ["dogs", "SPECIES", 63, 67], ["dogs", "SPECIES", 99, 103], ["CPIV", "SPECIES", 21, 25], ["A vaccine containing CPIV", "TREATMENT", 0, 25], ["CIRD", "TREATMENT", 73, 77]]], ["While none of the dogs with CIRD had been vaccinated against B. bronchiseptica, one healthy dog had received an intranasal vaccine with a live attenuated B. bronchiseptica strain (P = 1.000).Detection of respiratory pathogensInfections with CIRD pathogens were detected in 52/61 (85.2%) of dogs with CIRD and 47/90 (52.2%) healthy dogs (P < 0.001).", [["respiratory", "ANATOMY", 204, 215], ["CIRD", "DISEASE", 28, 32], ["respiratory pathogens", "DISEASE", 204, 225], ["CIRD", "DISEASE", 300, 304], ["dogs", "ORGANISM", 18, 22], ["B. bronchiseptica", "ORGANISM", 61, 78], ["dog", "ORGANISM", 92, 95], ["B. bronchiseptica", "ORGANISM", 154, 171], ["dogs", "ORGANISM", 290, 294], ["dogs", "ORGANISM", 331, 335], ["dogs", "SPECIES", 18, 22], ["B. bronchiseptica", "SPECIES", 61, 78], ["dog", "SPECIES", 92, 95], ["B. bronchiseptica", "SPECIES", 154, 171], ["dogs", "SPECIES", 290, 294], ["dogs", "SPECIES", 331, 335], ["B. bronchiseptica", "SPECIES", 61, 78], ["B. bronchiseptica", "SPECIES", 154, 171], ["an intranasal vaccine", "TREATMENT", 109, 130], ["a live attenuated B. bronchiseptica strain", "PROBLEM", 136, 178], ["respiratory pathogensInfections", "PROBLEM", 204, 235], ["CIRD pathogens", "PROBLEM", 241, 255], ["dogs", "TEST", 290, 294], ["CIRD", "TEST", 300, 304], ["respiratory", "ANATOMY", 204, 215], ["pathogens", "OBSERVATION", 216, 225]]], ["While CPIV and CRCoV were the only viral pathogens detected in dogs with CIRD, CPIV and CAV-2 were also isolated from healthy dogs (Table 1) .", [["CPIV", "GENE_OR_GENE_PRODUCT", 6, 10], ["CRCoV", "GENE_OR_GENE_PRODUCT", 15, 20], ["dogs", "ORGANISM", 63, 67], ["CAV-2", "CELL", 88, 93], ["dogs", "SPECIES", 63, 67], ["dogs", "SPECIES", 126, 130], ["CPIV", "SPECIES", 6, 10], ["CRCoV", "SPECIES", 15, 20], ["CIRD", "SPECIES", 73, 77], ["CPIV", "SPECIES", 79, 83], ["CRCoV", "TREATMENT", 15, 20], ["viral pathogens", "PROBLEM", 35, 50], ["CIRD", "TREATMENT", 73, 77], ["CPIV", "TREATMENT", 79, 83], ["CAV-2", "TREATMENT", 88, 93], ["CAV", "ANATOMY", 88, 91]]], ["CIV, CHV-1 and CDV were not detected in any of the dogs.Detection of respiratory pathogensWhen groups were compared, CPIV and CRCoV were significantly more frequently isolated from dogs with respiratory disease than from healthy dogs (P < 0.001 and P = 0.002, respectively).", [["respiratory", "ANATOMY", 191, 202], ["respiratory disease", "DISEASE", 191, 210], ["CIV", "ORGANISM", 0, 3], ["CHV-1", "ORGANISM", 5, 10], ["CDV", "ORGANISM", 15, 18], ["dogs", "ORGANISM", 51, 55], ["CRCoV", "GENE_OR_GENE_PRODUCT", 126, 131], ["dogs", "ORGANISM", 181, 185], ["dogs", "SPECIES", 51, 55], ["dogs", "SPECIES", 181, 185], ["dogs", "SPECIES", 229, 233], ["CIV", "SPECIES", 0, 3], ["CHV-1", "SPECIES", 5, 10], ["CDV", "SPECIES", 15, 18], ["CPIV", "SPECIES", 117, 121], ["CRCoV", "SPECIES", 126, 131], ["CIV", "TEST", 0, 3], ["CHV", "TEST", 5, 8], ["CDV", "PROBLEM", 15, 18], ["respiratory pathogens", "PROBLEM", 69, 90], ["CRCoV", "TREATMENT", 126, 131], ["respiratory disease", "PROBLEM", 191, 210], ["P", "TEST", 249, 250], ["respiratory", "ANATOMY", 69, 80], ["pathogens", "OBSERVATION", 81, 90], ["respiratory disease", "OBSERVATION", 191, 210]]], ["B. bronchiseptica was detected in dogs with CIRD and in healthy dogs, but a higher proportion of dogs with CIRD were positive for B. bronchiseptica than healthy dogs (P < 0.001).Detection of respiratory pathogensInfections with two or more pathogens were detected in 23/61 (37.7%) of dogs with CIRD and 2/90 (2.2%) healthy dogs (Table 2) .", [["respiratory", "ANATOMY", 191, 202], ["CIRD", "DISEASE", 44, 48], ["CIRD", "DISEASE", 107, 111], ["respiratory pathogens", "DISEASE", 191, 212], ["Infections", "DISEASE", 212, 222], ["CIRD", "DISEASE", 294, 298], ["B. bronchiseptica", "ORGANISM", 0, 17], ["dogs", "ORGANISM", 34, 38], ["dogs", "ORGANISM", 64, 68], ["dogs", "ORGANISM", 97, 101], ["B. bronchiseptica", "ORGANISM", 130, 147], ["dogs", "ORGANISM", 161, 165], ["dogs", "ORGANISM", 284, 288], ["dogs", "ORGANISM", 323, 327], ["B. bronchiseptica", "SPECIES", 0, 17], ["dogs", "SPECIES", 34, 38], ["dogs", "SPECIES", 64, 68], ["dogs", "SPECIES", 97, 101], ["B. bronchiseptica", "SPECIES", 130, 147], ["dogs", "SPECIES", 161, 165], ["dogs", "SPECIES", 284, 288], ["dogs", "SPECIES", 323, 327], ["B. bronchiseptica", "SPECIES", 0, 17], ["B. bronchiseptica", "SPECIES", 130, 147], ["B. bronchiseptica", "PROBLEM", 0, 17], ["B. bronchiseptica than healthy dogs", "PROBLEM", 130, 165], ["respiratory pathogensInfections", "PROBLEM", 191, 222], ["CIRD", "TEST", 294, 298], ["bronchiseptica", "OBSERVATION", 3, 17], ["respiratory", "ANATOMY", 191, 202], ["pathogens", "OBSERVATION", 203, 212]]], ["Mixed infections with CPIV and B. bronchiseptica, and CRCoV and B. bronchiseptica were more common in dogs with CIRD than in healthy dogs (P < 0.001 and P = 0.014, respectively).", [["infections", "DISEASE", 6, 16], ["CPIV and B. bronchiseptica", "DISEASE", 22, 48], ["CIRD", "DISEASE", 112, 116], ["B. bronchiseptica", "ORGANISM", 31, 48], ["CRCoV", "GENE_OR_GENE_PRODUCT", 54, 59], ["B. bronchiseptica", "ORGANISM", 64, 81], ["dogs", "ORGANISM", 102, 106], ["B. bronchiseptica", "SPECIES", 31, 48], ["B. bronchiseptica", "SPECIES", 64, 81], ["dogs", "SPECIES", 102, 106], ["dogs", "SPECIES", 133, 137], ["CPIV", "SPECIES", 22, 26], ["B. bronchiseptica", "SPECIES", 31, 48], ["CRCoV", "SPECIES", 54, 59], ["B. bronchiseptica", "SPECIES", 64, 81], ["Mixed infections", "PROBLEM", 0, 16], ["CPIV", "PROBLEM", 22, 26], ["B. bronchiseptica", "PROBLEM", 31, 48], ["CRCoV and B. bronchiseptica", "PROBLEM", 54, 81], ["P", "TEST", 153, 154], ["infections", "OBSERVATION", 6, 16], ["bronchiseptica", "OBSERVATION", 34, 48]]], ["Of the 23 dogs with CIRD that tested positive for CPIV, 14 (60.9%) had a history of vaccination against CPIV.Detection of respiratory pathogensWhen analysis was performed comparing the prevalence of positive PCR test results for each pathogen among dogs living in private households and dogs from an animal shelter or research kennel, significantly more dogs from private households were PCR positive for B. bronchiseptica (P < 0.001; Table 3 ).DiscussionCPIV, CRCoV and B. bronchiseptica were the only pathogens detected in dogs with acute respiratory signs in the present study and all three pathogens were significantly associated with respiratory disease when compared to healthy controls.", [["respiratory", "ANATOMY", 541, 552], ["respiratory", "ANATOMY", 639, 650], ["CIRD", "DISEASE", 20, 24], ["respiratory pathogens", "DISEASE", 122, 143], ["respiratory disease", "DISEASE", 639, 658], ["dogs", "ORGANISM", 10, 14], ["CIRD", "CANCER", 20, 24], ["dogs", "ORGANISM", 249, 253], ["dogs", "ORGANISM", 287, 291], ["dogs", "ORGANISM", 354, 358], ["B. bronchiseptica", "ORGANISM", 405, 422], ["CRCoV", "GENE_OR_GENE_PRODUCT", 461, 466], ["B. bronchiseptica", "ORGANISM", 471, 488], ["dogs", "ORGANISM", 525, 529], ["dogs", "SPECIES", 10, 14], ["dogs", "SPECIES", 249, 253], ["dogs", "SPECIES", 287, 291], ["dogs", "SPECIES", 354, 358], ["B. bronchiseptica", "SPECIES", 405, 422], ["B. bronchiseptica", "SPECIES", 471, 488], ["dogs", "SPECIES", 525, 529], ["CPIV", "SPECIES", 50, 54], ["CPIV", "SPECIES", 104, 108], ["B. bronchiseptica", "SPECIES", 405, 422], ["B. bronchiseptica", "SPECIES", 471, 488], ["CIRD", "TREATMENT", 20, 24], ["CPIV", "TEST", 50, 54], ["vaccination against CPIV", "TREATMENT", 84, 108], ["respiratory pathogens", "PROBLEM", 122, 143], ["positive PCR test", "TEST", 199, 216], ["PCR", "TEST", 388, 391], ["B. bronchiseptica", "PROBLEM", 405, 422], ["CRCoV", "TREATMENT", 461, 466], ["B. bronchiseptica", "PROBLEM", 471, 488], ["acute respiratory signs", "PROBLEM", 535, 558], ["the present study", "TEST", 562, 579], ["all three pathogens", "PROBLEM", 584, 603], ["respiratory disease", "PROBLEM", 639, 658], ["respiratory pathogens", "OBSERVATION", 122, 143], ["acute", "OBSERVATION_MODIFIER", 535, 540], ["respiratory signs", "OBSERVATION", 541, 558], ["respiratory disease", "OBSERVATION", 639, 658]]], ["CPIV was isolated from 37.7% of dogs with CIRD and was the most common viral pathogen detected.", [["CIRD", "DISEASE", 42, 46], ["CPIV", "GENE_OR_GENE_PRODUCT", 0, 4], ["dogs", "ORGANISM", 32, 36], ["CIRD", "CANCER", 42, 46], ["dogs", "SPECIES", 32, 36], ["CPIV", "SPECIES", 0, 4], ["CPIV", "TREATMENT", 0, 4], ["CIRD", "TREATMENT", 42, 46], ["the most common viral pathogen", "PROBLEM", 55, 85], ["pathogen", "OBSERVATION", 77, 85]]], ["In contrast to the high prevalence of CPIV in our population of German dogs, a Japanese investigation reported positive CPIV results in 5/68 (7.4%) nasal swabs from dogs with acute respiratory disease (Mochizuki et al., 2008) .", [["nasal swabs", "ANATOMY", 148, 159], ["respiratory", "ANATOMY", 181, 192], ["CPIV", "DISEASE", 38, 42], ["acute respiratory disease", "DISEASE", 175, 200], ["CPIV", "CANCER", 38, 42], ["dogs", "ORGANISM", 71, 75], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 148, 159], ["dogs", "ORGANISM", 165, 169], ["dogs", "SPECIES", 71, 75], ["dogs", "SPECIES", 165, 169], ["CPIV", "SPECIES", 38, 42], ["CPIV", "SPECIES", 120, 124], ["a Japanese investigation", "TEST", 77, 101], ["nasal swabs", "TEST", 148, 159], ["acute respiratory disease", "PROBLEM", 175, 200], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["respiratory disease", "OBSERVATION", 181, 200]]], ["Differences in geographical distribution or vaccination protocols might explain this.DiscussionIn the present study, 43.3% of all dogs with CIRD and 60.9% of CPIV positive dogs with CIRD had a history of parenteral vaccination against CPIV.", [["CIRD", "DISEASE", 140, 144], ["CIRD", "DISEASE", 182, 186], ["dogs", "ORGANISM", 130, 134], ["CIRD", "CANCER", 140, 144], ["dogs", "ORGANISM", 172, 176], ["parenteral", "ORGANISM_SUBDIVISION", 204, 214], ["dogs", "SPECIES", 130, 134], ["dogs", "SPECIES", 172, 176], ["CPIV", "SPECIES", 158, 162], ["CPIV", "SPECIES", 235, 239], ["vaccination protocols", "TREATMENT", 44, 65], ["the present study", "TEST", 98, 115], ["CIRD", "TEST", 140, 144], ["CPIV positive dogs", "PROBLEM", 158, 176], ["parenteral vaccination", "TREATMENT", 204, 226], ["CPIV", "PROBLEM", 235, 239]]], ["Since the time between vaccination and the onset of clinical CIRD was not documented, we could not determine if dogs developed clinical CPIV due to an insufficient immune response following vaccination or if some dogs tested positive for a vaccination strain of CPIV.", [["CIRD", "DISEASE", 61, 65], ["CPIV", "DISEASE", 136, 140], ["CIRD", "CANCER", 61, 65], ["dogs", "ORGANISM", 112, 116], ["dogs", "ORGANISM", 213, 217], ["CPIV", "CANCER", 262, 266], ["dogs", "SPECIES", 112, 116], ["dogs", "SPECIES", 213, 217], ["CPIV", "SPECIES", 136, 140], ["CPIV", "SPECIES", 262, 266], ["vaccination", "TREATMENT", 23, 34], ["clinical CPIV", "TREATMENT", 127, 140], ["an insufficient immune response", "PROBLEM", 148, 179], ["vaccination", "TREATMENT", 190, 201], ["some dogs", "PROBLEM", 208, 217], ["a vaccination strain of CPIV", "TREATMENT", 238, 266]]], ["It has been suggested that dogs vaccinated with a modified live CPIV vaccine could shed the virus for some time after vaccination (Ellis and Krakowka, 2012) ; the PCR used in the present study was unable to differentiate between vaccine and field strains of the virus.", [["CPIV", "CHEMICAL", 64, 68], ["dogs", "ORGANISM", 27, 31], ["CPIV", "ORGANISM", 64, 68], ["dogs", "SPECIES", 27, 31], ["CPIV", "SPECIES", 64, 68], ["dogs vaccinated", "TREATMENT", 27, 42], ["a modified live CPIV vaccine", "TREATMENT", 48, 76], ["the virus", "PROBLEM", 88, 97], ["the PCR", "TEST", 159, 166], ["the present study", "TEST", 175, 192], ["vaccine", "TREATMENT", 229, 236], ["the virus", "PROBLEM", 258, 267]]], ["In dogs experimentally infected with CPIV, only mild clinical signs were observed in some animals and others remained subclinical (Appel and Binn, 1987) .", [["dogs", "ORGANISM", 3, 7], ["dogs", "SPECIES", 3, 7], ["CPIV", "SPECIES", 37, 41], ["CPIV", "TREATMENT", 37, 41], ["mild clinical signs", "PROBLEM", 48, 67], ["infected", "OBSERVATION_MODIFIER", 23, 31], ["mild", "OBSERVATION_MODIFIER", 48, 52], ["subclinical", "OBSERVATION", 118, 129]]], ["In our study, infection with CPIV was detected in seven healthy dogs.", [["infection", "DISEASE", 14, 23], ["CPIV", "CANCER", 29, 33], ["dogs", "ORGANISM", 64, 68], ["dogs", "SPECIES", 64, 68], ["CPIV", "SPECIES", 29, 33], ["our study", "TEST", 3, 12], ["infection", "PROBLEM", 14, 23], ["CPIV", "PROBLEM", 29, 33], ["infection", "OBSERVATION", 14, 23]]], ["It has been postulated that most naturally acquired clinical infections with CPIV are co-infections with several pathogens (Appel and Percy, 1970) .", [["infections", "DISEASE", 61, 71], ["CPIV", "DISEASE", 77, 81], ["co-infections", "DISEASE", 86, 99], ["CPIV", "SPECIES", 77, 81], ["clinical infections", "PROBLEM", 52, 71], ["CPIV", "TREATMENT", 77, 81], ["co-infections", "PROBLEM", 86, 99], ["most naturally", "OBSERVATION_MODIFIER", 28, 42]]], ["This was supported by the results of the present study, since only 4/23 (17.4%) dogs in the CIRD group had CPIV infection as a single agent, and 2/7 (28.6%) healthy CPIV positive dogs had a co-infection with B. bronchiseptica or CAV-2.", [["CIRD", "CHEMICAL", 92, 96], ["CPIV infection", "DISEASE", 107, 121], ["dogs", "ORGANISM", 80, 84], ["CIRD", "CANCER", 92, 96], ["dogs", "ORGANISM", 179, 183], ["B. bronchiseptica", "ORGANISM", 208, 225], ["CAV-2", "ORGANISM", 229, 234], ["dogs", "SPECIES", 80, 84], ["dogs", "SPECIES", 179, 183], ["B. bronchiseptica", "SPECIES", 208, 225], ["CPIV", "SPECIES", 107, 111], ["CPIV", "SPECIES", 165, 169], ["B. bronchiseptica", "SPECIES", 208, 225], ["the present study", "TEST", 37, 54], ["CPIV infection", "PROBLEM", 107, 121], ["healthy CPIV positive dogs", "PROBLEM", 157, 183], ["a co-infection", "PROBLEM", 188, 202], ["B. bronchiseptica", "PROBLEM", 208, 225], ["infection", "OBSERVATION", 112, 121]]], ["It is possible that CPIV could impair the local host defence mechanisms in the canine respiratory tract, facilitating colonisation and infection with other respiratory pathogens, such as B. bronchiseptica, or vice versa (Appel and Binn, 1987) .DiscussionCRCoV was found in 9.8% of dogs with CIRD in the present study, indicating that the virus is circulating in the German dog population.", [["respiratory tract", "ANATOMY", 86, 103], ["respiratory", "ANATOMY", 156, 167], ["CPIV", "CHEMICAL", 20, 24], ["infection", "DISEASE", 135, 144], ["respiratory pathogens", "DISEASE", 156, 177], ["CIRD", "DISEASE", 291, 295], ["CPIV", "GENE_OR_GENE_PRODUCT", 20, 24], ["canine", "ORGANISM", 79, 85], ["respiratory tract", "ORGANISM_SUBDIVISION", 86, 103], ["B. bronchiseptica", "ORGANISM", 187, 204], ["dogs", "ORGANISM", 281, 285], ["dog", "ORGANISM", 373, 376], ["canine", "SPECIES", 79, 85], ["B. bronchiseptica", "SPECIES", 187, 204], ["dogs", "SPECIES", 281, 285], ["dog", "SPECIES", 373, 376], ["canine", "SPECIES", 79, 85], ["B. bronchiseptica", "SPECIES", 187, 204], ["German dog", "SPECIES", 366, 376], ["CPIV", "PROBLEM", 20, 24], ["infection", "PROBLEM", 135, 144], ["other respiratory pathogens", "PROBLEM", 150, 177], ["CIRD", "TREATMENT", 291, 295], ["the present study", "TEST", 299, 316], ["the virus", "PROBLEM", 334, 343], ["local host defence", "OBSERVATION", 42, 60], ["canine", "ANATOMY_MODIFIER", 79, 85], ["respiratory tract", "ANATOMY", 86, 103], ["colonisation", "OBSERVATION", 118, 130], ["infection", "OBSERVATION", 135, 144], ["virus", "OBSERVATION", 338, 343]]], ["To our knowledge, the prevalence of CRCoV and other respiratory viruses has not previously been investigated in the German dog population.", [["CRCoV", "DISEASE", 36, 41], ["respiratory viruses", "DISEASE", 52, 71], ["CRCoV", "CANCER", 36, 41], ["dog", "ORGANISM", 123, 126], ["dog", "SPECIES", 123, 126], ["CRCoV", "SPECIES", 36, 41], ["other respiratory viruses", "PROBLEM", 46, 71], ["respiratory", "ANATOMY", 52, 63], ["viruses", "OBSERVATION", 64, 71]]], ["Studies performed in Italy (Decaro et al., 2007) , the UK (Erles et al., 2003) , Japan (Yachi and Mochizuki, 2006) and Korea (An et al., 2010b) have detected CRCoV in respiratory samples from dogs with CIRD.", [["respiratory samples", "ANATOMY", 167, 186], ["CIRD", "DISEASE", 202, 206], ["CRCoV", "GENE_OR_GENE_PRODUCT", 158, 163], ["respiratory samples", "CANCER", 167, 186], ["dogs", "ORGANISM", 192, 196], ["CRCoV", "PROTEIN", 158, 163], ["dogs", "SPECIES", 192, 196], ["CIRD", "TREATMENT", 202, 206], ["respiratory", "ANATOMY", 167, 178]]], ["Additionally, antibodies against CRCoV have been detected in dog populations worldwide, including Italy (Priestnall et al., 2007) , New Zealand (Knesl et al., 2009) , Korea (An et al., 2010b) , and the USA, Canada, the UK and Ireland (Priestnall et al., 2006) .", [["CRCoV", "GENE_OR_GENE_PRODUCT", 33, 38], ["dog", "ORGANISM", 61, 64], ["antibodies", "PROTEIN", 14, 24], ["CRCoV", "PROTEIN", 33, 38], ["CRCoV", "SPECIES", 33, 38], ["CRCoV", "PROBLEM", 33, 38]]], ["CRCoV was only detected in dogs in the CIRD group in the present study and none of the healthy dogs were identified as carriers.", [["CRCoV", "GENE_OR_GENE_PRODUCT", 0, 5], ["dogs", "ORGANISM", 27, 31], ["CIRD", "CANCER", 39, 43], ["dogs", "ORGANISM", 95, 99], ["dogs", "SPECIES", 27, 31], ["dogs", "SPECIES", 95, 99], ["CRCoV", "SPECIES", 0, 5], ["the present study", "TEST", 53, 70]]], ["However, these results must be interpreted in the light of the small sample size and the fact that CRCoV was not present as a single agent in any of the infected dogs.", [["CRCoV", "GENE_OR_GENE_PRODUCT", 99, 104], ["dogs", "ORGANISM", 162, 166], ["dogs", "SPECIES", 162, 166], ["CRCoV", "SPECIES", 99, 104], ["the small sample size", "PROBLEM", 59, 80], ["the infected dogs", "PROBLEM", 149, 166], ["small", "OBSERVATION_MODIFIER", 63, 68], ["sample size", "OBSERVATION_MODIFIER", 69, 80], ["infected", "OBSERVATION_MODIFIER", 153, 161], ["dogs", "OBSERVATION", 162, 166]]], ["All six dogs that tested positive for CRCoV were co-infected with B. bronchiseptica; two of these dogs also tested positive for CPIV.", [["B. bronchiseptica", "DISEASE", 66, 83], ["dogs", "ORGANISM", 8, 12], ["CRCoV", "GENE_OR_GENE_PRODUCT", 38, 43], ["B. bronchiseptica", "ORGANISM", 66, 83], ["dogs", "ORGANISM", 98, 102], ["dogs", "SPECIES", 8, 12], ["B. bronchiseptica", "SPECIES", 66, 83], ["dogs", "SPECIES", 98, 102], ["CRCoV", "SPECIES", 38, 43], ["B. bronchiseptica", "SPECIES", 66, 83], ["CPIV", "SPECIES", 128, 132], ["All six dogs", "PROBLEM", 0, 12], ["CRCoV", "PROBLEM", 38, 43], ["B. bronchiseptica", "PROBLEM", 66, 83], ["CPIV", "PROBLEM", 128, 132]]], ["This is similar to findings in Korea, in which CAV-1 and CAV-2, canine parvovirus 2a and CDV were detected as coinfections in dogs with CRCoV (An et al., 2010a) .", [["coinfections", "DISEASE", 110, 122], ["CAV-1", "ORGANISM", 47, 52], ["CAV-2", "ORGANISM", 57, 62], ["canine parvovirus 2a", "ORGANISM", 64, 84], ["CDV", "ORGANISM", 89, 92], ["dogs", "ORGANISM", 126, 130], ["canine parvovirus", "SPECIES", 64, 81], ["dogs", "SPECIES", 126, 130], ["CAV-1", "SPECIES", 47, 52], ["canine parvovirus 2a", "SPECIES", 64, 84], ["CDV", "SPECIES", 89, 92], ["CRCoV", "SPECIES", 136, 141], ["CAV", "TEST", 47, 50], ["CAV", "TEST", 57, 60], ["canine parvovirus 2a", "TREATMENT", 64, 84], ["CDV", "PROBLEM", 89, 92], ["CAV", "ANATOMY", 47, 50]]], ["When Erles et al. (2003) first detected CRCoV in respiratory tissues of shelter dogs with acute respiratory disease in the UK, they suspected that the severity of clinical signs depended on additional factors, such as coinfections.", [["respiratory tissues", "ANATOMY", 49, 68], ["respiratory", "ANATOMY", 96, 107], ["acute respiratory disease", "DISEASE", 90, 115], ["coinfections", "DISEASE", 218, 230], ["CRCoV", "GENE_OR_GENE_PRODUCT", 40, 45], ["respiratory tissues", "TISSUE", 49, 68], ["dogs", "ORGANISM", 80, 84], ["CRCoV", "PROTEIN", 40, 45], ["dogs", "SPECIES", 80, 84], ["CRCoV", "SPECIES", 40, 45], ["acute respiratory disease", "PROBLEM", 90, 115], ["clinical signs", "PROBLEM", 163, 177], ["coinfections", "PROBLEM", 218, 230], ["respiratory tissues", "ANATOMY", 49, 68], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory disease", "OBSERVATION", 96, 115]]], ["In their study, almost all dogs that were antibody negative on entry to a shelter became CRCoV antibody positive within 3 weeks, but only 50% of them developed respiratory disease.", [["respiratory", "ANATOMY", 160, 171], ["respiratory disease", "DISEASE", 160, 179], ["dogs", "ORGANISM", 27, 31], ["CRCoV antibody", "PROTEIN", 89, 103], ["dogs", "SPECIES", 27, 31], ["their study", "TEST", 3, 14], ["antibody", "TEST", 42, 50], ["CRCoV antibody positive", "PROBLEM", 89, 112], ["respiratory disease", "PROBLEM", 160, 179], ["respiratory disease", "OBSERVATION", 160, 179]]], ["This is in contrast to our findings, in which CRCoV was not detected in any healthy dogs.DiscussionIn the present study, the respiratory pathogen with the highest prevalence was B. bronchiseptica, which was detected in 78.7% of dogs with CIRD.", [["CIRD", "DISEASE", 238, 242], ["CRCoV", "GENE_OR_GENE_PRODUCT", 46, 51], ["dogs", "ORGANISM", 84, 88], ["B. bronchiseptica", "ORGANISM", 178, 195], ["dogs", "ORGANISM", 228, 232], ["dogs", "SPECIES", 84, 88], ["B. bronchiseptica", "SPECIES", 178, 195], ["dogs", "SPECIES", 228, 232], ["CRCoV", "SPECIES", 46, 51], ["B. bronchiseptica", "SPECIES", 178, 195], ["the present study", "TEST", 102, 119], ["the respiratory pathogen", "PROBLEM", 121, 145], ["B. bronchiseptica", "PROBLEM", 178, 195], ["CIRD", "TREATMENT", 238, 242], ["respiratory", "ANATOMY", 125, 136], ["bronchiseptica", "OBSERVATION", 181, 195]]], ["Of these, 52.1% were infected only with B. bronchiseptica strongly implying a primary pathogenic role for B. bronchiseptica in CIRD.", [["CIRD", "DISEASE", 127, 131], ["B. bronchiseptica", "ORGANISM", 40, 57], ["B. bronchiseptica", "ORGANISM", 106, 123], ["CIRD", "CANCER", 127, 131], ["B. bronchiseptica", "SPECIES", 40, 57], ["B. bronchiseptica", "SPECIES", 106, 123], ["B. bronchiseptica", "SPECIES", 40, 57], ["B. bronchiseptica", "SPECIES", 106, 123], ["B. bronchiseptica", "PROBLEM", 40, 57], ["B. bronchiseptica in CIRD", "PROBLEM", 106, 131], ["bronchiseptica", "OBSERVATION", 109, 123]]], ["It has been shown that B. bronchiseptica possesses the ability to cause respiratory disease after experimentally induced or naturally acquired infection, without concurrent viral or bacterial co- infection (Thompson et al., 1976; Bemis et al., 1977; Keil and Fenwick, 1998) .", [["respiratory", "ANATOMY", 72, 83], ["respiratory disease", "DISEASE", 72, 91], ["infection", "DISEASE", 143, 152], ["viral or bacterial co- infection", "DISEASE", 173, 205], ["B. bronchiseptica", "ORGANISM", 23, 40], ["B. bronchiseptica", "SPECIES", 23, 40], ["B. bronchiseptica", "SPECIES", 23, 40], ["B. bronchiseptica", "PROBLEM", 23, 40], ["respiratory disease", "PROBLEM", 72, 91], ["naturally acquired infection", "PROBLEM", 124, 152], ["bacterial co- infection", "PROBLEM", 182, 205], ["infection", "OBSERVATION", 143, 152], ["without", "UNCERTAINTY", 154, 161], ["infection", "OBSERVATION", 196, 205]]], ["A recent retrospective study reported a prevalence of B. bronchiseptica of 20/99 (20.2%) in bronchoalveolar lavage fluid (BALF) from German dogs with respiratory signs (Steinfeld et al., 2012) .", [["bronchoalveolar lavage fluid", "ANATOMY", 92, 120], ["BALF", "ANATOMY", 122, 126], ["respiratory", "ANATOMY", 150, 161], ["respiratory signs", "DISEASE", 150, 167], ["B. bronchiseptica", "ORGANISM", 54, 71], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 92, 120], ["BALF", "ORGANISM_SUBSTANCE", 122, 126], ["dogs", "ORGANISM", 140, 144], ["B. bronchiseptica", "SPECIES", 54, 71], ["dogs", "SPECIES", 140, 144], ["B. bronchiseptica", "SPECIES", 54, 71], ["A recent retrospective study", "TEST", 0, 28], ["B. bronchiseptica", "TEST", 54, 71], ["bronchoalveolar lavage fluid (BALF", "TEST", 92, 126], ["respiratory signs", "PROBLEM", 150, 167], ["bronchoalveolar lavage", "OBSERVATION", 92, 114], ["respiratory signs", "OBSERVATION", 150, 167]]], ["There are several possible explanations for the relatively low prevalence in that study compared to ours.", [["that study", "TEST", 77, 87], ["relatively", "OBSERVATION_MODIFIER", 48, 58], ["low prevalence", "OBSERVATION_MODIFIER", 59, 73]]], ["First, Steinfeld et al. (2012) included dogs with acute and chronic respiratory signs, and therefore some dogs might have had non-infectious respiratory diseases.", [["respiratory", "ANATOMY", 68, 79], ["respiratory", "ANATOMY", 141, 152], ["respiratory diseases", "DISEASE", 141, 161], ["dogs", "ORGANISM", 40, 44], ["dogs", "ORGANISM", 106, 110], ["dogs", "SPECIES", 40, 44], ["dogs", "SPECIES", 106, 110], ["acute and chronic respiratory signs", "PROBLEM", 50, 85], ["non-infectious respiratory diseases", "PROBLEM", 126, 161], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["respiratory signs", "OBSERVATION", 68, 85], ["non-infectious", "OBSERVATION_MODIFIER", 126, 140], ["respiratory diseases", "OBSERVATION", 141, 161]]], ["Secondly, bacterial culture results were reported, but this method is less sensitive than PCR (Reizenstein et al., 1993) .", [["bacterial culture", "TEST", 10, 27], ["this method", "TEST", 55, 66], ["PCR", "TEST", 90, 93]]], ["Additionally, in our study, specimens were collected from the upper respiratory tract, an area colonised by different resident bacterial species to those expected from BALF specimens in dogs with respiratory disease; the prevalence of B. bronchiseptica might have been different in our study if samples from the lower airways had been collected for analysis.DiscussionIn the present study, information regarding antimicrobial treatment was not available for most dogs in the CIRD group, but it is possible that some of the dogs had been treated prior to presentation, leading to negative test results for B. bronchiseptica in dogs that were originally positive.", [["specimens", "ANATOMY", 28, 37], ["upper respiratory tract", "ANATOMY", 62, 85], ["BALF specimens", "ANATOMY", 168, 182], ["respiratory", "ANATOMY", 196, 207], ["samples", "ANATOMY", 295, 302], ["lower airways", "ANATOMY", 312, 325], ["respiratory disease", "DISEASE", 196, 215], ["B. bronchiseptica", "DISEASE", 235, 252], ["specimens", "CANCER", 28, 37], ["upper respiratory", "ORGANISM_SUBDIVISION", 62, 79], ["tract", "ORGANISM_SUBDIVISION", 80, 85], ["dogs", "ORGANISM", 186, 190], ["B. bronchiseptica", "ORGANISM", 235, 252], ["lower airways", "MULTI-TISSUE_STRUCTURE", 312, 325], ["dogs", "ORGANISM", 463, 467], ["CIRD", "CANCER", 475, 479], ["dogs", "ORGANISM", 523, 527], ["B. bronchiseptica", "ORGANISM", 605, 622], ["dogs", "ORGANISM", 626, 630], ["dogs", "SPECIES", 186, 190], ["B. bronchiseptica", "SPECIES", 235, 252], ["dogs", "SPECIES", 463, 467], ["dogs", "SPECIES", 523, 527], ["B. bronchiseptica", "SPECIES", 605, 622], ["dogs", "SPECIES", 626, 630], ["B. bronchiseptica", "SPECIES", 235, 252], ["B. bronchiseptica", "SPECIES", 605, 622], ["our study", "TEST", 17, 26], ["specimens", "TEST", 28, 37], ["bacterial species", "PROBLEM", 127, 144], ["BALF specimens", "TEST", 168, 182], ["respiratory disease", "PROBLEM", 196, 215], ["B. bronchiseptica", "PROBLEM", 235, 252], ["our study", "TEST", 282, 291], ["samples from the lower airways", "TEST", 295, 325], ["analysis", "TEST", 349, 357], ["the present study", "TEST", 371, 388], ["antimicrobial treatment", "TREATMENT", 412, 435], ["B. bronchiseptica in dogs", "PROBLEM", 605, 630], ["upper", "ANATOMY_MODIFIER", 62, 67], ["respiratory tract", "ANATOMY", 68, 85], ["bacterial species", "OBSERVATION", 127, 144], ["respiratory disease", "OBSERVATION", 196, 215], ["lower", "ANATOMY_MODIFIER", 312, 317], ["airways", "ANATOMY", 318, 325]]], ["Thus, we might have underestimated the true prevalence of this bacterium in dogs with CIRD.", [["CIRD", "DISEASE", 86, 90], ["dogs", "ORGANISM", 76, 80], ["dogs", "SPECIES", 76, 80], ["this bacterium", "PROBLEM", 58, 72], ["CIRD", "TREATMENT", 86, 90]]], ["Although significantly more dogs with respiratory signs tested positive for B. bronchiseptica, almost half of healthy dogs (45.6%) were also identified as carriers.", [["respiratory", "ANATOMY", 38, 49], ["B. bronchiseptica", "DISEASE", 76, 93], ["dogs", "ORGANISM", 28, 32], ["B. bronchiseptica", "ORGANISM", 76, 93], ["dogs", "ORGANISM", 118, 122], ["dogs", "SPECIES", 28, 32], ["B. bronchiseptica", "SPECIES", 76, 93], ["dogs", "SPECIES", 118, 122], ["B. bronchiseptica", "SPECIES", 76, 93], ["significantly more dogs", "PROBLEM", 9, 32], ["respiratory signs", "TEST", 38, 55], ["B. bronchiseptica", "PROBLEM", 76, 93]]], ["Since vaccination within the last 4 weeks was an exclusion criterion for the study and only one healthy dog had received an intranasal vaccination against B. bronchiseptica, the positive test results cannot be explained by recent vaccination in our study population.", [["dog", "ORGANISM", 104, 107], ["B. bronchiseptica", "ORGANISM", 155, 172], ["dog", "SPECIES", 104, 107], ["B. bronchiseptica", "SPECIES", 155, 172], ["dog", "SPECIES", 104, 107], ["B. bronchiseptica", "SPECIES", 155, 172], ["vaccination", "TREATMENT", 6, 17], ["the study", "TEST", 73, 82], ["an intranasal vaccination", "TREATMENT", 121, 146], ["B. bronchiseptica", "PROBLEM", 155, 172], ["the positive test", "TEST", 174, 191]]], ["In a British study, B. bronchiseptica was cultured from BALF specimens in 62.8% of dogs with clinical signs of respiratory disease and from 34.6% of healthy dogs in the same shelter (Chalker et al., 2003) .", [["BALF specimens", "ANATOMY", 56, 70], ["respiratory", "ANATOMY", 111, 122], ["respiratory disease", "DISEASE", 111, 130], ["B. bronchiseptica", "ORGANISM", 20, 37], ["BALF specimens", "CELL", 56, 70], ["dogs", "ORGANISM", 83, 87], ["dogs", "ORGANISM", 157, 161], ["B. bronchiseptica", "SPECIES", 20, 37], ["dogs", "SPECIES", 83, 87], ["dogs", "SPECIES", 157, 161], ["B. bronchiseptica", "SPECIES", 20, 37], ["a British study", "TEST", 3, 18], ["B. bronchiseptica", "PROBLEM", 20, 37], ["BALF specimens", "TEST", 56, 70], ["respiratory disease", "PROBLEM", 111, 130], ["respiratory disease", "OBSERVATION", 111, 130]]], ["Thus, healthy dogs can be carriers of B. bronchiseptica and, therefore, might represent a potential source of infection for susceptible dogs.DiscussionOnly one clinically healthy dog tested positive for CAV-2, and CIV, CHV-1 and CDV were not detected from the study population.", [["infection", "DISEASE", 110, 119], ["dogs", "ORGANISM", 14, 18], ["B. bronchiseptica", "ORGANISM", 38, 55], ["dogs", "ORGANISM", 136, 140], ["dog", "ORGANISM", 179, 182], ["CAV-2", "GENE_OR_GENE_PRODUCT", 203, 208], ["CIV", "ORGANISM", 214, 217], ["CHV-1", "ORGANISM", 219, 224], ["CDV", "ORGANISM", 229, 232], ["dogs", "SPECIES", 14, 18], ["B. bronchiseptica", "SPECIES", 38, 55], ["dogs", "SPECIES", 136, 140], ["dog", "SPECIES", 179, 182], ["B. bronchiseptica", "SPECIES", 38, 55], ["CIV", "SPECIES", 214, 217], ["CHV-1", "SPECIES", 219, 224], ["CDV", "SPECIES", 229, 232], ["B. bronchiseptica", "PROBLEM", 38, 55], ["infection", "PROBLEM", 110, 119], ["susceptible dogs", "PROBLEM", 124, 140], ["CAV", "TEST", 203, 206], ["CIV", "TEST", 214, 217], ["CHV", "TEST", 219, 222], ["CDV", "PROBLEM", 229, 232], ["the study population", "TEST", 256, 276], ["bronchiseptica", "OBSERVATION", 41, 55], ["infection", "OBSERVATION", 110, 119]]], ["Based on these results, these pathogens do not seem to play a significant role in CIRD in the German dog population; however, our results must be interpreted carefully because of the relatively small sample size.", [["CIRD", "DISEASE", 82, 86], ["dog", "ORGANISM", 101, 104], ["dog", "SPECIES", 101, 104], ["German dog", "SPECIES", 94, 104], ["the relatively small sample size", "PROBLEM", 179, 211], ["relatively", "OBSERVATION_MODIFIER", 183, 193], ["small", "OBSERVATION_MODIFIER", 194, 199], ["sample", "OBSERVATION_MODIFIER", 200, 206], ["size", "OBSERVATION_MODIFIER", 207, 211]]], ["In addition, the selection of dogs for inclusion in the study might have influenced these data.", [["dogs", "ORGANISM", 30, 34], ["the study", "TEST", 52, 61], ["these data", "TEST", 84, 94]]], ["Since only 26.2% of dogs with CIRD and 46.6% of healthy dogs were from a shelter or kennel environment, and the rest lived in private households, it is possible that infectious agents that can be endemic in multi-dog facilities might have been underdiagnosed in this investigation.", [["CIRD", "DISEASE", 30, 34], ["dogs", "ORGANISM", 20, 24], ["CIRD", "CANCER", 30, 34], ["dogs", "ORGANISM", 56, 60], ["dog", "ORGANISM", 213, 216], ["dogs", "SPECIES", 20, 24], ["dogs", "SPECIES", 56, 60], ["CIRD", "TREATMENT", 30, 34], ["infectious agents", "TREATMENT", 166, 183], ["this investigation", "TEST", 262, 280], ["infectious", "OBSERVATION", 166, 176]]], ["When privately owned dogs and shelter/kennel dogs were compared, there were more B. bronchiseptica positive dogs living in private households and all CRCoV positive dogs were privately owned.", [["dogs", "ORGANISM", 21, 25], ["dogs", "ORGANISM", 45, 49], ["B. bronchiseptica", "ORGANISM", 81, 98], ["dogs", "ORGANISM", 108, 112], ["dogs", "ORGANISM", 165, 169], ["dogs", "SPECIES", 21, 25], ["dogs", "SPECIES", 45, 49], ["B. bronchiseptica", "SPECIES", 81, 98], ["dogs", "SPECIES", 108, 112], ["dogs", "SPECIES", 165, 169], ["B. bronchiseptica", "SPECIES", 81, 98]]], ["This indicates that CIRD is not only a problem when large numbers of dogs are housed together, as the expression 'kennel cough' implies, but privately owned dogs are susceptible to infection and can act as carriers.DiscussionA limitation of our study was that geographical differences in the prevalence of pathogens could not be assessed, since most dogs originated from Southern Germany.", [["CIRD", "DISEASE", 20, 24], ["cough", "DISEASE", 121, 126], ["infection", "DISEASE", 181, 190], ["dogs", "ORGANISM", 69, 73], ["dogs", "ORGANISM", 157, 161], ["dogs", "ORGANISM", 350, 354], ["dogs", "SPECIES", 69, 73], ["dogs", "SPECIES", 350, 354], ["infection", "PROBLEM", 181, 190], ["our study", "TEST", 241, 250], ["pathogens", "PROBLEM", 306, 315], ["infection", "OBSERVATION", 181, 190]]], ["It would be interesting to test a larger sample of shelter dogs for respiratory pathogens in future studies and to include dogs from other regions of Germany.", [["respiratory", "ANATOMY", 68, 79], ["respiratory pathogens", "DISEASE", 68, 89], ["dogs", "ORGANISM", 59, 63], ["dogs", "ORGANISM", 123, 127], ["dogs", "SPECIES", 123, 127], ["shelter dogs", "TREATMENT", 51, 63], ["respiratory pathogens", "PROBLEM", 68, 89], ["future studies", "TEST", 93, 107], ["Germany", "OBSERVATION", 150, 157]]], ["Another limitation of our study was the limited sampling period.", [["our study", "TEST", 22, 31]]], ["Since most of the viral pathogens involved in CIRD can only be detected for 7-10 days after infection and peak shedding usually occurs during the incubation period , specimens from dogs tested outside this window could have yielded false negative PCR results and thus led to underestimation of pathogen prevalence.", [["specimens", "ANATOMY", 166, 175], ["CIRD", "DISEASE", 46, 50], ["infection", "DISEASE", 92, 101], ["CIRD", "GENE_OR_GENE_PRODUCT", 46, 50], ["dogs", "ORGANISM", 181, 185], ["dogs", "SPECIES", 181, 185], ["the viral pathogens", "PROBLEM", 14, 33], ["infection", "PROBLEM", 92, 101], ["peak shedding", "PROBLEM", 106, 119], ["specimens from dogs", "TEST", 166, 185], ["false negative PCR results", "PROBLEM", 232, 258], ["pathogen prevalence", "PROBLEM", 294, 313]]], ["In nine dogs from the CIRD group, no pathogens were detected, perhaps because specimens were collected outside the viral shedding period, or perhaps these dogs were infected with viral or bacterial pathogens not included in the diagnostic panel used.ConclusionsThis study demonstrated that CPIV and B. bronchiseptica represent the most common infectious agents in dogs with CIRD in Southern Germany.", [["specimens", "ANATOMY", 78, 87], ["CIRD", "DISEASE", 374, 378], ["dogs", "ORGANISM", 8, 12], ["CIRD", "CANCER", 22, 26], ["specimens", "CANCER", 78, 87], ["dogs", "ORGANISM", 155, 159], ["CPIV", "GENE_OR_GENE_PRODUCT", 290, 294], ["B. bronchiseptica", "ORGANISM", 299, 316], ["dogs", "ORGANISM", 364, 368], ["dogs", "SPECIES", 8, 12], ["dogs", "SPECIES", 155, 159], ["B. bronchiseptica", "SPECIES", 299, 316], ["dogs", "SPECIES", 364, 368], ["CPIV", "SPECIES", 290, 294], ["B. bronchiseptica", "SPECIES", 299, 316], ["pathogens", "PROBLEM", 37, 46], ["specimens", "TEST", 78, 87], ["these dogs", "PROBLEM", 149, 159], ["viral or bacterial pathogens", "PROBLEM", 179, 207], ["the diagnostic panel", "TEST", 224, 244], ["This study", "TEST", 261, 271], ["CPIV and B. bronchiseptica", "PROBLEM", 290, 316]]], ["However, clinically healthy dogs can also be subclinical carriers of these two pathogens, and therefore could act as a source of infection for susceptible dogs.", [["infection", "DISEASE", 129, 138], ["dogs", "ORGANISM", 28, 32], ["dogs", "ORGANISM", 155, 159], ["dogs", "SPECIES", 28, 32], ["dogs", "SPECIES", 155, 159], ["these two pathogens", "PROBLEM", 69, 88], ["infection", "PROBLEM", 129, 138], ["susceptible dogs", "PROBLEM", 143, 159], ["infection", "OBSERVATION", 129, 138]]], ["While CPIV and CRCoV commonly occur as part of mixed infections with multiple pathogens, the role of B. bronchiseptica as a primary respiratory pathogen was confirmed.Conflict of interest statementVet Med Labor GmbH Division of IDEXX Laboratories, performed the real-time PCR for detection of viruses in this study.", [["infections", "DISEASE", 53, 63], ["CPIV", "GENE_OR_GENE_PRODUCT", 6, 10], ["CRCoV", "GENE_OR_GENE_PRODUCT", 15, 20], ["B. bronchiseptica", "ORGANISM", 101, 118], ["B. bronchiseptica", "SPECIES", 101, 118], ["CPIV", "SPECIES", 6, 10], ["CRCoV", "SPECIES", 15, 20], ["B. bronchiseptica", "SPECIES", 101, 118], ["CRCoV", "TREATMENT", 15, 20], ["mixed infections", "PROBLEM", 47, 63], ["multiple pathogens", "PROBLEM", 69, 87], ["B. bronchiseptica", "PROBLEM", 101, 118], ["a primary respiratory pathogen", "PROBLEM", 122, 152], ["viruses", "PROBLEM", 293, 300], ["this study", "TEST", 304, 314], ["mixed", "OBSERVATION_MODIFIER", 47, 52], ["infections", "OBSERVATION", 53, 63], ["multiple", "OBSERVATION_MODIFIER", 69, 77], ["pathogens", "OBSERVATION", 78, 87], ["viruses", "OBSERVATION", 293, 300]]], ["Vet Med Labor GmbH played no role in the study design, in the collection and interpretation of data, or in the decision to submit the manuscript for publication.", [["the study", "TEST", 37, 46]]], ["He provided information on viral testing for the Materials and methods section of the manuscript.", [["viral testing", "TEST", 27, 40]]]], "PMC1762333": [["IntroductionRapidly spreading outbreaks of infectious diseases are an increasing concern for global public health [1], [2] and security [3].", [["infectious diseases", "DISEASE", 43, 62], ["infectious diseases", "PROBLEM", 43, 62], ["global public health", "PROBLEM", 93, 113], ["infectious", "OBSERVATION_MODIFIER", 43, 53]]], ["Emerging infections, which are typically defined as infectious diseases that have newly appeared in a population or are rapidly increasing in incidence or geographic range [4], are a particular concern because at the time of emergence little is known about their epidemiology, particularly pathology, symptomatology, and transmissibility.", [["infections", "DISEASE", 9, 19], ["Emerging infections", "PROBLEM", 0, 19], ["infectious diseases", "PROBLEM", 52, 71], ["symptomatology", "PROBLEM", 301, 315], ["infections", "OBSERVATION", 9, 19], ["infectious", "OBSERVATION_MODIFIER", 52, 62], ["rapidly", "OBSERVATION_MODIFIER", 120, 127], ["increasing", "OBSERVATION_MODIFIER", 128, 138]]], ["Thus, the crucial tasks of assessing epidemic risk and determining what public health interventions should be taken are complicated by uncertainty that borders on complete ignorance.", [["public health interventions", "TREATMENT", 72, 99]]], ["Of course, this uncertainty is rapidly reduced as the outbreak progresses and information concerning symptoms of infection, the biology of the infectious agent, the epidemiology of transmission, and the effectiveness of health precautions and intervention is collected and disseminated.IntroductionThis learning process has not been considered in theories of outbreak control [5], [6] or in near real-time models of emerging infections [7], [8] (compare correspondence in refs [9], [10]).", [["infection", "DISEASE", 113, 122], ["infections", "DISEASE", 425, 435], ["symptoms", "PROBLEM", 101, 109], ["infection", "PROBLEM", 113, 122], ["health precautions", "TREATMENT", 220, 238], ["intervention", "TREATMENT", 243, 255], ["emerging infections", "PROBLEM", 416, 435], ["rapidly", "OBSERVATION_MODIFIER", 31, 38], ["reduced", "OBSERVATION_MODIFIER", 39, 46], ["infection", "OBSERVATION", 113, 122], ["infectious", "OBSERVATION_MODIFIER", 143, 153], ["infections", "OBSERVATION", 425, 435]]], ["Here, we study the collective effects of various processes (including possibly unidentified phenomena) on the change in the rate at which infectious persons are isolated.", [["persons", "ORGANISM", 149, 156], ["persons", "SPECIES", 149, 156], ["various processes", "PROBLEM", 41, 58], ["unidentified phenomena", "PROBLEM", 79, 101], ["infectious", "OBSERVATION", 138, 148]]], ["A partial list of the processes contributing to societal learning includes isolation and identification of the infectious agent, development of tests for clinical diagnosis, disseminating information to public health and medical personnel, disseminating information to the public, and implementing public health policies including restrictions on individual movement or quarantine.IntroductionDisease control theory focuses on an quantity called the reproductive ratio, designated here as R0 at the start of the outbreak and, if changing over time, Rt at time t.", [["societal learning", "TREATMENT", 48, 65], ["isolation", "TREATMENT", 75, 84], ["the infectious agent", "TREATMENT", 107, 127], ["tests", "TEST", 144, 149], ["partial", "OBSERVATION_MODIFIER", 2, 9]]], ["Outbreaks are considered to be under control when Rt<1, implying that outbreak conditions are such that on average disease prevalence will decline.", [["Outbreaks", "PROBLEM", 0, 9], ["outbreak conditions", "PROBLEM", 70, 89]]], ["Most research in theoretical epidemiology has focused on how Rt is related to disease and population parameters in order to understand how to induce the change from R0>1, during emergence, to Rt<1.", [["disease", "PROBLEM", 78, 85], ["population parameters", "TEST", 90, 111], ["disease", "OBSERVATION", 78, 85]]], ["Recent developments include techniques for estimating R0 from the initial stages of an outbreak [11], [12] and a model to ascertain the effect of a delay between the onset of an outbreak and the implementation of public health policies aimed at controlling disease spread [13].", [["an outbreak", "PROBLEM", 175, 186], ["public health policies", "TREATMENT", 213, 235]]], ["Here, we contribute to this developing toolbox for disease forecasting a model to understand how societal learning affects the expected final size and duration of disease outbreak.", [["disease", "PROBLEM", 51, 58], ["disease outbreak", "PROBLEM", 163, 179], ["size", "OBSERVATION_MODIFIER", 142, 146]]], ["Though some computational disease-specific models have recognized the importance of time-varying rates in disease spread, particularly with respect to the outbreak of SARS in 2003 [14], [15] (compare [16]), we believe this is the first analytical treatment of the concept.IntroductionWe also retrospectively explore the effect of societal learning during the 2003 outbreak of SARS in Singapore, using weekly data on the time between onset of symptoms and removal of infectious individuals.", [["SARS", "DISEASE", 167, 171], ["SARS", "DISEASE", 376, 380], ["some computational disease", "PROBLEM", 7, 33], ["disease spread", "PROBLEM", 106, 120], ["SARS", "PROBLEM", 167, 171], ["societal learning", "TREATMENT", 330, 347], ["symptoms", "PROBLEM", 442, 450], ["removal", "TREATMENT", 455, 462], ["infectious individuals", "PROBLEM", 466, 488], ["computational disease", "OBSERVATION", 12, 33], ["infectious", "OBSERVATION", 466, 476]]], ["We speculate that societal learning will generally exhibit diminishing returns because increasing the removal rate becomes more difficult as individual isolation approaches a theoretical maximum rate.", [["the removal rate", "TREATMENT", 98, 114]]], ["Finally, we discuss societal and epidemiological factors that might affect societal learning, we observe that a difficult task during the early stages of an outbreak is to estimate the learning rate and suggest that the rate estimated here might be used as prior information in future outbreaks, and we conclude by recommending rapid investment in research at the time of initial detection when actions taken to reduce disease spread can be most efficient and cost effective.IntroductionPublic health officials routinely make judgments whether or not to raise alarms about developing outbreaks.", [["a difficult task", "PROBLEM", 110, 126], ["the rate", "TEST", 216, 224], ["initial detection", "TEST", 372, 389], ["disease spread", "PROBLEM", 419, 433]]], ["This decision is complicated by severe uncertainty during the early phases of an outbreak.", [["severe", "OBSERVATION_MODIFIER", 32, 38], ["uncertainty", "OBSERVATION", 39, 50]]], ["Further, bureaucratic inertia and the ignorance that necessarily accompanies emerging infections discourage rapid response.", [["infections", "DISEASE", 86, 96], ["bureaucratic inertia", "PROBLEM", 9, 29], ["emerging infections", "PROBLEM", 77, 96], ["bureaucratic inertia", "OBSERVATION", 9, 29], ["infections", "OBSERVATION", 86, 96]]], ["By contrast, false alarms resulting from hasty and premature assessment of outbreak risk can be very costly, and must be avoided if possible.", [["false alarms", "TEST", 13, 25], ["hasty and premature assessment", "PROBLEM", 41, 71], ["false alarms", "OBSERVATION", 13, 25]]], ["Understanding the role of societal learning in disease outbreaks is important for properly balancing these competing objectives.Basic theoretical model ::: MethodsOur concept of societal learning is characteristically reflected in outbreak dynamics as an increase over time in the rate at which infectious individuals are removed from circulating in the population.", [["individuals", "ORGANISM", 306, 317], ["increase", "OBSERVATION_MODIFIER", 255, 263], ["infectious", "OBSERVATION", 295, 305]]], ["That is, we expect that as information about clinical symptoms, modes of transmission, the duration of incubation, etc., is collected and disseminated, the average time between the onset of symptoms and individual self-removal from the population (for instance by admission to hospital) or forced isolation (e.g., quarantine) will decline.", [["clinical symptoms", "PROBLEM", 45, 62], ["symptoms", "PROBLEM", 190, 198], ["individual self-removal", "TREATMENT", 203, 226], ["forced isolation", "TREATMENT", 290, 306]]], ["From a dynamical perspective, we represent the average removal rate of individual cases as a function of time since the outbreak began, marked by the time at which the index case became infectious.", [["the average removal rate", "TREATMENT", 43, 67], ["infectious", "PROBLEM", 186, 196], ["infectious", "OBSERVATION", 186, 196]]], ["For emerging diseases we assume that direct transmission between infected persons is the primary source of infection and that development of immunity and removing infectious individuals have negligible impact on the susceptible population.", [["infection", "DISEASE", 107, 116], ["persons", "ORGANISM", 74, 81], ["persons", "SPECIES", 74, 81], ["emerging diseases", "PROBLEM", 4, 21], ["direct transmission between infected persons", "PROBLEM", 37, 81], ["infection", "PROBLEM", 107, 116], ["infectious individuals", "PROBLEM", 163, 185], ["the susceptible population", "PROBLEM", 212, 238], ["diseases", "OBSERVATION", 13, 21], ["infection", "OBSERVATION", 107, 116]]], ["These assumptions are reasonable for outbreaks that ultimately do not infect more than a small fraction of the total population, i.e., emerging infections with relatively low prevalence.", [["infections", "DISEASE", 144, 154], ["outbreaks", "PROBLEM", 37, 46], ["emerging infections", "PROBLEM", 135, 154], ["small", "OBSERVATION_MODIFIER", 89, 94], ["fraction", "OBSERVATION_MODIFIER", 95, 103], ["total", "OBSERVATION_MODIFIER", 111, 116], ["population", "OBSERVATION", 117, 127], ["infections", "OBSERVATION", 144, 154]]], ["Thus, representing the individual rate of infection by the constant parameter \u03b20 and the rate of removal as a function of time \u03b3(t), these assumptions imply that the growth of the epidemic is a time-inhomogeneous stochastic birth-death chain [18]\u2013[20].", [["infection", "DISEASE", 42, 51], ["death", "DISEASE", 230, 235], ["infection", "PROBLEM", 42, 51], ["removal", "TREATMENT", 97, 104], ["infection", "OBSERVATION", 42, 51]]], ["Accordingly, the change over time in the probability distribution of the number of infected individuals x is given by", [["infected individuals", "PROBLEM", 83, 103], ["change", "OBSERVATION_MODIFIER", 17, 23], ["infected", "OBSERVATION", 83, 91]]]], "37a32915a57d6b950b015dce218e9bc7340ef55e": [["A novel mutation resulting in keratin 1-linked palmoplantar keratoderma with epidermolytic 47 ichthyosis 48", [["palmoplantar keratoderma", "DISEASE", 47, 71], ["ichthyosis", "DISEASE", 94, 104], ["keratin 1", "GENE_OR_GENE_PRODUCT", 30, 39], ["keratin 1", "PROTEIN", 30, 39], ["A novel mutation", "PROBLEM", 0, 16], ["linked palmoplantar keratoderma", "PROBLEM", 40, 71], ["epidermolytic 47 ichthyosis", "PROBLEM", 77, 104], ["palmoplantar", "OBSERVATION_MODIFIER", 47, 59], ["keratoderma", "OBSERVATION", 60, 71]]]], "PMC7213621": [["AcknowledgementsThe authors thank the collaborators who participated in the original investigations during the 2002 to 2003 SARS outbreak.FundingThis work was supported by grants from the National Key Research and Development Program Projects of China (No. 2017YFD0500305), the National Key Program for Infectious Disease of China (No. 2018ZX10101002-002), the State Key Program of National Natural Science of China (No.", [["SARS", "DISEASE", 124, 128], ["Infectious Disease", "DISEASE", 303, 321], ["Infectious", "OBSERVATION", 303, 313]]], ["U1808202), Guangdong Province Key Area R & D Plan Project (No. 2018B020241002), and the Guangdong Provincial Science and Technology Project (No. 2018B020207013).Conflicts of interestNone.", [["U1808202", "CHEMICAL", 0, 8], ["U1808202", "CHEMICAL", 0, 8]]]], "662a1868c0caf453ecbb56174cb3a7190a98318d": [["IntroductionIn [1] the outbreak of COVID-19 pandemic causing severe health concerns and consequences for health care services worldwide has been described in a catchy way.", [["COVID-19", "CHEMICAL", 35, 43], ["COVID-19", "ORGANISM", 35, 43], ["COVID", "TREATMENT", 35, 40], ["severe health concerns", "PROBLEM", 61, 83]]], ["Furthermore, the importance of distinguishing patients that require immediate medical attention is described and that there is a lack of capacity to identify cases at imminent risk of death.", [["death", "DISEASE", 184, 189], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["death", "PROBLEM", 184, 189]]], ["So far, no prognostic biomarkers have been available to estimate the patients risks.IntroductionConsequently, the research group in [1] analysed blood samples of 485 patients from the region of Wuhan, China.", [["blood samples", "ANATOMY", 145, 158], ["patients", "ORGANISM", 69, 77], ["blood samples", "ORGANISM_SUBSTANCE", 145, 158], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 166, 174], ["prognostic biomarkers", "TEST", 11, 32], ["blood samples", "TEST", 145, 158]]], ["Most crucial biomarkers have been revealed through optimization of a supervised XGBoost classifier [5] .", [["Most crucial biomarkers", "TEST", 0, 23], ["a supervised XGBoost classifier", "TREATMENT", 67, 98]]], ["Three key features have been derived: lactic dehydrogenase (LDH), lymphocytes and high-sensitivity c-reactive protein (hs-CRP).", [["lymphocytes", "ANATOMY", 66, 77], ["lactic dehydrogenase", "GENE_OR_GENE_PRODUCT", 38, 58], ["LDH", "GENE_OR_GENE_PRODUCT", 60, 63], ["lymphocytes", "CELL", 66, 77], ["high-sensitivity c-reactive protein", "GENE_OR_GENE_PRODUCT", 82, 117], ["hs-CRP", "GENE_OR_GENE_PRODUCT", 119, 125], ["lactic dehydrogenase", "PROTEIN", 38, 58], ["LDH", "PROTEIN", 60, 63], ["lymphocytes", "CELL_TYPE", 66, 77], ["high-sensitivity c-reactive protein", "PROTEIN", 82, 117], ["hs", "PROTEIN", 119, 121], ["CRP", "PROTEIN", 122, 125], ["lactic dehydrogenase (LDH)", "PROBLEM", 38, 64], ["lymphocytes", "TEST", 66, 77], ["c-reactive protein", "TEST", 99, 117], ["CRP", "TEST", 122, 125], ["lymphocytes", "ANATOMY", 66, 77]]], ["Both classifiers are transparent in explaining a specific input transformation to a specific classification output.", [["a specific input transformation", "PROBLEM", 47, 78], ["transparent", "OBSERVATION_MODIFIER", 21, 32]]], ["The classifier FIS is different from the two others (decTree, SVM) as its output esteems the grade about how much the input belongs to one of two classes (positive, neagtive) specified as patient outcome in the data samples.", [["patient", "ORGANISM", 188, 195], ["FIS", "DNA", 15, 18], ["patient", "SPECIES", 188, 195], ["the data samples", "TEST", 207, 223], ["different", "OBSERVATION_MODIFIER", 22, 31]]], ["This may be an advantageous property when predicting the patients risk value.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65]]], ["In the following I shall describe the development and evaluation of the Fuzzy classifier.IntroductionThere are also many possibilities for feature analysis and selection.", [["evaluation", "TEST", 54, 64], ["feature analysis", "TEST", 139, 155]]], ["In my approach I put emphasis on finding those features that show signatures similar to the patient outcome and that are little to not correlated.", [["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99]]], ["Artificial neural networks of type Kohonen can be used to map the distribution of features in the feature space into 2D component planes (maps) revealing the signature of the according feature (Self Organizing Maps SOM [6] ) .", [["neural networks", "ANATOMY", 11, 26], ["neural networks", "MULTI-TISSUE_STRUCTURE", 11, 26], ["type Kohonen", "TREATMENT", 30, 42]]], ["These maps can be compared visually and those maps similar to the map of patient outcome can be identified for feature selection.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["These maps", "TEST", 0, 10], ["those maps", "TEST", 40, 50]]], ["In addition, correlation analysis about the features can be used to determine the minimum feature set covering the feature space in an efficient way, e.g. in terms of a minimum dominant set (MDS).", [["MDS", "DISEASE", 191, 194], ["correlation analysis", "TEST", 13, 33]]], ["Furthermore, two other features (Albumin, International Standard Ratio) have been proposed and than used with the FIS classifier in an extended analysis.IntroductionIf one looks at the determined biomarker values in the data base created by [1] , one will of course notice a change in the biomarkers from the day of admission to the discharge from the hospital.", [["Albumin", "GENE_OR_GENE_PRODUCT", 33, 40], ["Albumin", "TEST", 33, 40], ["an extended analysis", "TEST", 132, 152], ["a change", "PROBLEM", 273, 281], ["the biomarkers", "TEST", 285, 299]]], ["It is therefore obvious to consider the trend of the biomarkers over time to the last value in the risk assessment.", [["the biomarkers", "TEST", 49, 63], ["the risk assessment", "TEST", 95, 114]]], ["This is successfully examined here with an expansion of the Fuzzy model.Data resourcesBasically, all data for feature analysis as well as for training and testing the classifiers (SVM, FIS) have been taken from the original data base provided by [1] .", [["feature analysis", "TEST", 110, 126], ["expansion", "OBSERVATION_MODIFIER", 43, 52], ["Fuzzy model", "OBSERVATION", 60, 71]]], ["This data base contains two files with sample data taken from patients: 1) time series 375 prerpocess en.xlsx (in the following: train data) and 2) external test data time series test 110 preprocess en.xlsx (in the following: test data). train data collects 74 biomarkers (features) together with age, gender, data sample time, admission time, discharge time, and class of patient outcome (alive, deceased) for 375 patients. test data collects three biomarkers (key features) together with data sample time, admission time, discharge time, and class of patient outcome for 110 patients.Data resources.", [["patients", "ORGANISM", 62, 70], ["patient", "ORGANISM", 373, 380], ["patients", "ORGANISM", 415, 423], ["patient", "ORGANISM", 553, 560], ["patients", "ORGANISM", 577, 585], ["patients", "SPECIES", 62, 70], ["patient", "SPECIES", 373, 380], ["patients", "SPECIES", 415, 423], ["patient", "SPECIES", 553, 560], ["patients", "SPECIES", 577, 585], ["sample data", "TEST", 39, 50], ["external test data", "TEST", 148, 166], ["series test", "TEST", 172, 183], ["test data", "TEST", 226, 235], ["train data", "TEST", 238, 248], ["test data", "TEST", 425, 434], ["three biomarkers", "TEST", 444, 460]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Data resourcesThe copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.14.20130732 doi: medRxiv preprintData resourcesIn [1] only data of the final feature samples per patient is used for training and testing of the rule decision classifier decTree.", [["CC", "CHEMICAL", 0, 2], ["samples", "CANCER", 409, 416], ["patient", "ORGANISM", 421, 428], ["patient", "SPECIES", 421, 428], ["ND", "PROBLEM", 9, 11], ["medRxiv preprintData resourcesIn", "TREATMENT", 341, 373], ["testing", "TEST", 454, 461], ["med", "ANATOMY", 105, 108]]], ["There are also some patients with incomplete measurements for at least one of the selected key features leaving 351 patients in data base train data, and 110 patients in data base test data.", [["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 116, 124], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 158, 166], ["data base train data", "TEST", 128, 148], ["data base test data", "TEST", 170, 189]]], ["The distribution of patient outcome (classes alive \u2261 negative, deceased \u2261 positive) over the key feature space are depicted in Figure 1 and Figure 2 , resp.", [["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.14.20130732 doi: medRxiv preprintFeature analysisIn [1] feature analysis resulted in determination of three key features (lactic dehydrogenase, lymphocytes, and high-sensitivity c-reactive protein) out of 10 most promising features found with optimal XGBoost classifier output.", [["lymphocytes", "ANATOMY", 453, 464], ["CC", "CHEMICAL", 0, 2], ["lactic dehydrogenase", "GENE_OR_GENE_PRODUCT", 431, 451], ["lymphocytes", "CELL", 453, 464], ["lactic dehydrogenase", "PROTEIN", 431, 451], ["lymphocytes", "CELL_TYPE", 453, 464], ["high-sensitivity c-reactive protein", "PROTEIN", 470, 505], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["feature analysis", "TEST", 365, 381], ["lactic dehydrogenase", "TEST", 431, 451], ["lymphocytes", "TEST", 453, 464], ["high-sensitivity c-reactive protein)", "PROBLEM", 470, 506], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Here, feature analysis is carried out in two steps: 1) a Kohonen neural network (SOM) is used for transforming the feature data into component planes CP, and 2) a Greedy algorithm is used for finding the minimum dominant set MDS of features based on their mutual correlation.", [["neural network", "MULTI-TISSUE_STRUCTURE", 65, 79], ["feature analysis", "TEST", 6, 22], ["a Kohonen neural network", "TREATMENT", 55, 79], ["a Greedy algorithm", "TEST", 161, 179]]], ["Both, CP and MDS can be rendered and visually inspected.", [["MDS", "DISEASE", 13, 16], ["CP", "PROBLEM", 6, 8], ["MDS", "TREATMENT", 13, 16]]], ["Figure 3 shows the component maps of 10 features selected by [1] after training SOM with 344 complete data samples in train data.", [["the component maps", "TEST", 15, 33], ["training SOM", "TREATMENT", 71, 83], ["train data", "TEST", 118, 128]]], ["The map size of SOM was 8 \u00b7 3 = 24 neurons.", [["neurons", "ANATOMY", 35, 42], ["neurons", "CELL", 35, 42], ["The map size", "TEST", 0, 12], ["SOM", "TEST", 16, 19], ["size", "OBSERVATION_MODIFIER", 8, 12]]], ["The component planes represent the weights of the respective feature in each neuron (hexagon) of the SOM map.", [["neuron", "ANATOMY", 77, 83], ["component", "OBSERVATION_MODIFIER", 4, 13], ["planes", "OBSERVATION_MODIFIER", 14, 20]]], ["Each map position (hexagon) represents the weight value in color, and together with its neighbours around it corresponds with similar feature vectors of the training set.", [["the weight value", "TEST", 39, 55]]], ["A good approach for analyzing is to look for boundaries and color changes in a component plane and similar situations in other planes (colors must not be similar).", [["color changes", "PROBLEM", 60, 73], ["good", "OBSERVATION_MODIFIER", 2, 6]]], ["In this way we recognize good matches in Figure 3 between patient outcome, Lactate dehydrogenase, %lymphozyte, hypersensitive c-reactive protein, and with some restrictions also albumin, and International standard ratio.", [["Lactate", "CHEMICAL", 75, 82], ["Lactate", "CHEMICAL", 75, 82], ["patient", "ORGANISM", 58, 65], ["Lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 75, 96], ["lymphozyte", "SIMPLE_CHEMICAL", 99, 109], ["albumin", "GENE_OR_GENE_PRODUCT", 178, 185], ["Lactate dehydrogenase", "PROTEIN", 75, 96], ["lymphozyte", "PROTEIN", 99, 109], ["hypersensitive c-reactive protein", "PROTEIN", 111, 144], ["albumin", "PROTEIN", 178, 185], ["patient", "SPECIES", 58, 65], ["Lactate dehydrogenase", "TEST", 75, 96], ["lymphozyte", "TEST", 99, 109], ["hypersensitive c-reactive protein", "PROBLEM", 111, 144], ["albumin", "TEST", 178, 185], ["International standard ratio", "TEST", 191, 219], ["good", "OBSERVATION_MODIFIER", 25, 29], ["reactive protein", "OBSERVATION", 128, 144]]], ["The first three features correspond to the key features selected for decTree and replicate the results of XGBoost classifier.Feature analysisThe second step of our feature analysis is to find the minimum dominant set MDS of features.", [["MDS", "DISEASE", 217, 220], ["XGBoost classifier", "TREATMENT", 106, 124], ["Feature analysis", "TEST", 125, 141], ["our feature analysis", "TEST", 160, 180]]], ["For this, the mutual correlation of feature elements are evaluated and a greedy algorithm searches MDS after determination a threshold for mutual feature correlation [7] .", [["MDS", "DISEASE", 99, 102], ["feature elements", "DNA", 36, 52]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.14.20130732 doi: medRxiv preprint 4 Building a prediction model [1] used a decision tree decTree to predict patients at the highest risk.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 417, 425], ["patients", "SPECIES", 417, 425], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint", "TREATMENT", 326, 342], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Even if the classifier performance is good enough to be used in a operable environment the binary output of decTree conceals the grade to which a patient's feature vector belongs to one of the classes positive or negative.", [["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["negative", "OBSERVATION", 213, 221]]], ["I assume a human decision maker would prefer to refer to the technical estimation of risk grades when finally deciding about the risk and clinical treatment of patients.", [["human", "ORGANISM", 11, 16], ["patients", "ORGANISM", 160, 168], ["human", "SPECIES", 11, 16], ["patients", "SPECIES", 160, 168], ["human", "SPECIES", 11, 16], ["clinical treatment", "TREATMENT", 138, 156]]], ["Furthermore, the mapping of feature elements by humans likely will rather be in terms like small, high, or something unsharp like that than in sharply defined intervals.", [["humans", "ORGANISM", 48, 54], ["feature elements", "DNA", 28, 44], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 48, 54], ["small", "OBSERVATION_MODIFIER", 91, 96], ["high", "OBSERVATION_MODIFIER", 98, 102]]], ["Fuzzy systems enable the description of models based on Fuzzy rules of type R i : IFx 1 is small AND x 2 is large . . .", [["Fuzzy systems", "PROBLEM", 0, 13], ["IFx", "TEST", 82, 85], ["IFx", "OBSERVATION", 82, 85], ["small", "OBSERVATION_MODIFIER", 91, 96], ["large", "OBSERVATION_MODIFIER", 108, 113]]], ["T HEN y i is small with input vector X = (x1, x2, . . .) t in the premise (IF) part and output y i in the conclusion (T HEN) part .", [["small", "OBSERVATION_MODIFIER", 13, 18]]], ["Building up a Fuzzy model requires first the definition of unsharp terms like small, medium, . . ., so called Fuzzy terms, covering the input elements (fuzzyfication) and second the generation of the rule base R = {R i |i = 1, 2, . . . , N} describing the complete mapping of the input space into the output function.", [["small", "OBSERVATION_MODIFIER", 78, 83], ["output function", "OBSERVATION", 301, 316]]], ["Finally, the mapping of the rule's outputs y i (accumulation and defuzzyfication) into a sharp output value y = f (y i |i : 1, . . . , N), y \u2208 R has to be established.", [["N", "CHEMICAL", 135, 136], ["defuzzyfication", "TEST", 65, 80], ["a sharp output", "TEST", 87, 101]]], ["Fortunately, there are a lot of machine learning tools that can automatically generate an operable Fuzzy model from a training data set (supervised learning).(which was not certified by peer review)I used a Sugeno-type Fuzzy modell (there is no need for defuzzyfication) and Matlab\u00a9 function ANFIS for generating and training of the Fuzzy model.", [["defuzzyfication", "PROBLEM", 254, 269], ["Matlab\u00a9 function ANFIS", "TEST", 275, 297], ["no need for", "UNCERTAINTY", 242, 253]]], ["With train data and three key features as input ANFIS creates a Fuzzy model FIS with three Fuzzy terms per input (feature) element and N = 3 3 = 27 rules.", [["ANFIS", "DNA", 48, 53], ["Fuzzy model FIS", "DNA", 64, 79], ["train data", "TEST", 5, 15]]], ["The model is trained by ANFIS with 10 epochs and train data with all 351 patient's final data samples only.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["ANFIS", "TEST", 24, 29], ["train data", "TEST", 49, 59]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.14.20130732 doi: medRxiv preprint results of FIS for validation with train data.", [["CC", "CHEMICAL", 0, 2], ["FIS", "DNA", 354, 357], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["validation with train data", "TEST", 362, 388], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Figure 6 shows the results of classifier FIS with external test data test data (patient's final data samples only).", [["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["external test data test data", "TEST", 50, 78], ["patient's final data samples", "TEST", 80, 108]]], ["The performance data of this FIS classifier are also displayed in Table 1 (column FIS 3) in section 5. .", [["FIS classifier", "DNA", 29, 43]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.14.20130732 doi: medRxiv preprintEstimation of prediction outputThere are various possibilities for improvement of the FIS classifier.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["prediction output", "TEST", 356, 373], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In general, a Fuzzy system enables to create any nonlinear function or mapping of the input space.", [["input space", "OBSERVATION", 86, 97]]], ["From a system perspective one can increase the number of Fuzzy terms for the input and/or output variables thus enlarging the rule base and getting a more detailed function approximation, but at the risk of model overfitting.", [["output variables", "PROBLEM", 90, 106], ["enlarging the rule base", "PROBLEM", 112, 135], ["model overfitting", "PROBLEM", 207, 224], ["enlarging", "OBSERVATION_MODIFIER", 112, 121], ["base", "ANATOMY_MODIFIER", 131, 135], ["overfitting", "OBSERVATION", 213, 224]]], ["From a problem perspective one can consider an increased number of input variables -if not already optimally chosen by feature analysis.", [["feature analysis", "TEST", 119, 135], ["increased", "OBSERVATION_MODIFIER", 47, 56]]], ["For evaluation of the classifier results the following performances measures have been considered based on [1] : total number of classification errors E, AUC score of ROC curve, precision Pre = T P/(T P + FP), recall Rec = T P/(T P + FN), and accuracy Acc = (T P + T N)/(T P + T N + FP + FN); TP, TN, FP and FN stand for true positive, true negative, false positive and false negative rates, respectively.Estimation of prediction outputAs mentioned in section 3 there are two other features with good resemblance to patient outcome: albumin and International standard ratio.", [["TP", "GENE_OR_GENE_PRODUCT", 293, 295], ["patient", "ORGANISM", 516, 523], ["albumin", "GENE_OR_GENE_PRODUCT", 533, 540], ["FN", "PROTEIN", 234, 236], ["FP", "PROTEIN", 283, 285], ["FN", "PROTEIN", 288, 290], ["TP", "PROTEIN", 293, 295], ["TN", "PROTEIN", 297, 299], ["FN", "PROTEIN", 308, 310], ["patient", "SPECIES", 516, 523], ["evaluation", "TEST", 4, 14], ["AUC score", "TEST", 154, 163], ["ROC curve", "TEST", 167, 176], ["precision", "TEST", 178, 187], ["P", "TEST", 196, 197], ["P", "TEST", 201, 202], ["FP", "TEST", 205, 207], ["recall", "TEST", 210, 216], ["Rec", "TEST", 217, 220], ["P", "TEST", 225, 226], ["P", "TEST", 230, 231], ["FN", "TEST", 234, 236], ["accuracy", "TEST", 243, 251], ["Acc", "TEST", 252, 255], ["T", "TEST", 259, 260], ["P", "TEST", 261, 262], ["T", "TEST", 271, 272], ["P", "TEST", 273, 274], ["FP", "TEST", 283, 285], ["FN", "TEST", 288, 290], ["TP", "TEST", 293, 295], ["TN", "TEST", 297, 299], ["FP", "TEST", 301, 303], ["FN stand", "TEST", 308, 316], ["true", "TEST", 321, 325], ["true", "TEST", 336, 340], ["albumin", "TEST", 533, 540], ["International standard ratio", "TEST", 545, 573], ["TP", "ANATOMY", 293, 295], ["TN", "ANATOMY", 297, 299], ["false positive", "OBSERVATION", 351, 365], ["false negative", "OBSERVATION", 370, 384]]], ["I trained a FIS classifier with now five feature elements. train data contains in total 344 complete final data samples with the selected five features.", [["samples", "CANCER", 112, 119], ["FIS classifier", "DNA", 12, 26], ["train data", "TEST", 59, 69]]], ["Validation results with this FIS classifier are displayed in column FIS 5 in Table 1 .", [["FIS classifier", "DNA", 29, 43]]], ["We see a slight improvement in all performance measures.", [["slight", "OBSERVATION_MODIFIER", 9, 15], ["improvement", "OBSERVATION_MODIFIER", 16, 27]]], ["Unfortunately test data doesn't contain these additional features and therefore a test with the external test data was not possible.Estimation of prediction outputEven as a medical layperson, it can be assumed that the patient's physiological state and the health risk can also be judged by the development of the biomarkers and not only by their last value.", [["patient", "ORGANISM", 219, 226], ["patient", "SPECIES", 219, 226], ["test data", "TEST", 14, 23], ["a test", "TEST", 80, 86], ["the external test data", "TEST", 92, 114], ["the biomarkers", "TEST", 310, 324]]], ["Therefore, I tried to include the biomarkers' trend in time into the model for risk assessment.", [["the biomarkers", "TEST", 30, 44], ["risk assessment", "TEST", 79, 94]]], ["However, it is now the case here that the blood samples and thus the biomarkers in the data records were not systematically recorded over time.", [["blood samples", "ANATOMY", 42, 55], ["blood samples", "ORGANISM_SUBSTANCE", 42, 55], ["the blood samples", "TEST", 38, 55], ["the biomarkers", "TEST", 65, 79]]], ["The FIS model FIS 3 with the three key features is used as the model basis and the input vector is expanded with the features' trend values.Validation and test results with this FIS classifier are displayed in column FIS trend in Table 1 .", [["FIS model FIS 3", "DNA", 4, 19], ["FIS classifier", "DNA", 178, 192], ["The FIS model FIS", "TEST", 0, 17], ["Validation and test results", "TEST", 140, 167], ["this FIS classifier", "TEST", 173, 192]]], ["These results were achieved regardless of whether the trend of one, two or all three key features was used in the FIS model FIS trend.Estimation of prediction outputSince the blood values were obviously not systematically recorded, only 195 trend values could be determined in train data for training and validation, and only 79 in test data for testing the classifier.", [["blood", "ANATOMY", 175, 180], ["blood", "ORGANISM_SUBSTANCE", 175, 180], ["the blood values", "TEST", 171, 187], ["validation", "TEST", 305, 315], ["test data", "TEST", 332, 341], ["testing", "TEST", 346, 353]]], ["And thus the results are not similarly representative like those of the other models FIS 3 and FIS 5. .", [["FIS 5", "DNA", 95, 100]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.14.20130732 doi: medRxiv preprintDiscussionThis study shows the potential of Fuzzy models for the risk assessment of COVID-19 patients in several ways.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 435, 443], ["patients", "SPECIES", 435, 443], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprintDiscussion", "TREATMENT", 326, 352], ["This study", "TEST", 352, 362], ["the risk assessment", "TEST", 403, 422], ["COVID", "TEST", 426, 431], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["First of all, the results in [1] could be replicated and at the same time an improvement of the risk assessment could be achieved.", [["the risk assessment", "TEST", 92, 111]]], ["The consideration of the temporal development of the biomarkers in the models had a decisive influence on the model performance.", [["the biomarkers", "TEST", 49, 63], ["temporal", "OBSERVATION_MODIFIER", 25, 33]]], ["However, this could not be tested in detail because the training and external test data contained too few examples and in particular the blood samples had not been recorded systematically over time.DiscussionIn addition, a non-binary risk assessment has been introduced.", [["blood samples", "ANATOMY", 137, 150], ["blood samples", "ORGANISM_SUBSTANCE", 137, 150], ["external test data", "TEST", 69, 87], ["the blood samples", "TEST", 133, 150], ["a non-binary risk assessment", "TEST", 221, 249]]], ["If one looks at the real risk values that model FIS 3 calculates for the external test data, one can see that the wrongly classified items in most cases are very close to the decision limit 0.5 for binarization.", [["FIS 3", "DNA", 48, 53], ["the external test data", "TEST", 69, 91]]], ["Figures 7 and 8 show the statistical values of the risk assessment with the training and test data using boxplots.", [["Figures", "TEST", 0, 7], ["the risk assessment", "TEST", 47, 66], ["the training", "TEST", 72, 84], ["test data", "TEST", 89, 98], ["boxplots", "TREATMENT", 105, 113]]], ["After assigning the incorrectly classified examples (FN = 2, FP = 1 in Figure 8 ), the associated boxplot shows that the real output values are close to the decision value 0.5 and can therefore be better assessed by a medical expert than the wrong binary decision.", [["FN", "TEST", 53, 55], ["FP", "TEST", 61, 63], ["the real output values", "TEST", 117, 139]]], ["The continuous model output enables further opportunities for technical support for medical experts in COVID-19 risk assessment.ConclusionIn summary, this study introduces a Fuzzy logic based prediction system for COVID-19 risk assessment with improved performance compared with other approaches in literature ( [1] ).", [["technical support", "TREATMENT", 62, 79], ["COVID", "TEST", 103, 108], ["risk assessment", "TEST", 112, 127], ["this study", "TEST", 150, 160], ["COVID", "TEST", 214, 219], ["risk assessment", "TEST", 223, 238]]], ["This provides a good basis for the development of a transparent and operational system for .", [["a transparent and operational system", "TREATMENT", 50, 86]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)ConclusionThe copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.14.20130732 doi: medRxiv preprint risk assessment of COVID-19 patients.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 382, 390], ["patients", "SPECIES", 382, 390], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 212, 232], ["COVID", "TEST", 373, 378], ["med", "ANATOMY", 105, 108]]], ["In addition to the selection and consideration of the final biomarker or feature elements, a model extension is also successfully tested that takes their changes over time into account.", [["a model extension", "PROBLEM", 91, 108]]], ["The model output is non-binary and is therefore particularly suitable for a decisive interpretation by medical experts.", [["The model output", "TEST", 0, 16], ["output", "OBSERVATION_MODIFIER", 10, 16]]], ["A further investigation of the time horizon of the risk assessment was initially not carried out since the blood samples were not recorded systematically in the currently available training and test data.", [["blood samples", "ANATOMY", 107, 120], ["blood samples", "ORGANISM_SUBSTANCE", 107, 120], ["A further investigation", "TEST", 0, 23], ["the risk assessment", "TEST", 47, 66], ["the blood samples", "TEST", 103, 120], ["test data", "TEST", 194, 203]]]], "22d52f6dd0a34849278420b06ef136db7e9a8a38": [["IntroductionThe SARS-CoV-2 virus causes the coronavirus disease 2019 (COVID-19), with varying degrees of illness that include the frequent requirement of mechanical ventilation and high mortality in the elderly.", [["coronavirus disease", "DISEASE", 44, 63], ["illness", "DISEASE", 105, 112], ["SARS-CoV-2 virus", "ORGANISM", 16, 32], ["coronavirus", "ORGANISM", 44, 55], ["CoV-2 virus", "SPECIES", 21, 32], ["coronavirus", "SPECIES", 44, 55], ["SARS-CoV-2 virus", "SPECIES", 16, 32], ["The SARS", "TEST", 12, 20], ["CoV", "TEST", 21, 24], ["the coronavirus disease", "PROBLEM", 40, 63], ["COVID", "TEST", 70, 75], ["varying degrees of illness", "PROBLEM", 86, 112], ["mechanical ventilation", "TREATMENT", 154, 176], ["coronavirus disease", "OBSERVATION", 44, 63], ["illness", "OBSERVATION", 105, 112], ["mechanical ventilation", "OBSERVATION", 154, 176]]], ["After the initial outbreak in China, it is now causing a pandemic with severe economic and health consequences.", [["a pandemic with severe economic and health consequences", "PROBLEM", 55, 110], ["severe", "OBSERVATION_MODIFIER", 71, 77]]], ["1 The key factors influencing the spread of the new SARS-CoV-2 virus are mostly unknown.", [["SARS", "DISEASE", 52, 56], ["SARS-CoV-2 virus", "ORGANISM", 52, 68], ["CoV-2 virus", "SPECIES", 57, 68], ["SARS-CoV-2 virus", "SPECIES", 52, 68], ["the new SARS", "TEST", 44, 56], ["CoV-2 virus", "PROBLEM", 57, 68]]], ["2 The higher incidence of COVID-19 cases in inland territories (e.g., Wuhan, Lombardy, Madrid), as opposed to coastal territories, suggests that climatological factors might influence the course of the pandemic.", [["COVID", "DISEASE", 26, 31], ["climatological factors", "PROTEIN", 145, 167], ["COVID", "TEST", 26, 31], ["climatological factors", "PROBLEM", 145, 167], ["the pandemic", "PROBLEM", 198, 210], ["higher", "OBSERVATION_MODIFIER", 6, 12]]], ["This is further supported by the seasonal nature of other betacoronaviruses, 3 and by previous research showing that environmental variables, such as high temperatures and high humidity, slowed the influenza spread.", [["influenza", "DISEASE", 198, 207], ["other betacoronaviruses", "PROBLEM", 52, 75], ["high temperatures", "PROBLEM", 150, 167], ["high humidity", "PROBLEM", 172, 185], ["the influenza spread", "PROBLEM", 194, 214], ["high humidity", "OBSERVATION", 172, 185], ["influenza spread", "OBSERVATION", 198, 214]]], ["4 Accordingly, some have suggested that COVID-19 will subside with the warmer weather expected in the Northern Hemisphere in the coming months, 5 while others claim that the effect of increasing temperatures and humidity during the summer will likely be modest, and not enough to stop transmission.", [["COVID", "TEST", 40, 45], ["increasing temperatures", "PROBLEM", 184, 207], ["humidity", "TREATMENT", 212, 220]]], ["Learning about the factors influencing COVID-19 spreading could help anticipate the extent of its consequences and guide governments in the design of mitigation measures worldwide.", [["mitigation measures", "TREATMENT", 150, 169]]], ["7 Here, we studied whether differences in the occurrence of COVID-19 disease are associated with well-defined climatological factors, as well as population density.", [["climatological factors", "PROTEIN", 110, 132], ["COVID-19 disease", "PROBLEM", 60, 76], ["well-defined climatological factors", "PROBLEM", 97, 132], ["disease", "OBSERVATION", 69, 76], ["climatological factors", "OBSERVATION", 110, 132], ["population", "OBSERVATION_MODIFIER", 145, 155], ["density", "OBSERVATION", 156, 163]]], ["For this purpose, we correlated the number of COVID-19 cases in the first weeks of the epidemic in each country and region with matching geolocalized information on climatological measurements in the same period.IntroductionA c c e p t e d M a n u s c r i p tInformation on COVID-19The datasets on the number of COVID-19 affected persons around the world were the country for each region.", [["persons", "ORGANISM", 330, 337], ["persons", "SPECIES", 330, 337], ["COVID", "TEST", 46, 51], ["climatological measurements", "TEST", 165, 192], ["tInformation", "TEST", 258, 270], ["COVID", "TEST", 274, 279]]], ["After determining the date in which the number of confirmed cases was \uf0b3 10 for each of the studied regions, we defined the beginning of the study period at day -7 to account for the incubation period of around one week and prolonged it until day +30 or the day of the analysis (March 23, 2020) if shorter.", [["the analysis", "TEST", 264, 276]]], ["1 We gathered information on population and density of each of the studied regions (available in Wikipedia from several sources) and calculated the cumulative incidence of COVID-19 / 100,000 inhabitants during the study period.Climatological measurementsWe accessed the Weatherbit application-programming interface (weatherbit.io) to compile geolocalized information on daily measures of the following weather variables: average relative humidity (%); average dew point (Celsius); average, maximum and minimum temperature (Celsius); average pressure (mb); average sea level pressure (mb); average wind speed (m/s); wind gust speed (m/s); maximum 2-minute wind speed (m/s); average wind direction (degrees); average cloud coverage (%); A c c e p t e d M a n u s c r i p t accumulated precipitation (mm); accumulated snowfall (mm); snow depth (mm); average diffuse horizontal solar irradiance (W/m 2 ); average global horizontal solar irradiance (W/m 2 ); maximum ultraviolet (UV) index (0-11+).Statistical analysisWe described the study variables through descriptive statistics and histograms.", [["COVID", "TEST", 172, 177], ["the study", "TEST", 210, 219], ["Climatological measurements", "TEST", 227, 254], ["average pressure (mb", "TEST", 533, 553], ["average sea level pressure", "TEST", 556, 582], ["mb", "TEST", 584, 586], ["average wind speed", "TEST", 589, 607], ["wind gust speed", "TEST", 615, 630], ["average cloud coverage", "TEST", 707, 729], ["a n u s", "TEST", 753, 760], ["accumulated precipitation", "PROBLEM", 771, 796], ["accumulated snowfall (mm)", "PROBLEM", 803, 828], ["average diffuse horizontal solar irradiance (W/m", "PROBLEM", 847, 895], ["average global horizontal solar irradiance", "PROBLEM", 901, 943], ["maximum ultraviolet (UV) index", "TEST", 954, 984], ["the study variables", "TEST", 1026, 1045], ["descriptive statistics", "TEST", 1054, 1076], ["histograms", "TEST", 1081, 1091], ["density", "OBSERVATION", 44, 51], ["diffuse", "OBSERVATION_MODIFIER", 855, 862], ["horizontal", "OBSERVATION_MODIFIER", 863, 873], ["solar irradiance", "OBSERVATION", 874, 890]]], ["The correlations between the primary outcome measure (incidence of COVID-19) and the mean and variance of each physical variable during the study period were studied with Spearman's rho correlation because of the asymmetric distribution of the incidence of COVID-19.", [["COVID-19", "CHEMICAL", 257, 265], ["COVID", "TEST", 67, 72], ["the study", "TEST", 136, 145], ["Spearman's rho correlation", "TEST", 171, 197], ["COVID", "TEST", 257, 262], ["asymmetric", "OBSERVATION_MODIFIER", 213, 223], ["distribution", "OBSERVATION_MODIFIER", 224, 236]]], ["The independent predictors of the (log-transformed) incidence of COVID-19Statistical analysiswere tested with multiple linear regression analysis.", [["COVID-19Statistical analysiswere", "TREATMENT", 65, 97], ["multiple linear regression analysis", "TEST", 110, 145]]], ["The parent geographical location was forced into the model (as dummy variables) in order to account for differentially distributed factors likely to influence the course of the epidemic.", [["the epidemic", "PROBLEM", 173, 185]]], ["Given the number of correlation tests, Bonferroni's correction was applied, and p values < 0.0025 were considered significant.", [["correlation tests", "TEST", 20, 37], ["Bonferroni's correction", "TREATMENT", 39, 62]]], ["We used Python 3.7.6 with the Numpy, Pandas, Matplotlib, and Seaborn libraries for the analyses.ResultsThe cumulative incidence of COVID-19 was highly variable across the world (medianDiscussionIt is unclear how the COVID-19 pandemic will spread and whether it will have a seasonal nature.", [["Python", "TREATMENT", 8, 14], ["Matplotlib", "TREATMENT", 45, 55], ["Seaborn libraries", "TREATMENT", 61, 78], ["the analyses", "TEST", 83, 95], ["COVID", "TEST", 131, 136], ["the COVID", "TEST", 212, 221]]], ["Efforts to combat the growth of SARS-CoV-2 are ubiquitous and rather overwhelming, from mandatory quarantines to imposed house confinement.", [["SARS", "DISEASE", 32, 36], ["SARS-CoV-2", "ORGANISM", 32, 42], ["SARS-CoV", "SPECIES", 32, 40], ["SARS", "PROBLEM", 32, 36]]], ["Evidence from previous studies in other viral diseases, such as influenza, suggests that temperature or humidity may have only limited influence on the spread of COVID-19 throughout the world.", [["viral diseases", "DISEASE", 40, 54], ["influenza", "DISEASE", 64, 73], ["previous studies", "TEST", 14, 30], ["other viral diseases", "PROBLEM", 34, 54], ["influenza", "PROBLEM", 64, 73], ["temperature or humidity", "PROBLEM", 89, 112], ["COVID", "TEST", 162, 167]]], ["6 Our results show that the influence of ultraviolet radiation may be more important than any other climatological factor in determining the spread of COVID-19 disease.DiscussionUVB radiation from sunlight (the primary source of UV radiation) is the principal environmentally effective virucide, several orders of magnitude more relevant than other primary physical factors, such as temperature and relative humidity.", [["ultraviolet", "CHEMICAL", 41, 52], ["DiscussionUVB", "CHEMICAL", 168, 181], ["COVID-19", "CANCER", 151, 159], ["COVID-19", "SPECIES", 151, 159], ["ultraviolet radiation", "TREATMENT", 41, 62], ["COVID-19 disease", "PROBLEM", 151, 167], ["DiscussionUVB radiation", "TREATMENT", 168, 191], ["UV radiation", "TREATMENT", 229, 241]]], ["Moreover, inactivation of viruses in the environment by solar UV radiation plays a role in the seasonal occurrence of influenza pandemics.", [["UV", "CHEMICAL", 62, 64], ["influenza pandemics", "DISEASE", 118, 137], ["viruses", "PROBLEM", 26, 33], ["solar UV radiation", "TREATMENT", 56, 74], ["influenza pandemics", "PROBLEM", 118, 137], ["viruses", "OBSERVATION", 26, 33], ["influenza", "OBSERVATION", 118, 127]]], ["8, 9 There is evidence on the A c c e p t e d M a n u s c r i p t environmental contamination as a potential medium of transmission of SARS-CoV-2, as it seems to remain active on the surface of different materials for several hours to days 1 , thus higher solar radiation may help inactivate the virus.", [["surface", "ANATOMY", 183, 190], ["SARS", "DISEASE", 135, 139], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 135, 145], ["SARS-CoV", "SPECIES", 135, 143], ["a n u s", "TEST", 48, 55], ["t environmental contamination", "PROBLEM", 64, 93], ["SARS", "PROBLEM", 135, 139], ["CoV", "TEST", 140, 143], ["higher solar radiation", "TREATMENT", 249, 271], ["the virus", "PROBLEM", 292, 301], ["active", "OBSERVATION", 169, 175]]], ["We found that higher variance on the weather variables that protected from COVID-19 was associated with a higher incidence of the disease.", [["higher variance", "PROBLEM", 14, 29], ["the disease", "PROBLEM", 126, 137], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["variance", "OBSERVATION_MODIFIER", 21, 29], ["disease", "OBSERVATION", 130, 137]]], ["This was especially apparent for measurements of solar irradiance, suggesting that prolonged exposure to UV radiation may be needed for its protective effect.", [["UV", "CHEMICAL", 105, 107], ["solar irradiance", "TREATMENT", 49, 65], ["UV radiation", "TREATMENT", 105, 117], ["solar irradiance", "OBSERVATION", 49, 65]]], ["In addition to the potential virucidal effect of UV radiation, it also modulates host immunity against viral infections, both directly activating the innate immune response and controlling vitamin D production, which in turn harbor positive immune effects.", [["UV", "CHEMICAL", 49, 51], ["viral infections", "DISEASE", 103, 119], ["vitamin D", "CHEMICAL", 189, 198], ["vitamin D", "CHEMICAL", 189, 198], ["vitamin D", "SIMPLE_CHEMICAL", 189, 198], ["UV radiation", "TREATMENT", 49, 61], ["viral infections", "PROBLEM", 103, 119], ["vitamin D production", "TREATMENT", 189, 209], ["virucidal", "OBSERVATION_MODIFIER", 29, 38], ["UV radiation", "OBSERVATION", 49, 61], ["positive immune effects", "OBSERVATION", 232, 255]]], ["10 However, the relationship between higher UV radiation and reduced incidence of COVID-19 was modest, and the independent association between population density and incidence of COVID-19 highlighted the risks of close interpersonal contacts during the epidemic and the need for social distancing measures to prevent its growth.DiscussionPrevious studies have shown that, in addition to population density, crowding may influence the intensity of viral epidemics like influenza and also COVID-19 as well.", [["UV", "CHEMICAL", 44, 46], ["influenza", "DISEASE", 468, 477], ["COVID-19", "GENE_OR_GENE_PRODUCT", 82, 90], ["higher UV radiation", "TREATMENT", 37, 56], ["COVID", "TEST", 82, 87], ["COVID", "TEST", 179, 184], ["social distancing measures", "TREATMENT", 279, 305], ["its growth", "PROBLEM", 317, 327], ["DiscussionPrevious studies", "TEST", 328, 354], ["population density", "PROBLEM", 387, 405], ["crowding", "PROBLEM", 407, 415], ["viral epidemics", "PROBLEM", 447, 462], ["influenza", "PROBLEM", 468, 477], ["COVID", "TEST", 487, 492], ["reduced", "OBSERVATION_MODIFIER", 61, 68], ["population", "OBSERVATION_MODIFIER", 143, 153], ["density", "OBSERVATION", 154, 161], ["population", "OBSERVATION_MODIFIER", 387, 397], ["density", "OBSERVATION", 398, 405], ["viral", "OBSERVATION_MODIFIER", 447, 452], ["epidemics", "OBSERVATION", 453, 462]]], ["11, 12 The significant contribution of the geographic location over the incidence of COVID-19 suggests that several factors not included in our analysis may have been crucial for the Further studies on the potential protective effect of sunlight over COVID-19 will be needed to study the effect of changes in weather conditions in the next months on the spread of COVID-19, and to ascertain whether UV radiation may have a meaningful protective effect on the disease.", [["COVID-19", "CHEMICAL", 251, 259], ["COVID-19", "CHEMICAL", 364, 372], ["COVID", "TEST", 85, 90], ["our analysis", "TEST", 140, 152], ["sunlight over COVID", "TREATMENT", 237, 256], ["COVID", "TEST", 364, 369], ["UV radiation", "TREATMENT", 399, 411], ["the disease", "PROBLEM", 455, 466], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["geographic", "OBSERVATION_MODIFIER", 43, 53], ["disease", "OBSERVATION", 459, 466]]]], "76bb21e2ca48559adc7f72a545e77215738b1dcb": [["Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood H epatitis B virus (HBV) was first identified in the 1960s by Baruch Blumberg, who went on to win the Nobel prize for this discovery.", [["Misunderstood H epatitis B virus", "ORGANISM", 66, 98], ["HBV", "ORGANISM", 100, 103], ["epatitis B virus", "SPECIES", 82, 98], ["HBV", "SPECIES", 37, 40], ["H epatitis B virus", "SPECIES", 80, 98], ["HBV", "SPECIES", 100, 103], ["the HBV Genome", "PROBLEM", 33, 47], ["Tiny, and Misunderstood H epatitis B virus (HBV", "PROBLEM", 56, 103], ["Deep", "ANATOMY_MODIFIER", 14, 18], ["HBV Genome", "OBSERVATION", 37, 47], ["Tiny", "OBSERVATION_MODIFIER", 56, 60]]], ["1, 2 The virus is a leading cause of liver disease worldwide: an estimated 250-260 million individuals are chronically infected, and approximately one third of the world's population has serologic evidence of exposure.", [["liver", "ANATOMY", 37, 42], ["liver disease", "DISEASE", 37, 50], ["chronically infected", "DISEASE", 107, 127], ["liver", "ORGAN", 37, 42], ["individuals", "ORGANISM", 91, 102], ["liver disease", "PROBLEM", 37, 50], ["chronically infected", "PROBLEM", 107, 127], ["virus", "OBSERVATION", 9, 14], ["leading cause of", "UNCERTAINTY", 20, 36], ["liver", "ANATOMY", 37, 42], ["disease", "OBSERVATION", 43, 50], ["chronically", "OBSERVATION_MODIFIER", 107, 118], ["infected", "OBSERVATION", 119, 127], ["serologic evidence of", "UNCERTAINTY", 187, 208], ["exposure", "OBSERVATION", 209, 217]]], ["3 HBV is a global public health problem with endemic levels of infection in Southeast Asia and Africa, where prevalence rates are at least 8% in many populations.", [["infection", "DISEASE", 63, 72], ["3 HBV", "ORGANISM", 0, 5], ["HBV", "SPECIES", 2, 5], ["HBV", "PROBLEM", 2, 5], ["a global public health problem", "PROBLEM", 9, 39], ["infection", "PROBLEM", 63, 72], ["Africa", "PROBLEM", 95, 101], ["prevalence rates", "TEST", 109, 125], ["global", "OBSERVATION_MODIFIER", 11, 17], ["infection", "OBSERVATION", 63, 72]]], ["4, 5 However, HBV is under-represented in terms of resource allocation, political advocacy, and research.", [["HBV", "ORGANISM", 14, 17], ["HBV", "SPECIES", 14, 17], ["HBV", "PROBLEM", 14, 17]]], ["6 Chronic HBV infection leads to liver inflammation, with long-term risks of cirrhosis and hepatocellular carcinoma (HCC).", [["liver", "ANATOMY", 33, 38], ["hepatocellular carcinoma", "ANATOMY", 91, 115], ["HCC", "ANATOMY", 117, 120], ["HBV infection", "DISEASE", 10, 23], ["liver inflammation", "DISEASE", 33, 51], ["cirrhosis", "DISEASE", 77, 86], ["hepatocellular carcinoma", "DISEASE", 91, 115], ["HCC", "DISEASE", 117, 120], ["HBV", "ORGANISM", 10, 13], ["liver", "ORGAN", 33, 38], ["hepatocellular carcinoma", "CANCER", 91, 115], ["HCC", "CANCER", 117, 120], ["HBV", "SPECIES", 10, 13], ["Chronic HBV infection", "PROBLEM", 2, 23], ["liver inflammation", "PROBLEM", 33, 51], ["cirrhosis", "PROBLEM", 77, 86], ["hepatocellular carcinoma", "PROBLEM", 91, 115], ["HCC", "PROBLEM", 117, 120], ["Chronic", "OBSERVATION_MODIFIER", 2, 9], ["HBV", "OBSERVATION", 10, 13], ["infection", "OBSERVATION", 14, 23], ["liver", "ANATOMY", 33, 38], ["inflammation", "OBSERVATION", 39, 51], ["long-term", "OBSERVATION_MODIFIER", 58, 67], ["cirrhosis", "OBSERVATION", 77, 86], ["hepatocellular", "ANATOMY", 91, 105], ["carcinoma", "OBSERVATION", 106, 115], ["HCC", "OBSERVATION", 117, 120]]], ["7, 8 In contrast to the decrease in mortality from human immunodeficiency virus (HIV), tuberculosis, and malaria, HBV-associated mortality is increasing.", [["human immunodeficiency virus (HIV), tuberculosis", "DISEASE", 51, 99], ["malaria", "DISEASE", 105, 112], ["human immunodeficiency virus", "ORGANISM", 51, 79], ["HIV", "ORGANISM", 81, 84], ["HBV", "ORGANISM", 114, 117], ["human", "SPECIES", 51, 56], ["immunodeficiency virus (HIV", "SPECIES", 57, 84], ["human immunodeficiency virus", "SPECIES", 51, 79], ["HIV", "SPECIES", 81, 84], ["HBV", "SPECIES", 114, 117], ["human immunodeficiency virus", "PROBLEM", 51, 79], ["HIV)", "PROBLEM", 81, 85], ["tuberculosis", "PROBLEM", 87, 99], ["malaria", "PROBLEM", 105, 112], ["HBV", "PROBLEM", 114, 117], ["decrease", "OBSERVATION_MODIFIER", 24, 32], ["human immunodeficiency virus", "OBSERVATION", 51, 79], ["tuberculosis", "OBSERVATION", 87, 99], ["malaria", "OBSERVATION", 105, 112], ["increasing", "OBSERVATION_MODIFIER", 142, 152]]], ["9 The United Nations Sustainable Development Goals set the challenge of eliminating HBV infection as a public health threat by 2030.", [["HBV infection", "DISEASE", 84, 97], ["HBV", "ORGANISM", 84, 87], ["HBV", "SPECIES", 84, 87], ["HBV infection", "PROBLEM", 84, 97], ["infection", "OBSERVATION", 88, 97]]], ["10, 11 However, substantial barriers to elimination include gaps in vaccine coverage, long periods between vaccination and its effects on population prevalence, 12 and lack of a cure.", [["gaps in vaccine coverage", "TREATMENT", 60, 84], ["vaccination", "TREATMENT", 107, 118]]], ["Other challenges include the virus's resistance to drugs (and to a lesser extent vaccines), 13, 14 HIV coinfection, stigma, poverty, lack of education, and limited access to diagnostic tests.", [["HIV coinfection", "DISEASE", 99, 114], ["poverty", "DISEASE", 124, 131], ["HIV", "SPECIES", 99, 102], ["HIV", "SPECIES", 99, 102], ["the virus", "PROBLEM", 25, 34], ["drugs", "TREATMENT", 51, 56], ["a lesser extent vaccines", "TREATMENT", 65, 89], ["HIV coinfection", "PROBLEM", 99, 114], ["diagnostic tests", "TEST", 174, 190], ["virus", "OBSERVATION", 29, 34]]], ["6 HBV infection is treated with interferon and nucleos(t)ide analogue reverse transcriptase (RT) inhibitors-primarily tenofovir or entecavir-which can limit liver damage by suppressing viral replication.", [["liver", "ANATOMY", 157, 162], ["HBV infection", "DISEASE", 2, 15], ["nucleos(t)ide", "CHEMICAL", 47, 60], ["tenofovir", "CHEMICAL", 118, 127], ["entecavir", "CHEMICAL", 131, 140], ["liver damage", "DISEASE", 157, 169], ["tenofovir", "CHEMICAL", 118, 127], ["entecavir", "CHEMICAL", 131, 140], ["HBV", "ORGANISM", 2, 5], ["interferon", "GENE_OR_GENE_PRODUCT", 32, 42], ["nucleos(t)ide analogue reverse transcriptase", "SIMPLE_CHEMICAL", 47, 91], ["tenofovir", "SIMPLE_CHEMICAL", 118, 127], ["entecavir", "SIMPLE_CHEMICAL", 131, 140], ["liver", "ORGAN", 157, 162], ["interferon", "PROTEIN", 32, 42], ["reverse transcriptase", "PROTEIN", 70, 91], ["HBV", "SPECIES", 2, 5], ["HBV infection", "PROBLEM", 2, 15], ["interferon", "TREATMENT", 32, 42], ["nucleos(t)ide analogue reverse transcriptase (RT) inhibitors", "TREATMENT", 47, 107], ["tenofovir", "TREATMENT", 118, 127], ["entecavir", "TREATMENT", 131, 140], ["liver damage", "PROBLEM", 157, 169], ["infection", "OBSERVATION", 6, 15], ["liver", "ANATOMY", 157, 162]]], ["15 However, interferon therapy is associated with unpleasant side effects and cures only a small percentage of patients.", [["interferon", "CHEMICAL", 12, 22], ["patients", "ORGANISM", 111, 119], ["interferon", "PROTEIN", 12, 22], ["patients", "SPECIES", 111, 119], ["interferon therapy", "TREATMENT", 12, 30], ["unpleasant side effects", "PROBLEM", 50, 73], ["small", "OBSERVATION_MODIFIER", 91, 96]]], ["Nucleos(t)ide analogue RT inhibitors decrease viremia but have no consistent effect on clearance.", [["Nucleos(t)ide", "CHEMICAL", 0, 13], ["viremia", "DISEASE", 46, 53], ["Nucleos(t)ide", "CHEMICAL", 0, 13], ["Nucleos(t)ide", "SIMPLE_CHEMICAL", 0, 13], ["Nucleos(t)ide analogue RT inhibitors", "TREATMENT", 0, 36], ["viremia", "PROBLEM", 46, 53], ["viremia", "OBSERVATION", 46, 53], ["no consistent", "UNCERTAINTY", 63, 76]]], ["Therefore, rebound viremia after cessation is common.", [["viremia", "DISEASE", 19, 26], ["rebound viremia", "PROBLEM", 11, 26], ["rebound", "OBSERVATION_MODIFIER", 11, 18], ["viremia", "OBSERVATION", 19, 26]]], ["There is a great need to cure HBV infection if we are to achieve elimination targets; curative therapy for HBV is an important goal for individual patients and the international public health agenda.", [["HBV infection", "DISEASE", 30, 43], ["HBV", "ORGANISM", 30, 33], ["HBV", "ORGANISM", 107, 110], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["HBV", "SPECIES", 30, 33], ["HBV", "SPECIES", 107, 110], ["HBV infection", "PROBLEM", 30, 43], ["curative therapy", "TREATMENT", 86, 102], ["HBV", "PROBLEM", 107, 110], ["infection", "OBSERVATION", 34, 43]]], ["16 Curing HBV infection requires a detailed and robust understanding of the genetic sequence, structure, and diversity of HBV.", [["HBV infection", "DISEASE", 10, 23], ["HBV", "ORGANISM", 122, 125], ["HBV", "SPECIES", 10, 13], ["HBV", "SPECIES", 122, 125], ["HBV infection", "PROBLEM", 10, 23], ["the genetic sequence", "TEST", 72, 92], ["HBV", "PROBLEM", 122, 125], ["HBV", "OBSERVATION_MODIFIER", 10, 13], ["infection", "OBSERVATION", 14, 23], ["HBV", "OBSERVATION", 122, 125]]], ["Scientific investment is required to develop 32 This dataset was further supplemented with hepadnavirus isolates from chimpanzees, orangutans, and gorillas (AF193863, FJ798097, FJ798098) and some widely cited HBV genotype strains (X02763, D00330, AY123041, V01460, X75657, X69798, AF160501, AY090454).", [["AY090454", "CHEMICAL", 291, 299], ["chimpanzees", "ORGANISM", 118, 129], ["orangutans", "ORGANISM", 131, 141], ["gorillas", "ORGANISM", 147, 155], ["HBV", "ORGANISM", 209, 212], ["HBV", "SPECIES", 209, 212], ["hepadnavirus isolates", "TREATMENT", 91, 112], ["some widely cited HBV genotype strains", "PROBLEM", 191, 229]]], ["(B) Midpoint-rooted maximum likelihood phylogenetic tree generated using MEGA7 33 with bootstrap replicates of 1000 used, indicating relations between HBV genotypes and subtypes and their typical geographic distribution.", [["HBV", "ORGANISM", 151, 154], ["MEGA7 33", "DNA", 73, 81], ["HBV", "SPECIES", 151, 154], ["MEGA7", "TEST", 73, 78], ["bootstrap", "TEST", 87, 96], ["HBV genotypes and subtypes", "PROBLEM", 151, 177], ["typical", "OBSERVATION_MODIFIER", 188, 195], ["geographic", "OBSERVATION_MODIFIER", 196, 206], ["distribution", "OBSERVATION_MODIFIER", 207, 219]]], ["For genotypes with a single subtype, the reference sequences were used to generate the tree.", [["genotypes", "PROBLEM", 4, 13], ["the reference sequences", "TEST", 37, 60]]], ["1 panels of diverse infectious clones that replicate in cell lines and in animals, to support drug resistance-screening programs.", [["cell lines", "ANATOMY", 56, 66], ["clones", "CELL", 31, 37], ["cell lines", "CELL", 56, 66], ["cell lines", "CELL_LINE", 56, 66], ["diverse infectious clones", "PROBLEM", 12, 37], ["cell lines", "TREATMENT", 56, 66], ["diverse", "OBSERVATION_MODIFIER", 12, 19], ["infectious", "OBSERVATION", 20, 30], ["cell lines", "OBSERVATION", 56, 66]]], ["17 Detailed insights into immune control and clearance can be gained from identifying sites of immune selection pressure in the virus genome.", [["virus genome", "DNA", 128, 140], ["immune control", "TREATMENT", 26, 40], ["immune selection pressure", "TREATMENT", 95, 120], ["virus genome", "OBSERVATION", 128, 140]]], ["18 This approach has helped identify immune correlates of HIV control over the past decade.", [["HIV", "ORGANISM", 58, 61], ["HIV", "SPECIES", 58, 61], ["HIV control", "TREATMENT", 58, 69]]], ["18, 19 Increasing our understanding of virus genetics can improve management of patients-in stratification, selection of therapy, identification of drug-and vaccine-resistant strains, and development of new approaches to monitoring.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["virus genetics", "TREATMENT", 39, 53], ["therapy", "TREATMENT", 121, 128], ["drug", "TREATMENT", 148, 152], ["vaccine", "TREATMENT", 157, 164], ["resistant strains", "PROBLEM", 165, 182], ["monitoring", "TEST", 221, 231], ["new", "OBSERVATION_MODIFIER", 203, 206]]], ["20 HBV sequence data largely consist of consensus sequences of individual viral genes derived by Sanger sequencing.", [["consensus sequences", "DNA", 40, 59], ["viral genes", "DNA", 74, 85], ["HBV", "SPECIES", 3, 6], ["20 HBV sequence data", "TEST", 0, 20], ["consensus sequences", "TEST", 40, 59], ["individual viral genes", "PROBLEM", 63, 85], ["Sanger sequencing", "TEST", 97, 114]]], ["[21] [22] [23] In addition to enabling whole-genome sequencing, NGS offers a powerful method for detection of minor variants relevant to the identification of drug resistance, 24-26 studies of quasispecies dynamics, 27 and characterization of complex viral populations.", [["minor variants", "PROBLEM", 110, 124], ["drug resistance", "TEST", 159, 174], ["quasispecies dynamics", "TEST", 193, 214], ["complex viral populations", "PROBLEM", 243, 268], ["complex", "OBSERVATION_MODIFIER", 243, 250], ["viral populations", "OBSERVATION", 251, 268]]], ["28 Together with improved curation and publication of clinical metadata, these accurate, full-length, ultra-deep HBV sequence data provide increasing opportunities for developing new insights into HBV evolution, diversity, pathogenesis, immune control, and treatment outcomes.", [["HBV", "ORGANISM", 197, 200], ["HBV", "SPECIES", 113, 116], ["HBV", "SPECIES", 197, 200], ["ultra", "TEST", 102, 107], ["deep HBV sequence data", "TEST", 108, 130], ["HBV evolution", "PROBLEM", 197, 210], ["pathogenesis", "PROBLEM", 223, 235], ["immune control", "TREATMENT", 237, 251], ["treatment outcomes", "TREATMENT", 257, 275], ["HBV", "OBSERVATION", 197, 200]]]], "PMC7340747": [["IntroductionCoronaviruses (CoV) are large RNA viruses, spherical in shape, from which protrude corona-shaped spicules (S-protein, basically made up of cysteine and tryptophan).", [["spicules", "ANATOMY", 109, 117], ["tryptophan", "CHEMICAL", 164, 174], ["cysteine", "CHEMICAL", 151, 159], ["tryptophan", "CHEMICAL", 164, 174], ["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoV", "ORGANISM", 27, 30], ["cysteine", "AMINO_ACID", 151, 159], ["tryptophan", "SIMPLE_CHEMICAL", 164, 174], ["S-protein", "PROTEIN", 119, 128], ["CoV", "SPECIES", 27, 30], ["IntroductionCoronaviruses", "TEST", 0, 25], ["large RNA viruses", "PROBLEM", 36, 53], ["spherical in shape", "PROBLEM", 55, 73], ["S-protein", "TEST", 119, 128], ["large", "OBSERVATION_MODIFIER", 36, 41], ["RNA viruses", "OBSERVATION", 42, 53], ["spherical", "OBSERVATION_MODIFIER", 55, 64], ["shape", "OBSERVATION_MODIFIER", 68, 73], ["shaped", "OBSERVATION_MODIFIER", 102, 108], ["spicules", "OBSERVATION_MODIFIER", 109, 117]]], ["They can cause pathology in animals (mammals and birds) and humans.", [["birds", "ORGANISM_SUBDIVISION", 49, 54], ["humans", "ORGANISM", 60, 66], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 60, 66], ["pathology", "PROBLEM", 15, 24]]], ["Human coronaviruses were first isolated in 1960.", [["Human", "ORGANISM", 0, 5], ["coronaviruses", "ORGANISM", 6, 19], ["Human", "SPECIES", 0, 5], ["Human coronaviruses", "SPECIES", 0, 19], ["Human coronaviruses", "PROBLEM", 0, 19]]], ["Seven types of human CoV are known, of which four cause the common cold (HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1).", [["human", "ORGANISM", 15, 20], ["CoV", "ORGANISM", 21, 24], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 84, 93], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 95, 104], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 110, 119], ["HCoV", "PROTEIN", 110, 114], ["HKU1", "PROTEIN", 115, 119], ["human", "SPECIES", 15, 20], ["human CoV", "SPECIES", 15, 24], ["human CoV", "PROBLEM", 15, 24], ["HCoV", "TEST", 73, 77], ["HCoV", "TEST", 84, 88], ["OC43", "TEST", 89, 93], ["HCoV", "TEST", 95, 99], ["NL63", "TEST", 100, 104], ["HCoV", "TEST", 110, 114], ["human CoV", "OBSERVATION", 15, 24]]], ["In this twenty-first century, three other new CoV have appeared whose pathogenicity is much more serious and causes severe acute respiratory syndrome (SARS), which are SARS-CoV (China, 2002), MERS-CoV (Middle East, 2012), and SARS-CoV-2 [1, 2].IntroductionAn outbreak of cases of pneumonia caused by a new coronavirus, SARS-CoV-2 or COVID-19, has been reported in December 2019 in Wuhan, Hubei province (China) [3].", [["acute respiratory syndrome", "DISEASE", 123, 149], ["SARS", "DISEASE", 151, 155], ["SARS-CoV", "DISEASE", 168, 176], ["SARS", "DISEASE", 226, 230], ["pneumonia", "DISEASE", 280, 289], ["coronavirus", "DISEASE", 306, 317], ["SARS", "DISEASE", 319, 323], ["CoV", "ORGANISM", 46, 49], ["MERS-CoV", "ORGANISM", 192, 200], ["SARS-CoV-2", "ORGANISM", 319, 329], ["COVID-19", "CELL", 333, 341], ["coronavirus", "SPECIES", 306, 317], ["SARS-CoV", "SPECIES", 168, 176], ["MERS-CoV", "SPECIES", 192, 200], ["SARS-CoV", "SPECIES", 226, 234], ["SARS-CoV", "SPECIES", 319, 327], ["severe acute respiratory syndrome", "PROBLEM", 116, 149], ["SARS", "PROBLEM", 151, 155], ["pneumonia", "PROBLEM", 280, 289], ["a new coronavirus", "PROBLEM", 300, 317], ["CoV", "TEST", 324, 327], ["COVID", "TEST", 333, 338], ["new", "OBSERVATION_MODIFIER", 42, 45], ["CoV", "OBSERVATION", 46, 49], ["pathogenicity", "OBSERVATION", 70, 83], ["much more serious", "OBSERVATION_MODIFIER", 87, 104], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory syndrome", "OBSERVATION", 129, 149], ["pneumonia", "OBSERVATION", 280, 289], ["new", "OBSERVATION_MODIFIER", 302, 305], ["coronavirus", "OBSERVATION", 306, 317]]], ["This pandemic has had an impact on health systems, which to date (April 5, 2020), there are 897,013 confirmed cases in 196 countries and more than 65,712 deaths [4].IntroductionThe current pandemic confirms that SARS-CoV-2 is a highly infectious virus with a high transmission capacity.", [["deaths", "DISEASE", 154, 160], ["SARS", "DISEASE", 212, 216], ["SARS-CoV-2", "ORGANISM", 212, 222], ["SARS-CoV-2", "SPECIES", 212, 222], ["SARS", "PROBLEM", 212, 216], ["a highly infectious virus", "PROBLEM", 226, 251], ["a high transmission capacity", "PROBLEM", 257, 285], ["impact", "OBSERVATION_MODIFIER", 25, 31], ["highly", "OBSERVATION_MODIFIER", 228, 234], ["infectious", "OBSERVATION", 235, 245]]], ["It is transmitted through Fl\u00fcgge droplets from the respiratory secretions of an infected person (by exhaling, coughing, or sneezing) and is capable of transmission over distances of up to 2 m.", [["respiratory secretions", "ANATOMY", 51, 73], ["coughing", "DISEASE", 110, 118], ["person", "SPECIES", 89, 95], ["the respiratory secretions", "PROBLEM", 47, 73], ["coughing", "PROBLEM", 110, 118], ["sneezing", "PROBLEM", 123, 131], ["respiratory", "ANATOMY", 51, 62], ["secretions", "OBSERVATION", 63, 73], ["infected", "OBSERVATION", 80, 88]]], ["When Fl\u00fcgge droplets fall, they deposit on surfaces, where they can infect other people if they touch those objects or surfaces with their hands and then bring them to their eyes, nose, or mouth [5].IntroductionThe high infectivity rate and the high incubation time (between 1 and 14 days) of this virus provide great pre-symptomatic transmissibility.", [["eyes", "ANATOMY", 174, 178], ["nose", "ANATOMY", 180, 184], ["mouth", "ANATOMY", 189, 194], ["people", "ORGANISM", 81, 87], ["hands", "ORGANISM_SUBDIVISION", 139, 144], ["eyes", "ORGAN", 174, 178], ["nose", "ORGANISM_SUBDIVISION", 180, 184], ["mouth", "ORGANISM_SUBDIVISION", 189, 194], ["people", "SPECIES", 81, 87], ["The high infectivity rate", "PROBLEM", 211, 236], ["this virus", "TREATMENT", 293, 303], ["nose", "ANATOMY", 180, 184], ["mouth", "ANATOMY", 189, 194], ["high infectivity", "OBSERVATION_MODIFIER", 215, 231]]], ["Fecal-oral transmission is plausible, causing digestive symptoms (diarrhea).", [["Fecal", "ANATOMY", 0, 5], ["oral", "ANATOMY", 6, 10], ["digestive", "ANATOMY", 46, 55], ["diarrhea", "DISEASE", 66, 74], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["oral", "ORGANISM_SUBDIVISION", 6, 10], ["digestive", "ORGAN", 46, 55], ["digestive symptoms", "PROBLEM", 46, 64], ["diarrhea", "PROBLEM", 66, 74]]], ["No cases of perinatal or breast milk transmission have been reported [6].IntroductionTo date, there is no effective antiviral treatment against SARS-CoV-2.", [["breast milk", "ANATOMY", 25, 36], ["breast milk transmission", "DISEASE", 25, 49], ["SARS", "DISEASE", 144, 148], ["breast", "ORGANISM_SUBDIVISION", 25, 31], ["milk", "ORGANISM_SUBSTANCE", 32, 36], ["SARS-CoV-2", "ORGANISM", 144, 154], ["SARS-CoV", "SPECIES", 144, 152], ["effective antiviral treatment", "TREATMENT", 106, 135], ["SARS", "PROBLEM", 144, 148], ["breast", "ANATOMY", 25, 31], ["no", "UNCERTAINTY", 103, 105]]], ["Antiviral drugs and systemic corticosteroids used in other viral infections (SARS-CoV and MERS-CoV) have not demonstrated validity for SARS-CoV-2 [7].", [["corticosteroids", "CHEMICAL", 29, 44], ["viral infections", "DISEASE", 59, 75], ["SARS", "DISEASE", 77, 81], ["corticosteroids", "CHEMICAL", 29, 44], ["SARS-CoV", "ORGANISM", 77, 85], ["MERS-CoV", "ORGANISM", 90, 98], ["SARS-CoV", "SPECIES", 77, 85], ["MERS-CoV", "SPECIES", 90, 98], ["SARS-CoV", "SPECIES", 135, 143], ["Antiviral drugs", "TREATMENT", 0, 15], ["systemic corticosteroids", "TREATMENT", 20, 44], ["other viral infections", "PROBLEM", 53, 75], ["SARS", "PROBLEM", 135, 139], ["CoV", "TEST", 140, 143], ["viral", "OBSERVATION_MODIFIER", 59, 64], ["infections", "OBSERVATION", 65, 75]]], ["Some authors highlight the use of corticosteroids at the start of the hyper inflammatory response and not in early stages, where their early use could favor viral replication [8].", [["corticosteroids", "CHEMICAL", 34, 49], ["corticosteroids", "SIMPLE_CHEMICAL", 34, 49], ["corticosteroids", "TREATMENT", 34, 49], ["the hyper inflammatory response", "PROBLEM", 66, 97], ["viral replication", "PROBLEM", 157, 174], ["inflammatory", "OBSERVATION", 76, 88]]], ["Remdesivir (antiviral RNA) has been successfully used to treat the first case of SARS-CoV-2 in the United States [9].", [["Remdesivir", "CHEMICAL", 0, 10], ["SARS", "DISEASE", 81, 85], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["SARS-CoV-2", "ORGANISM", 81, 91], ["antiviral RNA", "RNA", 12, 25], ["SARS-CoV", "SPECIES", 81, 89], ["Remdesivir (antiviral RNA", "TREATMENT", 0, 25], ["SARS", "PROBLEM", 81, 85], ["CoV", "TEST", 86, 89]]], ["Remdesivir is the most promising antiviral currently investigated, although neither its efficacy nor safety is established [9].", [["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["Remdesivir", "TREATMENT", 0, 10]]], ["Lopinavir/Ritonavir significantly decreased viral load in one case of SARS-CoV-2, although the efficacy of this combination is not definitively established [10].", [["Lopinavir", "CHEMICAL", 0, 9], ["Ritonavir", "CHEMICAL", 10, 19], ["SARS", "DISEASE", 70, 74], ["Lopinavir", "CHEMICAL", 0, 9], ["Ritonavir", "CHEMICAL", 10, 19], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["Ritonavir", "SIMPLE_CHEMICAL", 10, 19], ["SARS-CoV", "SPECIES", 70, 78], ["Lopinavir", "TREATMENT", 0, 9], ["Ritonavir", "TREATMENT", 10, 19], ["viral load", "TREATMENT", 44, 54], ["SARS", "PROBLEM", 70, 74], ["CoV", "TEST", 75, 78]]], ["Several studies have found that hydroxychloroquine may inhibit some steps in the replication of several viruses, including CoV [11].", [["hydroxychloroquine", "CHEMICAL", 32, 50], ["hydroxychloroquine", "CHEMICAL", 32, 50], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 32, 50], ["Several studies", "TEST", 0, 15], ["hydroxychloroquine", "TREATMENT", 32, 50], ["some steps", "PROBLEM", 63, 73], ["several viruses", "PROBLEM", 96, 111], ["several", "OBSERVATION_MODIFIER", 96, 103], ["viruses", "OBSERVATION", 104, 111]]], ["Hydroxychloroquine also has an immunomodulatory effect, suppressing production and release of TNF-\u03b1 and IL-6 [12].", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-6", "GENE_OR_GENE_PRODUCT", 104, 108], ["TNF", "PROTEIN", 94, 97], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["an immunomodulatory effect", "TREATMENT", 28, 54], ["TNF", "TEST", 94, 97]]], ["Currently, the efficacy, dose, and safety of hydroxychloroquine for the treatment and prevention of SARS-CoV-2 are not established, and more data is needed on whether the in vitro activity corresponds to clinical efficacy [12].", [["hydroxychloroquine", "CHEMICAL", 45, 63], ["SARS", "DISEASE", 100, 104], ["hydroxychloroquine", "CHEMICAL", 45, 63], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 45, 63], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 100, 110], ["SARS-CoV", "SPECIES", 100, 108], ["hydroxychloroquine", "TREATMENT", 45, 63], ["the treatment", "TREATMENT", 68, 81], ["SARS", "PROBLEM", 100, 104]]], ["A recent publication states that the combined use of hydroxychloroquine and azithromycin is more effective in eliminating the virus [13].IntroductionVarious quasi-experimental protocols are being evaluated at the hospital level to modulate the excessive immune response, to suppress different proinflammatory cytokines, and thus to avoid the damage produced by the cytokine storm, because this phenomenon is responsible for the fatal outcome in infection by SARS-Cov-2 [14].IntroductionSeveral studies (Cuba, Italy, Germany, Russia, and Spain) and years of experience have shown that ozone (O3) is capable of modulating inflammation and pain, in addition to having demonstrated a bactericidal, fungicidal, virucidal, and antiparasitic effect [15, 16].", [["hydroxychloroquine", "CHEMICAL", 53, 71], ["azithromycin", "CHEMICAL", 76, 88], ["infection", "DISEASE", 445, 454], ["SARS", "DISEASE", 458, 462], ["ozone", "CHEMICAL", 584, 589], ["O3", "CHEMICAL", 591, 593], ["inflammation", "DISEASE", 620, 632], ["pain", "DISEASE", 637, 641], ["hydroxychloroquine", "CHEMICAL", 53, 71], ["azithromycin", "CHEMICAL", 76, 88], ["ozone", "CHEMICAL", 584, 589], ["O3", "CHEMICAL", 591, 593], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 53, 71], ["azithromycin", "SIMPLE_CHEMICAL", 76, 88], ["ozone", "SIMPLE_CHEMICAL", 584, 589], ["O3", "SIMPLE_CHEMICAL", 591, 593], ["proinflammatory cytokines", "PROTEIN", 293, 318], ["cytokine", "PROTEIN", 365, 373], ["hydroxychloroquine", "TREATMENT", 53, 71], ["azithromycin", "TREATMENT", 76, 88], ["the virus", "PROBLEM", 122, 131], ["IntroductionVarious quasi-experimental protocols", "TREATMENT", 137, 185], ["different proinflammatory cytokines", "PROBLEM", 283, 318], ["the damage", "PROBLEM", 338, 348], ["the cytokine storm", "TREATMENT", 361, 379], ["this phenomenon", "PROBLEM", 389, 404], ["the fatal outcome in infection", "PROBLEM", 424, 454], ["IntroductionSeveral studies", "TEST", 474, 501], ["modulating inflammation", "PROBLEM", 609, 632], ["pain", "PROBLEM", 637, 641], ["a bactericidal, fungicidal, virucidal", "PROBLEM", 678, 715], ["antiparasitic effect", "PROBLEM", 721, 741], ["publication", "OBSERVATION", 9, 20], ["infection", "OBSERVATION", 445, 454], ["inflammation", "OBSERVATION", 620, 632], ["bactericidal", "OBSERVATION", 680, 692]]], ["These antimicrobial properties have made ozone recognized as such an effective disinfectant that it is used in many water purification plants worldwide [15].", [["ozone", "CHEMICAL", 41, 46], ["ozone", "CHEMICAL", 41, 46], ["ozone", "SIMPLE_CHEMICAL", 41, 46]]], ["In this context, we reasonably believe that ozone has a place in the management of the present SARS-CoV-2 pandemic, so we will carry out a review on the subject and its therapeutic possibilities.IntroductionCurrently, about 80 clinical trials are being carried out that seek to define the best therapy for the management of SARS-Cov-2 infections, of which only 3 are dedicated to the study of ozone on this disease and its potential therapeutic use [4].IntroductionThe objective of this review is to analyze the physiological bases and therapeutic possibilities of ozone on SARS-Cov2 (COVID-19) infection according to evolutionary stage and perhaps propose its use as complementary therapy in the compassionate treatment of COVID-19, using as a systemically administered rectal insufflation route, because it is the simplest, safest, and cheapest technique.Physiopathology of SARS-Cov-2SARS-CoV-2 infection produces an immune response in two phases [17]; a first in which viral pathogenicity predominates, and a second, in which the pathology is mainly due to the excessive host immune response [17].", [["rectal", "ANATOMY", 771, 777], ["ozone", "CHEMICAL", 44, 49], ["SARS-CoV-2 pandemic", "DISEASE", 95, 114], ["SARS-Cov-2 infections", "DISEASE", 324, 345], ["ozone", "CHEMICAL", 393, 398], ["ozone", "CHEMICAL", 565, 570], ["SARS", "DISEASE", 574, 578], ["infection", "DISEASE", 595, 604], ["COVID-19", "CHEMICAL", 724, 732], ["infection", "DISEASE", 897, 906], ["ozone", "CHEMICAL", 44, 49], ["ozone", "CHEMICAL", 393, 398], ["ozone", "CHEMICAL", 565, 570], ["COVID-19", "CHEMICAL", 724, 732], ["ozone", "SIMPLE_CHEMICAL", 44, 49], ["CoV-2", "ORGANISM", 100, 105], ["ozone", "SIMPLE_CHEMICAL", 393, 398], ["ozone", "SIMPLE_CHEMICAL", 565, 570], ["COVID-19", "CELL", 585, 593], ["rectal", "ORGAN", 771, 777], ["SARS-Cov-2SARS-CoV-2", "ORGANISM", 876, 896], ["SARS-Cov-2SARS-CoV-2", "SPECIES", 876, 896], ["pandemic", "PROBLEM", 106, 114], ["the management", "TREATMENT", 306, 320], ["SARS", "PROBLEM", 324, 328], ["Cov-2 infections", "PROBLEM", 329, 345], ["the study", "TEST", 380, 389], ["this disease", "PROBLEM", 402, 414], ["SARS", "TEST", 574, 578], ["COVID", "TEST", 585, 590], ["infection", "PROBLEM", 595, 604], ["complementary therapy", "TREATMENT", 668, 689], ["COVID", "TEST", 724, 729], ["a systemically administered rectal insufflation route", "TREATMENT", 743, 796], ["Physiopathology", "TEST", 857, 872], ["SARS-", "TEST", 876, 881], ["Cov-2SARS", "TEST", 881, 890], ["CoV", "PROBLEM", 891, 894], ["2 infection", "PROBLEM", 895, 906], ["viral pathogenicity", "PROBLEM", 972, 991], ["ozone", "OBSERVATION", 44, 49], ["SARS", "OBSERVATION", 95, 99], ["viral pathogenicity", "OBSERVATION", 972, 991]]], ["The transition from one phase to another is progressive, both clinically and analytically [14].Physiopathology of SARS-Cov-2During incubation and in the non-severe phase of the disease, a specific adaptive immune response is required to try to eliminate the virus and limit progression to more advanced stages of infection.", [["SARS", "DISEASE", 114, 118], ["infection", "DISEASE", 313, 322], ["SARS", "PROBLEM", 114, 118], ["the disease", "PROBLEM", 173, 184], ["the virus", "PROBLEM", 254, 263], ["infection", "PROBLEM", 313, 322], ["progressive", "OBSERVATION_MODIFIER", 44, 55], ["SARS", "OBSERVATION", 114, 118], ["disease", "OBSERVATION", 177, 184], ["advanced stages", "OBSERVATION_MODIFIER", 294, 309], ["infection", "OBSERVATION", 313, 322]]], ["An immune system dysfunction generates a decrease in CD3 + and CD4 + T lymphocytes accompanied by an increase in neutrophils and an increase in the neutrophil/lymphocyte index, especially in the most severe cases, being a predictive sign of torpid evolution [18].Physiopathology of SARS-Cov-2Immune system dysfunction originates disproportionate and negative immune responses for the different affected tissues.", [["immune system", "ANATOMY", 3, 16], ["CD3 +", "ANATOMY", 53, 58], ["CD4 + T lymphocytes", "ANATOMY", 63, 82], ["neutrophils", "ANATOMY", 113, 124], ["neutrophil", "ANATOMY", 148, 158], ["lymphocyte", "ANATOMY", 159, 169], ["tissues", "ANATOMY", 403, 410], ["SARS", "DISEASE", 282, 286], ["CD3", "GENE_OR_GENE_PRODUCT", 53, 56], ["CD4", "GENE_OR_GENE_PRODUCT", 63, 66], ["neutrophils", "CELL", 113, 124], ["neutrophil", "CELL", 148, 158], ["lymphocyte", "CELL", 159, 169], ["tissues", "TISSUE", 403, 410], ["CD3", "PROTEIN", 53, 56], ["CD4", "PROTEIN", 63, 66], ["T lymphocytes", "CELL_TYPE", 69, 82], ["neutrophils", "CELL_TYPE", 113, 124], ["neutrophil", "CELL_TYPE", 148, 158], ["An immune system dysfunction", "PROBLEM", 0, 28], ["a decrease in CD3", "PROBLEM", 39, 56], ["CD4 + T lymphocytes", "PROBLEM", 63, 82], ["an increase in neutrophils", "PROBLEM", 98, 124], ["an increase", "PROBLEM", 129, 140], ["the neutrophil/lymphocyte index", "TEST", 144, 175], ["torpid evolution", "PROBLEM", 241, 257], ["SARS", "PROBLEM", 282, 286], ["Cov-2Immune system dysfunction", "PROBLEM", 287, 317], ["the different affected tissues", "PROBLEM", 380, 410], ["immune system dysfunction", "OBSERVATION", 3, 28], ["decrease", "OBSERVATION_MODIFIER", 41, 49], ["increase", "OBSERVATION_MODIFIER", 101, 109], ["neutrophils", "OBSERVATION", 113, 124], ["increase", "OBSERVATION_MODIFIER", 132, 140], ["neutrophil", "OBSERVATION_MODIFIER", 148, 158], ["lymphocyte index", "OBSERVATION", 159, 175], ["most severe", "OBSERVATION_MODIFIER", 195, 206], ["torpid", "OBSERVATION_MODIFIER", 241, 247], ["SARS", "OBSERVATION", 282, 286]]], ["Recruitment of signaling complexes develops a molecular cascade that activates nuclear transcription factor-\u041a\u03b2 (NF-\u041a\u03b2) and interferon regulatory factor 3 (IRF3) and the production of type I interferons (IFN-\u03b1/\u03b2) and a series of pro-inflammatory cytokines (mainly IL-1\u03b2, IL-6, macrophage colony-stimulating factor [MCSF], IP-10, MCP-1, hepatocyte growth factor [HGF], interferon-\u03b3 [IFN- \u03b3], and tumor necrosis factor-\u03b1 [TNF-\u03b1]).", [["necrosis", "DISEASE", 400, 408], ["nuclear transcription factor-\u041a\u03b2", "GENE_OR_GENE_PRODUCT", 79, 110], ["NF-\u041a\u03b2", "GENE_OR_GENE_PRODUCT", 112, 117], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 123, 153], ["IRF3", "GENE_OR_GENE_PRODUCT", 155, 159], ["type I interferons", "GENE_OR_GENE_PRODUCT", 183, 201], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 203, 208], ["\u03b2", "GENE_OR_GENE_PRODUCT", 209, 210], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 263, 268], ["IL-6", "GENE_OR_GENE_PRODUCT", 270, 274], ["macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 276, 312], ["MCSF", "GENE_OR_GENE_PRODUCT", 314, 318], ["IP-10", "GENE_OR_GENE_PRODUCT", 321, 326], ["MCP-1", "GENE_OR_GENE_PRODUCT", 328, 333], ["hepatocyte growth factor", "GENE_OR_GENE_PRODUCT", 335, 359], ["HGF", "GENE_OR_GENE_PRODUCT", 361, 364], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 367, 379], ["IFN- \u03b3", "GENE_OR_GENE_PRODUCT", 381, 387], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 394, 417], ["TNF-\u03b1]", "GENE_OR_GENE_PRODUCT", 419, 425], ["signaling complexes", "PROTEIN", 15, 34], ["nuclear transcription factor-\u041a\u03b2 (NF-\u041a\u03b2", "PROTEIN", 79, 117], ["interferon regulatory factor 3", "PROTEIN", 123, 153], ["IRF3", "PROTEIN", 155, 159], ["type I interferons", "PROTEIN", 183, 201], ["IFN", "PROTEIN", 203, 206], ["\u03b1", "PROTEIN", 207, 208], ["\u03b2", "PROTEIN", 209, 210], ["pro-inflammatory cytokines", "PROTEIN", 228, 254], ["IL-1\u03b2, IL-6", "PROTEIN", 263, 274], ["macrophage colony-stimulating factor", "PROTEIN", 276, 312], ["MCSF", "PROTEIN", 314, 318], ["MCP", "PROTEIN", 328, 331], ["hepatocyte growth factor", "PROTEIN", 335, 359], ["HGF", "PROTEIN", 361, 364], ["interferon-\u03b3", "PROTEIN", 367, 379], ["IFN", "PROTEIN", 381, 384], ["tumor necrosis factor-\u03b1", "PROTEIN", 394, 417], ["TNF", "PROTEIN", 419, 422], ["signaling complexes", "PROBLEM", 15, 34], ["a molecular cascade", "PROBLEM", 44, 63], ["nuclear transcription factor", "TEST", 79, 107], ["NF", "TEST", 112, 114], ["interferon regulatory factor", "PROBLEM", 123, 151], ["type I interferons", "PROBLEM", 183, 201], ["IFN", "TEST", 203, 206], ["pro-inflammatory cytokines", "TEST", 228, 254], ["IL", "TEST", 263, 265], ["IL", "TEST", 270, 272], ["macrophage colony", "TEST", 276, 293], ["MCSF", "TEST", 314, 318], ["IP", "TEST", 321, 323], ["MCP", "TEST", 328, 331], ["hepatocyte growth factor", "TEST", 335, 359], ["HGF", "TEST", 361, 364], ["interferon", "TREATMENT", 367, 377], ["tumor necrosis factor", "PROBLEM", 394, 415], ["signaling complexes", "OBSERVATION", 15, 34], ["hepatocyte", "ANATOMY", 335, 345], ["tumor", "ANATOMY", 394, 399], ["necrosis", "OBSERVATION", 400, 408]]], ["The cytokine profile associated with COVID-19 severity resembles that seen in Secondary Haemophagocytic Lymphohistiocytosis (SHLH) [19].", [["Secondary Haemophagocytic Lymphohistiocytosis", "ANATOMY", 78, 123], ["Secondary Haemophagocytic Lymphohistiocytosis", "DISEASE", 78, 123], ["SHLH", "DISEASE", 125, 129], ["Secondary Haemophagocytic Lymphohistiocytosis", "CANCER", 78, 123], ["cytokine", "PROTEIN", 4, 12], ["COVID", "PROTEIN", 37, 42], ["The cytokine profile", "TEST", 0, 20], ["COVID", "TEST", 37, 42], ["Secondary Haemophagocytic Lymphohistiocytosis", "PROBLEM", 78, 123], ["Secondary", "OBSERVATION_MODIFIER", 78, 87], ["Haemophagocytic Lymphohistiocytosis", "OBSERVATION", 88, 123]]], ["SHLH is a poorly understood hyper inflammatory syndrome characterized by fulminant hypercytokinemia and fatal multiorgan failure, representing 3.7\u20134.3% of cases of viral sepsis in adults.", [["multiorgan", "ANATOMY", 110, 120], ["SHLH", "DISEASE", 0, 4], ["hypercytokinemia", "DISEASE", 83, 99], ["multiorgan failure", "DISEASE", 110, 128], ["viral sepsis", "DISEASE", 164, 176], ["multiorgan", "ORGAN", 110, 120], ["hyper inflammatory syndrome", "PROBLEM", 28, 55], ["fulminant hypercytokinemia", "PROBLEM", 73, 99], ["fatal multiorgan failure", "PROBLEM", 104, 128], ["viral sepsis", "PROBLEM", 164, 176], ["inflammatory syndrome", "OBSERVATION", 34, 55], ["fulminant", "OBSERVATION_MODIFIER", 73, 82], ["hypercytokinemia", "OBSERVATION", 83, 99], ["fatal", "OBSERVATION_MODIFIER", 104, 109], ["multiorgan failure", "OBSERVATION", 110, 128], ["viral", "OBSERVATION_MODIFIER", 164, 169], ["sepsis", "OBSERVATION", 170, 176]]], ["SHLH is associated with sustained fever, cytopenia, elevated ferritin, and lung involvement in 50% of patients [20].", [["lung", "ANATOMY", 75, 79], ["SHLH", "DISEASE", 0, 4], ["fever", "DISEASE", 34, 39], ["cytopenia", "DISEASE", 41, 50], ["ferritin", "GENE_OR_GENE_PRODUCT", 61, 69], ["lung", "ORGAN", 75, 79], ["patients", "ORGANISM", 102, 110], ["ferritin", "PROTEIN", 61, 69], ["patients", "SPECIES", 102, 110], ["sustained fever", "PROBLEM", 24, 39], ["cytopenia", "PROBLEM", 41, 50], ["elevated ferritin", "PROBLEM", 52, 69], ["lung involvement", "PROBLEM", 75, 91], ["associated with", "UNCERTAINTY", 8, 23], ["sustained", "OBSERVATION_MODIFIER", 24, 33], ["fever", "OBSERVATION", 34, 39], ["cytopenia", "OBSERVATION", 41, 50], ["elevated", "OBSERVATION_MODIFIER", 52, 60], ["ferritin", "OBSERVATION", 61, 69], ["lung", "ANATOMY", 75, 79], ["involvement", "OBSERVATION", 80, 91]]], ["In a multicenter retrospective study of 150 cases of COVID-19 in Wuhan, the mortality was attributed to viral hyper inflammation, and increased ferritin and IL-6 were considered markers of serious disease [21].", [["viral hyper inflammation", "DISEASE", 104, 128], ["ferritin", "GENE_OR_GENE_PRODUCT", 144, 152], ["IL-6", "GENE_OR_GENE_PRODUCT", 157, 161], ["ferritin", "PROTEIN", 144, 152], ["IL-6", "PROTEIN", 157, 161], ["COVID", "TEST", 53, 58], ["viral hyper inflammation", "PROBLEM", 104, 128], ["increased ferritin", "PROBLEM", 134, 152], ["serious disease", "PROBLEM", 189, 204], ["viral", "OBSERVATION_MODIFIER", 104, 109], ["hyper inflammation", "OBSERVATION", 110, 128], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["ferritin", "OBSERVATION_MODIFIER", 144, 152]]], ["Other predictors of severe SARS-CoV-2 disease were elevated D-Dimer, lymphopenia, and increased ultra-sensitive troponin-I [22].Physiopathology of SARS-Cov-2The current treatment for COVID-19 is maintenance, and respiratory failure due to acute respiratory distress syndrome (ARDS) is the main cause of mortality.", [["respiratory", "ANATOMY", 212, 223], ["respiratory", "ANATOMY", 245, 256], ["SARS-CoV-2 disease", "DISEASE", 27, 45], ["lymphopenia", "DISEASE", 69, 80], ["SARS", "DISEASE", 147, 151], ["COVID-19", "CHEMICAL", 183, 191], ["respiratory failure", "DISEASE", 212, 231], ["acute respiratory distress syndrome", "DISEASE", 239, 274], ["ARDS", "DISEASE", 276, 280], ["COVID-19", "CHEMICAL", 183, 191], ["D-Dimer", "SIMPLE_CHEMICAL", 60, 67], ["troponin-I", "GENE_OR_GENE_PRODUCT", 112, 122], ["troponin", "PROTEIN", 112, 120], ["severe SARS", "PROBLEM", 20, 31], ["CoV-2 disease", "PROBLEM", 32, 45], ["elevated D-Dimer", "PROBLEM", 51, 67], ["lymphopenia", "PROBLEM", 69, 80], ["increased ultra-sensitive troponin", "PROBLEM", 86, 120], ["Physiopathology of SARS", "PROBLEM", 128, 151], ["Cov", "TEST", 152, 155], ["The current treatment", "TREATMENT", 157, 178], ["COVID", "TEST", 183, 188], ["respiratory failure", "PROBLEM", 212, 231], ["acute respiratory distress syndrome", "PROBLEM", 239, 274], ["ARDS", "PROBLEM", 276, 280], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["SARS", "OBSERVATION", 27, 31], ["lymphopenia", "OBSERVATION", 69, 80], ["SARS", "OBSERVATION", 147, 151], ["respiratory failure", "OBSERVATION", 212, 231], ["acute", "OBSERVATION_MODIFIER", 239, 244], ["respiratory distress", "OBSERVATION", 245, 265], ["main", "OBSERVATION_MODIFIER", 289, 293], ["mortality", "OBSERVATION", 303, 312]]], ["A subgroup of patients with severe COVID-19 could develop \u201ccytokine storm\u201d syndrome [23].", [["patients", "ORGANISM", 14, 22], ["cytokine", "PROTEIN", 59, 67], ["patients", "SPECIES", 14, 22], ["severe COVID", "PROBLEM", 28, 40], ["cytokine storm\u201d syndrome", "PROBLEM", 59, 83], ["cytokine storm", "OBSERVATION", 59, 73]]], ["To reduce mortality, there is a need to identify and treat hyper inflammation using all existing therapies with acceptable safety profiles, as soon as possible [24].Clinical Presentation of SARS-CoV-2SARS-Cov-2 infection does not progress similarly in everyone who comes in contact with the virus.", [["inflammation", "DISEASE", 65, 77], ["infection", "DISEASE", 211, 220], ["hyper inflammation", "PROBLEM", 59, 77], ["all existing therapies", "TREATMENT", 84, 106], ["SARS-", "TEST", 190, 195], ["2 infection", "PROBLEM", 209, 220], ["inflammation", "OBSERVATION", 65, 77], ["infection", "OBSERVATION", 211, 220]]], ["A small percentage of exposed people do not become infected or develop clinical symptoms (30%).", [["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36], ["clinical symptoms", "PROBLEM", 71, 88], ["small", "OBSERVATION_MODIFIER", 2, 7], ["percentage", "OBSERVATION_MODIFIER", 8, 18], ["infected", "OBSERVATION", 51, 59]]], ["The interest in the clinical classification lies in being able to propose the most appropriate therapeutic approach for each patient according to the phase in which they are found [14].Clinical Presentation of SARS-CoV-2Siddiqi and Mehra have proposed a classification of the disease in three states or phases [25].State I (mild or early infection), ranging from inoculation to the early establishment of the disease, characterized by nonspecific symptoms such as malaise, fever, dry cough, headache, anosmia, or ageusia.", [["infection", "DISEASE", 338, 347], ["fever", "DISEASE", 473, 478], ["dry cough", "DISEASE", 480, 489], ["headache", "DISEASE", 491, 499], ["anosmia", "DISEASE", 501, 508], ["ageusia", "DISEASE", 513, 520], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["Mehra", "TREATMENT", 232, 237], ["the disease", "PROBLEM", 272, 283], ["State I (mild or early infection", "PROBLEM", 315, 347], ["the disease", "PROBLEM", 405, 416], ["nonspecific symptoms", "PROBLEM", 435, 455], ["malaise", "PROBLEM", 464, 471], ["fever", "PROBLEM", 473, 478], ["dry cough", "PROBLEM", 480, 489], ["headache", "PROBLEM", 491, 499], ["anosmia", "PROBLEM", 501, 508], ["ageusia", "PROBLEM", 513, 520], ["disease", "OBSERVATION", 276, 283], ["mild", "OBSERVATION_MODIFIER", 324, 328], ["early", "OBSERVATION_MODIFIER", 332, 337], ["infection", "OBSERVATION", 338, 347], ["disease", "OBSERVATION", 409, 416], ["nonspecific", "OBSERVATION_MODIFIER", 435, 446]]], ["At the analytical level, the hemogram can reveal lymphopenia and neutrophilia without other significant abnormalities (Table 1) [25].State II (moderate infection, with respiratory involvement without hypoxemia [IIa] or with hypoxemia [IIb]).", [["respiratory", "ANATOMY", 168, 179], ["lymphopenia", "DISEASE", 49, 60], ["neutrophilia", "DISEASE", 65, 77], ["infection", "DISEASE", 152, 161], ["hypoxemia", "DISEASE", 200, 209], ["hypoxemia", "DISEASE", 224, 233], ["the hemogram", "TEST", 25, 37], ["lymphopenia", "PROBLEM", 49, 60], ["neutrophilia", "PROBLEM", 65, 77], ["other significant abnormalities", "PROBLEM", 86, 117], ["State II (moderate infection", "PROBLEM", 133, 161], ["respiratory involvement", "PROBLEM", 168, 191], ["hypoxemia", "PROBLEM", 200, 209], ["hypoxemia", "PROBLEM", 224, 233], ["lymphopenia", "OBSERVATION", 49, 60], ["neutrophilia", "OBSERVATION", 65, 77], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["abnormalities", "OBSERVATION", 104, 117], ["moderate", "OBSERVATION_MODIFIER", 143, 151], ["infection", "OBSERVATION", 152, 161], ["hypoxemia", "OBSERVATION", 224, 233]]], ["Establishment of respiratory disease with worsening of symptoms and the appearance of radiological signs of viral pneumonia (infiltrates or ground-glass opacities that are characteristically bilateral [radiography and tomography observed in Table 1]) and analytical features (exacerbation of lymphocytopenia, moderate elevation of D-dimer and transaminases), as well as the beginning of elevation of systemic markers of inflammation but not exaggerated (normal or low procalcitonin).", [["respiratory", "ANATOMY", 17, 28], ["respiratory disease", "DISEASE", 17, 36], ["pneumonia", "DISEASE", 114, 123], ["lymphocytopenia", "DISEASE", 292, 307], ["inflammation", "DISEASE", 420, 432], ["D-dimer", "GENE_OR_GENE_PRODUCT", 331, 338], ["transaminases", "SIMPLE_CHEMICAL", 343, 356], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 468, 481], ["D-dimer", "PROTEIN", 331, 338], ["transaminases", "PROTEIN", 343, 356], ["respiratory disease", "PROBLEM", 17, 36], ["worsening of symptoms", "PROBLEM", 42, 63], ["viral pneumonia", "PROBLEM", 108, 123], ["infiltrates", "PROBLEM", 125, 136], ["ground-glass opacities", "PROBLEM", 140, 162], ["radiography", "TEST", 202, 213], ["tomography", "TEST", 218, 228], ["analytical features", "PROBLEM", 255, 274], ["lymphocytopenia", "PROBLEM", 292, 307], ["moderate elevation of D-dimer", "PROBLEM", 309, 338], ["transaminases", "TEST", 343, 356], ["elevation of systemic markers", "PROBLEM", 387, 416], ["inflammation", "PROBLEM", 420, 432], ["respiratory disease", "OBSERVATION", 17, 36], ["worsening", "OBSERVATION_MODIFIER", 42, 51], ["viral", "OBSERVATION_MODIFIER", 108, 113], ["pneumonia", "OBSERVATION", 114, 123], ["infiltrates", "OBSERVATION", 125, 136], ["ground", "OBSERVATION_MODIFIER", 140, 146], ["glass opacities", "OBSERVATION", 147, 162], ["bilateral", "ANATOMY_MODIFIER", 191, 200], ["lymphocytopenia", "OBSERVATION", 292, 307], ["moderate", "OBSERVATION_MODIFIER", 309, 317], ["elevation", "OBSERVATION_MODIFIER", 318, 327], ["D-dimer", "OBSERVATION_MODIFIER", 331, 338], ["elevation", "OBSERVATION_MODIFIER", 387, 396], ["systemic markers", "OBSERVATION", 400, 416], ["inflammation", "OBSERVATION", 420, 432], ["not", "UNCERTAINTY", 437, 440], ["exaggerated", "OBSERVATION_MODIFIER", 441, 452]]], ["At this stage, most patients with COVID-19 would need to be hospitalized for observation and treatment (15%).", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["COVID", "TEST", 34, 39], ["treatment", "TREATMENT", 93, 102]]], ["A relevant clinical aspect in this period is the appearance of hypoxemia as a marker of the progress of the infection and the need for mechanical ventilation as a result of the pulmonary inflammatory hyper response, which, if not interrupted, will lead to the next state (Table 1) [25].State III (severe or of systemic hyper inflammation).", [["pulmonary", "ANATOMY", 177, 186], ["hypoxemia", "DISEASE", 63, 72], ["infection", "DISEASE", 108, 117], ["inflammation", "DISEASE", 325, 337], ["pulmonary", "ORGAN", 177, 186], ["hypoxemia", "PROBLEM", 63, 72], ["the infection", "PROBLEM", 104, 117], ["mechanical ventilation", "TREATMENT", 135, 157], ["the pulmonary inflammatory hyper response", "PROBLEM", 173, 214], ["systemic hyper inflammation", "PROBLEM", 310, 337], ["hypoxemia", "OBSERVATION", 63, 72], ["infection", "OBSERVATION", 108, 117], ["pulmonary", "ANATOMY", 177, 186], ["inflammatory", "OBSERVATION", 187, 199], ["severe", "OBSERVATION_MODIFIER", 297, 303], ["inflammation", "OBSERVATION", 325, 337]]], ["Clinically, in this phase, multiorgan involvement is observed in many patients with a progressive evolution towards worsening and hemodynamic instability and sepsis.", [["multiorgan", "ANATOMY", 27, 37], ["hemodynamic instability", "DISEASE", 130, 153], ["sepsis", "DISEASE", 158, 164], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["multiorgan involvement", "PROBLEM", 27, 49], ["a progressive evolution", "PROBLEM", 84, 107], ["hemodynamic instability", "PROBLEM", 130, 153], ["sepsis", "PROBLEM", 158, 164], ["multiorgan", "ANATOMY", 27, 37], ["involvement", "OBSERVATION", 38, 49], ["progressive", "OBSERVATION_MODIFIER", 86, 97], ["worsening", "OBSERVATION_MODIFIER", 116, 125], ["hemodynamic instability", "OBSERVATION", 130, 153], ["sepsis", "OBSERVATION", 158, 164]]], ["This period is characterized by a significant elevation of systemic inflammation markers (IL-2, IL-6, and IL-7, granulocyte colony stimulating factor, macrophage inflammatory protein 1-\u03b1, TNF-\u03b1, C-reactive protein [PCR], ferritin, and D-dimer).", [["IL-2", "GENE_OR_GENE_PRODUCT", 90, 94], ["IL-6", "GENE_OR_GENE_PRODUCT", 96, 100], ["IL-7", "GENE_OR_GENE_PRODUCT", 106, 110], ["granulocyte colony stimulating factor", "GENE_OR_GENE_PRODUCT", 112, 149], ["macrophage inflammatory protein 1-\u03b1", "GENE_OR_GENE_PRODUCT", 151, 186], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 188, 193], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 195, 213], ["ferritin", "GENE_OR_GENE_PRODUCT", 221, 229], ["D-dimer", "SIMPLE_CHEMICAL", 235, 242], ["systemic inflammation markers", "PROTEIN", 59, 88], ["IL-2, IL-6", "PROTEIN", 90, 100], ["IL-7", "PROTEIN", 106, 110], ["granulocyte colony stimulating factor", "PROTEIN", 112, 149], ["macrophage inflammatory protein 1-\u03b1", "PROTEIN", 151, 186], ["TNF", "PROTEIN", 188, 191], ["\u03b1", "PROTEIN", 192, 193], ["C-reactive protein", "PROTEIN", 195, 213], ["ferritin", "PROTEIN", 221, 229], ["D-dimer", "PROTEIN", 235, 242], ["a significant elevation of systemic inflammation markers", "PROBLEM", 32, 88], ["IL", "TEST", 90, 92], ["IL", "TEST", 96, 98], ["IL", "TEST", 106, 108], ["granulocyte colony stimulating factor", "TEST", 112, 149], ["macrophage inflammatory protein", "TEST", 151, 182], ["TNF", "TEST", 188, 191], ["C-reactive protein", "TEST", 195, 213], ["PCR", "TEST", 215, 218], ["ferritin", "TEST", 221, 229], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["elevation", "OBSERVATION_MODIFIER", 46, 55], ["systemic", "OBSERVATION_MODIFIER", 59, 67], ["inflammation", "OBSERVATION", 68, 80], ["granulocyte", "ANATOMY", 112, 123]]], ["Ferritin is the key indicator of macrophage activation.", [["macrophage", "ANATOMY", 33, 43], ["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["macrophage", "CELL", 33, 43], ["Ferritin", "PROTEIN", 0, 8], ["Ferritin", "TEST", 0, 8], ["macrophage activation", "PROBLEM", 33, 54], ["macrophage activation", "OBSERVATION", 33, 54]]], ["D-dimer rises in a similar way to antiphospholipid syndrome together with low platelets and coagulation disorders (Table 1) [25].Ozone and Medicinal PropertiesOzone is a strong oxidizing agent (the third if compared to fluorine and persulfate) and a molecule with a high reactivity [26].Ozone and Medicinal PropertiesOzone (O3) is the unstable (allotropic) form of oxygen [27\u201329].", [["platelets", "ANATOMY", 78, 87], ["antiphospholipid syndrome", "DISEASE", 34, 59], ["low platelets", "DISEASE", 74, 87], ["coagulation disorders", "DISEASE", 92, 113], ["Ozone", "CHEMICAL", 129, 134], ["PropertiesOzone", "CHEMICAL", 149, 164], ["fluorine and persulfate", "CHEMICAL", 219, 242], ["Ozone", "CHEMICAL", 287, 292], ["PropertiesOzone", "CHEMICAL", 307, 322], ["O3", "CHEMICAL", 324, 326], ["oxygen", "CHEMICAL", 365, 371], ["D-dimer", "CHEMICAL", 0, 7], ["Ozone", "CHEMICAL", 129, 134], ["PropertiesOzone", "CHEMICAL", 149, 164], ["fluorine", "CHEMICAL", 219, 227], ["persulfate", "CHEMICAL", 232, 242], ["Ozone", "CHEMICAL", 287, 292], ["PropertiesOzone", "CHEMICAL", 307, 322], ["O3", "CHEMICAL", 324, 326], ["oxygen", "CHEMICAL", 365, 371], ["D-dimer", "GENE_OR_GENE_PRODUCT", 0, 7], ["platelets", "CELL", 78, 87], ["Ozone", "SIMPLE_CHEMICAL", 129, 134], ["PropertiesOzone", "SIMPLE_CHEMICAL", 149, 164], ["fluorine", "SIMPLE_CHEMICAL", 219, 227], ["persulfate", "SIMPLE_CHEMICAL", 232, 242], ["Ozone", "SIMPLE_CHEMICAL", 287, 292], ["Medicinal PropertiesOzone", "SIMPLE_CHEMICAL", 297, 322], ["O3", "SIMPLE_CHEMICAL", 324, 326], ["oxygen", "SIMPLE_CHEMICAL", 365, 371], ["platelets", "CELL_TYPE", 78, 87], ["D-dimer rises", "TEST", 0, 13], ["antiphospholipid syndrome", "PROBLEM", 34, 59], ["low platelets", "PROBLEM", 74, 87], ["coagulation disorders", "PROBLEM", 92, 113], ["Ozone", "TREATMENT", 129, 134], ["Medicinal PropertiesOzone", "TREATMENT", 139, 164], ["a strong oxidizing agent", "TREATMENT", 168, 192], ["fluorine and persulfate", "TREATMENT", 219, 242], ["Ozone", "TREATMENT", 287, 292], ["Medicinal PropertiesOzone (O3)", "TREATMENT", 297, 327], ["the unstable (allotropic)", "TREATMENT", 331, 356], ["rises", "OBSERVATION_MODIFIER", 8, 13], ["antiphospholipid syndrome", "OBSERVATION", 34, 59], ["low platelets", "OBSERVATION_MODIFIER", 74, 87]]], ["Various infectious, autoimmune, and degenerative diseases are treated by O3 [30].", [["infectious, autoimmune, and degenerative diseases", "DISEASE", 8, 57], ["O3", "CHEMICAL", 73, 75], ["O3 [30]", "CHEMICAL", 73, 80], ["Various infectious", "PROBLEM", 0, 18], ["autoimmune", "PROBLEM", 20, 30], ["degenerative diseases", "PROBLEM", 36, 57], ["infectious", "OBSERVATION", 8, 18], ["autoimmune", "OBSERVATION", 20, 30], ["degenerative", "OBSERVATION_MODIFIER", 36, 48], ["diseases", "OBSERVATION", 49, 57]]], ["Ozone is an immunomodulatory, anti-inflammatory, analgesic, and trophic agent [29].Ozone and Medicinal PropertiesOzone is not storable because it decomposes spontaneously.", [["Ozone", "CHEMICAL", 0, 5], ["Ozone", "CHEMICAL", 83, 88], ["PropertiesOzone", "CHEMICAL", 103, 118], ["Ozone", "CHEMICAL", 0, 5], ["Ozone", "CHEMICAL", 83, 88], ["PropertiesOzone", "CHEMICAL", 103, 118], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["Ozone", "SIMPLE_CHEMICAL", 83, 88], ["Ozone", "TREATMENT", 0, 5], ["an immunomodulatory", "TREATMENT", 9, 28], ["anti-inflammatory", "TREATMENT", 30, 47], ["analgesic", "TREATMENT", 49, 58], ["trophic agent", "TREATMENT", 64, 77], ["Ozone", "TREATMENT", 83, 88], ["Medicinal PropertiesOzone", "TREATMENT", 93, 118], ["immunomodulatory", "OBSERVATION_MODIFIER", 12, 28], ["anti-inflammatory", "OBSERVATION_MODIFIER", 30, 47]]], ["To date, O3 concentration is halved at 30 \u00b0C within 25 min, at 20 \u00b0C in 40 min, and at \u2212 50 \u00b0C in 3 months [26].", [["O3", "CHEMICAL", 9, 11], ["O3", "CHEMICAL", 9, 11], ["O3", "SIMPLE_CHEMICAL", 9, 11]]], ["Ozone decomposes rapidly, dividing into O2 and O\u2212 (monatomic O).", [["Ozone", "CHEMICAL", 0, 5], ["Ozone", "CHEMICAL", 0, 5], ["O2", "CHEMICAL", 40, 42], ["O\u2212", "CHEMICAL", 47, 49], ["O", "CHEMICAL", 61, 62], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["O2", "SIMPLE_CHEMICAL", 40, 42], ["O\u2212", "SIMPLE_CHEMICAL", 47, 49], ["monatomic O", "SIMPLE_CHEMICAL", 51, 62]]], ["Ozone disintegration releases heat (24.27 kcal) and produces vasodilator effect.", [["Ozone", "CHEMICAL", 0, 5], ["Ozone", "CHEMICAL", 0, 5], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["vasodilator effect", "TREATMENT", 61, 79]]], ["This molecule is highly reactive, and therefore, antifungal, antiparasitic, and antiviral properties are attributed [31].Ozone and Medicinal PropertiesOzone has a dose/effect relationship and therefore is not considered a homeopathic medicine.", [["Ozone", "CHEMICAL", 121, 126], ["Ozone", "CHEMICAL", 151, 156], ["Ozone", "CHEMICAL", 121, 126], ["Ozone", "CHEMICAL", 151, 156], ["Ozone", "SIMPLE_CHEMICAL", 121, 126], ["Ozone", "SIMPLE_CHEMICAL", 151, 156], ["highly reactive", "PROBLEM", 17, 32], ["antifungal", "TREATMENT", 49, 59], ["antiparasitic", "TREATMENT", 61, 74], ["antiviral properties", "TREATMENT", 80, 100], ["Ozone", "TREATMENT", 121, 126], ["Medicinal Properties", "TREATMENT", 131, 151], ["a homeopathic medicine", "TREATMENT", 220, 242], ["highly", "OBSERVATION_MODIFIER", 17, 23], ["reactive", "OBSERVATION_MODIFIER", 24, 32], ["antifungal", "OBSERVATION_MODIFIER", 49, 59], ["Medicinal Properties", "OBSERVATION_MODIFIER", 131, 151]]], ["On the contrary [26, 32], ozone generators release concentrations from 1 to 70\u2013100 \u03bcg/ml, although the therapeutic window is between 10 and 80 \u03bcg/ml [31].", [["ozone", "CHEMICAL", 26, 31], ["ozone", "CHEMICAL", 26, 31], ["ozone", "SIMPLE_CHEMICAL", 26, 31], ["ozone generators release concentrations", "TREATMENT", 26, 65]]], ["The O3 total dose is equivalent to the volume of gas (ml) multiplied by O3 concentration (\u03bcg/ml).Ozone and Medicinal PropertiesOzone, when dissolved in plasma, reacts with a series of biomolecules and then disappears.", [["plasma", "ANATOMY", 152, 158], ["O3", "CHEMICAL", 4, 6], ["O3", "CHEMICAL", 72, 74], ["Ozone", "CHEMICAL", 97, 102], ["PropertiesOzone", "CHEMICAL", 117, 132], ["O3", "CHEMICAL", 4, 6], ["O3", "CHEMICAL", 72, 74], ["Ozone", "CHEMICAL", 97, 102], ["PropertiesOzone", "CHEMICAL", 117, 132], ["O3", "SIMPLE_CHEMICAL", 4, 6], ["O3", "SIMPLE_CHEMICAL", 72, 74], ["Ozone", "SIMPLE_CHEMICAL", 97, 102], ["PropertiesOzone", "SIMPLE_CHEMICAL", 117, 132], ["plasma", "ORGANISM_SUBSTANCE", 152, 158], ["The O3 total dose", "TREATMENT", 0, 17], ["the volume of gas", "TREATMENT", 35, 52], ["Ozone", "TREATMENT", 97, 102], ["Medicinal PropertiesOzone", "TREATMENT", 107, 132]]], ["There are two compounds (reactive species of oxygen or ROS and lipid oxidation products or LOPs) that represent the \u201cozone messengers\u201d.", [["oxygen", "CHEMICAL", 45, 51], ["ROS", "CHEMICAL", 55, 58], ["oxygen", "CHEMICAL", 45, 51], ["ozone", "CHEMICAL", 117, 122], ["oxygen", "SIMPLE_CHEMICAL", 45, 51], ["ROS", "SIMPLE_CHEMICAL", 55, 58], ["lipid", "SIMPLE_CHEMICAL", 63, 68], ["LOPs", "SIMPLE_CHEMICAL", 91, 95], ["ozone", "SIMPLE_CHEMICAL", 117, 122], ["two compounds", "PROBLEM", 10, 23], ["reactive species of oxygen", "TREATMENT", 25, 51], ["ROS", "TREATMENT", 55, 58], ["lipid oxidation products", "TREATMENT", 63, 87], ["two", "OBSERVATION_MODIFIER", 10, 13], ["compounds", "OBSERVATION_MODIFIER", 14, 23], ["reactive", "OBSERVATION_MODIFIER", 25, 33], ["species", "OBSERVATION_MODIFIER", 34, 41]]], ["ROS are produced immediately in the initial phase (mainly hydrogen peroxide or H2O2) and are responsible for the early biological effects on the blood (erythrocytes, leukocytes, platelets).", [["blood", "ANATOMY", 145, 150], ["erythrocytes", "ANATOMY", 152, 164], ["leukocytes", "ANATOMY", 166, 176], ["platelets", "ANATOMY", 178, 187], ["ROS", "CHEMICAL", 0, 3], ["hydrogen peroxide", "CHEMICAL", 58, 75], ["H2O2", "CHEMICAL", 79, 83], ["hydrogen peroxide", "CHEMICAL", 58, 75], ["H2O2", "CHEMICAL", 79, 83], ["ROS", "SIMPLE_CHEMICAL", 0, 3], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 58, 75], ["H2O2", "SIMPLE_CHEMICAL", 79, 83], ["blood", "ORGANISM_SUBSTANCE", 145, 150], ["erythrocytes", "CELL", 152, 164], ["leukocytes", "CELL", 166, 176], ["platelets", "CELL", 178, 187], ["erythrocytes", "CELL_TYPE", 152, 164], ["leukocytes", "CELL_TYPE", 166, 176], ["platelets", "CELL_TYPE", 178, 187], ["hydrogen peroxide", "TREATMENT", 58, 75], ["the blood (erythrocytes", "TEST", 141, 164], ["leukocytes", "TEST", 166, 176], ["platelets", "TEST", 178, 187]]], ["In contrast, LOPs, which are produced simultaneously, have a longer half-life, reach the vascular system, and interact with various organs, where they trigger late effects.", [["vascular system", "ANATOMY", 89, 104], ["organs", "ANATOMY", 132, 138], ["LOPs", "SIMPLE_CHEMICAL", 13, 17], ["vascular system", "MULTI-TISSUE_STRUCTURE", 89, 104], ["organs", "ORGAN", 132, 138], ["LOPs", "PROTEIN", 13, 17], ["LOPs", "TEST", 13, 17], ["vascular system", "ANATOMY", 89, 104]]], ["Some of these target organs are the liver (in chronic hepatitis), the vascular system (in vasculopathies), while other organs are likely involved in the restoration of normal homeostasis (central nervous system, gastrointestinal tract, lymphoid tissue associated with mucosa) [26, 30, 32].Ozone and Medicinal PropertiesThe biological effects of ozone in plasma are due to the formation of ROS and LOPs (ozone messengers).", [["organs", "ANATOMY", 21, 27], ["liver", "ANATOMY", 36, 41], ["vascular system", "ANATOMY", 70, 85], ["vasculopathies", "ANATOMY", 90, 104], ["organs", "ANATOMY", 119, 125], ["central nervous system", "ANATOMY", 188, 210], ["gastrointestinal tract", "ANATOMY", 212, 234], ["lymphoid tissue", "ANATOMY", 236, 251], ["mucosa", "ANATOMY", 268, 274], ["plasma", "ANATOMY", 354, 360], ["hepatitis", "DISEASE", 54, 63], ["Ozone", "CHEMICAL", 289, 294], ["ozone", "CHEMICAL", 345, 350], ["ROS", "CHEMICAL", 389, 392], ["ozone", "CHEMICAL", 403, 408], ["Ozone", "CHEMICAL", 289, 294], ["ozone", "CHEMICAL", 345, 350], ["ozone", "CHEMICAL", 403, 408], ["organs", "ORGAN", 21, 27], ["liver", "ORGAN", 36, 41], ["vascular system", "MULTI-TISSUE_STRUCTURE", 70, 85], ["vasculopathies", "CANCER", 90, 104], ["organs", "ORGAN", 119, 125], ["central nervous system", "ANATOMICAL_SYSTEM", 188, 210], ["gastrointestinal tract", "ORGAN", 212, 234], ["lymphoid tissue", "TISSUE", 236, 251], ["mucosa", "MULTI-TISSUE_STRUCTURE", 268, 274], ["Ozone", "SIMPLE_CHEMICAL", 289, 294], ["ozone", "SIMPLE_CHEMICAL", 345, 350], ["plasma", "ORGANISM_SUBSTANCE", 354, 360], ["ROS", "SIMPLE_CHEMICAL", 389, 392], ["LOPs", "SIMPLE_CHEMICAL", 397, 401], ["ozone", "SIMPLE_CHEMICAL", 403, 408], ["chronic hepatitis", "PROBLEM", 46, 63], ["vasculopathies", "PROBLEM", 90, 104], ["lymphoid tissue", "PROBLEM", 236, 251], ["Ozone", "TREATMENT", 289, 294], ["Medicinal Properties", "TREATMENT", 299, 319], ["ozone in plasma", "TEST", 345, 360], ["ROS", "PROBLEM", 389, 392], ["liver", "ANATOMY", 36, 41], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["hepatitis", "OBSERVATION", 54, 63], ["vascular system", "ANATOMY", 70, 85], ["vasculopathies", "OBSERVATION", 90, 104], ["normal homeostasis", "OBSERVATION", 168, 186], ["central", "ANATOMY_MODIFIER", 188, 195], ["nervous system", "ANATOMY", 196, 210], ["gastrointestinal tract", "ANATOMY", 212, 234], ["lymphoid tissue", "OBSERVATION", 236, 251], ["Medicinal Properties", "OBSERVATION_MODIFIER", 299, 319]]], ["ROS improve O2 delivery in erythrocytes.", [["erythrocytes", "ANATOMY", 27, 39], ["ROS", "CHEMICAL", 0, 3], ["O2", "CHEMICAL", 12, 14], ["O2", "CHEMICAL", 12, 14], ["ROS", "SIMPLE_CHEMICAL", 0, 3], ["O2", "SIMPLE_CHEMICAL", 12, 14], ["erythrocytes", "CELL", 27, 39], ["erythrocytes", "CELL_TYPE", 27, 39], ["O2 delivery", "TREATMENT", 12, 23]]], ["ROS also activate the immune system by stimulation of leukocytes.", [["immune system", "ANATOMY", 22, 35], ["leukocytes", "ANATOMY", 54, 64], ["ROS", "CHEMICAL", 0, 3], ["ROS", "SIMPLE_CHEMICAL", 0, 3], ["leukocytes", "CELL", 54, 64], ["leukocytes", "CELL_TYPE", 54, 64], ["leukocytes", "TEST", 54, 64], ["leukocytes", "ANATOMY", 54, 64]]], ["In platelets, ozone favors the release of cytokines (local hormones) and growth factors.", [["platelets", "ANATOMY", 3, 12], ["ozone", "CHEMICAL", 14, 19], ["ozone", "CHEMICAL", 14, 19], ["platelets", "CELL", 3, 12], ["ozone", "SIMPLE_CHEMICAL", 14, 19], ["platelets", "CELL_TYPE", 3, 12], ["cytokines", "PROTEIN", 42, 51], ["growth factors", "PROTEIN", 73, 87], ["cytokines (local hormones", "TREATMENT", 42, 67], ["growth factors", "PROBLEM", 73, 87], ["ozone", "OBSERVATION_MODIFIER", 14, 19]]], ["In the endothelium, LOPs increase the release of NO (nitric oxide).", [["endothelium", "ANATOMY", 7, 18], ["NO", "CHEMICAL", 49, 51], ["nitric oxide", "CHEMICAL", 53, 65], ["NO", "CHEMICAL", 49, 51], ["nitric oxide", "CHEMICAL", 53, 65], ["endothelium", "TISSUE", 7, 18], ["LOPs", "SIMPLE_CHEMICAL", 20, 24], ["NO", "SIMPLE_CHEMICAL", 49, 51], ["nitric oxide", "SIMPLE_CHEMICAL", 53, 65], ["NO (nitric oxide", "TREATMENT", 49, 65], ["endothelium", "ANATOMY", 7, 18]]], ["In bone marrow, LOPs favor the release of stem cells and generation of gifted erythrocytes.", [["bone marrow", "ANATOMY", 3, 14], ["stem cells", "ANATOMY", 42, 52], ["erythrocytes", "ANATOMY", 78, 90], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 3, 14], ["LOPs", "SIMPLE_CHEMICAL", 16, 20], ["stem cells", "CELL", 42, 52], ["erythrocytes", "CELL", 78, 90], ["stem cells", "CELL_TYPE", 42, 52], ["gifted erythrocytes", "CELL_TYPE", 71, 90], ["stem cells", "PROBLEM", 42, 52], ["gifted erythrocytes", "PROBLEM", 71, 90], ["bone marrow", "ANATOMY", 3, 14], ["stem cells", "OBSERVATION", 42, 52], ["gifted erythrocytes", "OBSERVATION", 71, 90]]], ["Finally, LOPs act on other organs, activating the positive regulation of oxidative shock proteins (OSP) and antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase) [26, 32].Ozone and Medicinal PropertiesOzone modulates inflammation and oxidative stress, stabilizing the pro-oxidant and antioxidant balance [31].", [["organs", "ANATOMY", 27, 33], ["superoxide", "CHEMICAL", 129, 139], ["glutathione", "CHEMICAL", 165, 176], ["Ozone", "CHEMICAL", 198, 203], ["Ozone", "CHEMICAL", 228, 233], ["inflammation", "DISEASE", 244, 256], ["superoxide", "CHEMICAL", 129, 139], ["glutathione", "CHEMICAL", 165, 176], ["Ozone", "CHEMICAL", 198, 203], ["Ozone", "CHEMICAL", 228, 233], ["LOPs", "SIMPLE_CHEMICAL", 9, 13], ["organs", "ORGAN", 27, 33], ["oxidative shock proteins", "GENE_OR_GENE_PRODUCT", 73, 97], ["OSP", "GENE_OR_GENE_PRODUCT", 99, 102], ["antioxidant enzymes", "GENE_OR_GENE_PRODUCT", 108, 127], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 129, 149], ["catalase", "SIMPLE_CHEMICAL", 151, 159], ["glutathione", "SIMPLE_CHEMICAL", 165, 176], ["peroxidase", "GENE_OR_GENE_PRODUCT", 177, 187], ["Ozone", "SIMPLE_CHEMICAL", 198, 203], ["Ozone", "SIMPLE_CHEMICAL", 228, 233], ["LOPs", "PROTEIN", 9, 13], ["oxidative shock proteins", "PROTEIN", 73, 97], ["OSP", "PROTEIN", 99, 102], ["antioxidant enzymes", "PROTEIN", 108, 127], ["superoxide dismutase", "PROTEIN", 129, 149], ["catalase", "PROTEIN", 151, 159], ["glutathione peroxidase", "PROTEIN", 165, 187], ["oxidative shock proteins", "TREATMENT", 73, 97], ["antioxidant enzymes (superoxide dismutase", "TREATMENT", 108, 149], ["catalase", "TEST", 151, 159], ["glutathione peroxidase", "TEST", 165, 187], ["Ozone", "TREATMENT", 198, 203], ["Medicinal Properties", "TREATMENT", 208, 228], ["Ozone modulates inflammation", "PROBLEM", 228, 256], ["oxidative stress", "PROBLEM", 261, 277], ["antioxidant balance", "TEST", 311, 330], ["Medicinal Properties", "OBSERVATION_MODIFIER", 208, 228], ["inflammation", "OBSERVATION", 244, 256], ["oxidative stress", "OBSERVATION", 261, 277]]], ["In summary, ozone increases the rheological properties of the blood, improves the delivery of O2, the endothelial production of NO, and modulation of immunity via cytokine induction.", [["blood", "ANATOMY", 62, 67], ["endothelial", "ANATOMY", 102, 113], ["ozone", "CHEMICAL", 12, 17], ["NO", "CHEMICAL", 128, 130], ["ozone", "CHEMICAL", 12, 17], ["O2", "CHEMICAL", 94, 96], ["NO", "CHEMICAL", 128, 130], ["ozone", "SIMPLE_CHEMICAL", 12, 17], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["O2", "SIMPLE_CHEMICAL", 94, 96], ["endothelial", "CELL", 102, 113], ["NO", "GENE_OR_GENE_PRODUCT", 128, 130], ["cytokine", "PROTEIN", 163, 171], ["the delivery of O2", "TREATMENT", 78, 96], ["cytokine induction", "TREATMENT", 163, 181]]], ["In this sense, ozone (O3) is the \u201cideal\u201d cytokine inducer (Table 2) [26, 32].Property 1 ::: Potential Properties of Ozone on SARS-COV-2Rowen states that ozone is capable of directly inactivating many viruses (Norwalk virus, Hepatitis A virus, poliovirus and MS3 colofagus) [34].", [["ozone", "CHEMICAL", 15, 20], ["O3", "CHEMICAL", 22, 24], ["Ozone", "CHEMICAL", 116, 121], ["SARS-COV-2Rowen", "CHEMICAL", 125, 140], ["ozone", "CHEMICAL", 153, 158], ["Hepatitis A virus", "DISEASE", 224, 241], ["ozone", "CHEMICAL", 15, 20], ["O3", "CHEMICAL", 22, 24], ["Ozone", "CHEMICAL", 116, 121], ["ozone", "CHEMICAL", 153, 158], ["ozone", "SIMPLE_CHEMICAL", 15, 20], ["O3", "SIMPLE_CHEMICAL", 22, 24], ["Ozone", "SIMPLE_CHEMICAL", 116, 121], ["ozone", "SIMPLE_CHEMICAL", 153, 158], ["Norwalk virus", "ORGANISM", 209, 222], ["Hepatitis A virus", "ORGANISM", 224, 241], ["poliovirus", "ORGANISM", 243, 253], ["MS3 colofagus", "ORGANISM", 258, 271], ["cytokine", "PROTEIN", 41, 49], ["Hepatitis A virus", "SPECIES", 224, 241], ["MS3 colofagus", "SPECIES", 258, 271], ["Norwalk virus", "SPECIES", 209, 222], ["Hepatitis A virus", "SPECIES", 224, 241], ["MS3 colofagus", "SPECIES", 258, 271], ["SARS", "PROBLEM", 125, 129], ["many viruses (Norwalk virus", "PROBLEM", 195, 222], ["Hepatitis A virus", "PROBLEM", 224, 241], ["poliovirus", "PROBLEM", 243, 253], ["Ozone", "OBSERVATION_MODIFIER", 116, 121]]], ["The explanation for the \u201cvirucidal\u201d effect is that ozone is capable of oxidizing the glycoprotein of its membrane, transforming it from the reduced form (R-S-H) to the oxidized form (R-S-S-R).", [["membrane", "ANATOMY", 105, 113], ["ozone", "CHEMICAL", 51, 56], ["ozone", "CHEMICAL", 51, 56], ["R-S-H", "CHEMICAL", 154, 159], ["ozone", "SIMPLE_CHEMICAL", 51, 56], ["membrane", "CELLULAR_COMPONENT", 105, 113], ["glycoprotein", "PROTEIN", 85, 97], ["the \u201cvirucidal\u201d effect", "TREATMENT", 20, 42]]], ["The virus normally requires the reduced form to enter cells and infect them [34].", [["cells", "ANATOMY", 54, 59], ["cells", "CELL", 54, 59], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["Mirazmi has observed that CMV (cytomegalovirus) loses infectivity if its \u201cthiol\u201d or sulfhydryl (R-S-H) group is oxidized (R-S-S-R), as Rowen observed.", [["Mirazmi", "CHEMICAL", 0, 7], ["thiol", "CHEMICAL", 74, 79], ["sulfhydryl", "CHEMICAL", 84, 94], ["R-S-H", "CHEMICAL", 96, 101], ["thiol", "CHEMICAL", 74, 79], ["sulfhydryl", "CHEMICAL", 84, 94], ["R-S-H", "CHEMICAL", 96, 101], ["CMV", "ORGANISM", 26, 29], ["cytomegalovirus", "ORGANISM", 31, 46], ["\u201cthiol\u201d", "SIMPLE_CHEMICAL", 73, 80], ["sulfhydryl", "SIMPLE_CHEMICAL", 84, 94], ["R-S-H", "SIMPLE_CHEMICAL", 96, 101], ["R-S-S-R", "SIMPLE_CHEMICAL", 122, 129], ["CMV", "SPECIES", 26, 29], ["Mirazmi", "TREATMENT", 0, 7], ["CMV (cytomegalovirus)", "PROBLEM", 26, 47], ["sulfhydryl", "TEST", 84, 94], ["CMV", "OBSERVATION", 26, 29]]], ["Coronaviruses, as well as Ebola virus, have regions rich in cysteine and tryptophan in their membrane S-protein (spike-S) [34, 35].", [["membrane", "ANATOMY", 93, 101], ["Ebola virus", "DISEASE", 26, 37], ["cysteine", "CHEMICAL", 60, 68], ["tryptophan", "CHEMICAL", 73, 83], ["cysteine", "CHEMICAL", 60, 68], ["tryptophan", "CHEMICAL", 73, 83], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["Ebola virus", "ORGANISM", 26, 37], ["cysteine", "AMINO_ACID", 60, 68], ["tryptophan", "AMINO_ACID", 73, 83], ["membrane", "CELLULAR_COMPONENT", 93, 101], ["membrane S-protein", "PROTEIN", 93, 111], ["Ebola virus", "SPECIES", 26, 37], ["Ebola virus", "SPECIES", 26, 37], ["Coronaviruses", "PROBLEM", 0, 13], ["Ebola virus", "PROBLEM", 26, 37], ["tryptophan in their membrane S-protein", "TEST", 73, 111], ["Ebola virus", "OBSERVATION", 26, 37]]], ["Rowen and Eren postulate that ozone would directly oxidize the \u201cthiol\u201d (R-S-H) groups of cysteine and tryptophan to the R-S-S-H form, inactivating them, directly blocking their cellular fusion.", [["cellular", "ANATOMY", 177, 185], ["ozone", "CHEMICAL", 30, 35], ["thiol", "CHEMICAL", 64, 69], ["R-S-H", "CHEMICAL", 72, 77], ["cysteine", "CHEMICAL", 89, 97], ["tryptophan", "CHEMICAL", 102, 112], ["ozone", "CHEMICAL", 30, 35], ["\u201cthiol\u201d (R-S-H", "CHEMICAL", 63, 77], ["cysteine", "CHEMICAL", 89, 97], ["tryptophan", "CHEMICAL", 102, 112], ["R-S-S-H", "CHEMICAL", 120, 127], ["ozone", "SIMPLE_CHEMICAL", 30, 35], ["\u201cthiol\u201d", "SIMPLE_CHEMICAL", 63, 70], ["cysteine", "AMINO_ACID", 89, 97], ["tryptophan", "AMINO_ACID", 102, 112], ["cellular", "CELL", 177, 185], ["R-S-S-H form", "PROTEIN", 120, 132], ["cysteine", "TREATMENT", 89, 97], ["tryptophan", "TREATMENT", 102, 112], ["their cellular fusion", "TREATMENT", 171, 192], ["cellular fusion", "OBSERVATION", 177, 192]]], ["If the ozone does not arrive directly, its messengers, such as ROS or LOPs (H2O2, superoxide, nitric oxide, etc.), still maintain their oxidizing power to inactivate viruses (Fig. 1) [34\u201338].", [["ozone", "CHEMICAL", 7, 12], ["ROS", "CHEMICAL", 63, 66], ["H2O2", "CHEMICAL", 76, 80], ["superoxide", "CHEMICAL", 82, 92], ["nitric oxide", "CHEMICAL", 94, 106], ["ozone", "CHEMICAL", 7, 12], ["H2O2", "CHEMICAL", 76, 80], ["superoxide", "CHEMICAL", 82, 92], ["nitric oxide", "CHEMICAL", 94, 106], ["ozone", "SIMPLE_CHEMICAL", 7, 12], ["ROS", "SIMPLE_CHEMICAL", 63, 66], ["LOPs", "SIMPLE_CHEMICAL", 70, 74], ["H2O2", "SIMPLE_CHEMICAL", 76, 80], ["superoxide", "SIMPLE_CHEMICAL", 82, 92], ["nitric oxide", "SIMPLE_CHEMICAL", 94, 106], ["LOPs (H2O2", "TREATMENT", 70, 80], ["superoxide", "TREATMENT", 82, 92], ["nitric oxide", "TREATMENT", 94, 106]]], ["If ozone by the peroxidation process damages the capsid, the reproductive cycle of the virus is altered, therein would be the therapeutic effect of ozone in the initial phase (state 1) of early infection (Table 1, Fig. 2).Property 2 ::: Potential Properties of Ozone on SARS-COV-2Ozone, via second messengers (H2O2), is capable of stimulating cellular and humoral immunity, through the NFAT (nuclear factor activated T cells) signaling pathway and the AP-1 (activated protein-1) pathway [39].", [["cellular", "ANATOMY", 343, 351], ["T cells", "ANATOMY", 417, 424], ["ozone", "CHEMICAL", 3, 8], ["ozone", "CHEMICAL", 148, 153], ["infection", "DISEASE", 194, 203], ["Ozone", "CHEMICAL", 261, 266], ["SARS-COV-2Ozone", "CHEMICAL", 270, 285], ["H2O2", "CHEMICAL", 310, 314], ["ozone", "CHEMICAL", 3, 8], ["ozone", "CHEMICAL", 148, 153], ["Ozone", "CHEMICAL", 261, 266], ["2Ozone", "CHEMICAL", 279, 285], ["H2O2", "CHEMICAL", 310, 314], ["ozone", "SIMPLE_CHEMICAL", 3, 8], ["ozone", "SIMPLE_CHEMICAL", 148, 153], ["Ozone", "SIMPLE_CHEMICAL", 261, 266], ["SARS-COV-2Ozone", "SIMPLE_CHEMICAL", 270, 285], ["H2O2", "SIMPLE_CHEMICAL", 310, 314], ["cellular", "CELL", 343, 351], ["NFAT", "GENE_OR_GENE_PRODUCT", 386, 390], ["nuclear factor activated T cells", "GENE_OR_GENE_PRODUCT", 392, 424], ["AP-1 (activated protein-1", "GENE_OR_GENE_PRODUCT", 452, 477], ["NFAT", "PROTEIN", 386, 390], ["nuclear factor activated T cells", "PROTEIN", 392, 424], ["AP-1 (activated protein-1", "PROTEIN", 452, 477], ["the peroxidation process", "PROBLEM", 12, 36], ["the capsid", "PROBLEM", 45, 55], ["the virus", "PROBLEM", 83, 92], ["early infection", "PROBLEM", 188, 203], ["SARS", "PROBLEM", 270, 274], ["2Ozone", "TREATMENT", 279, 285], ["signaling pathway", "TEST", 426, 443], ["the AP", "TEST", 448, 454], ["activated protein", "TEST", 458, 475], ["early", "OBSERVATION_MODIFIER", 188, 193], ["infection", "OBSERVATION", 194, 203], ["Ozone", "OBSERVATION_MODIFIER", 261, 266]]], ["These pathways are crucial transcription factors since they would induce the expression of genes to release inflammatory cytokines (IL-2, IL-6, IL-8, TNF-\u03b1, and IFN-\u03b3) that will produce the inflammation that will recruit the neutrophils, lymphocytes, and macrophages, in order to carry out phagocytosis to limit infection at that level, killing local pathogens [26, 39].", [["neutrophils", "ANATOMY", 225, 236], ["lymphocytes", "ANATOMY", 238, 249], ["macrophages", "ANATOMY", 255, 266], ["inflammation", "DISEASE", 190, 202], ["infection", "DISEASE", 312, 321], ["IL-2", "GENE_OR_GENE_PRODUCT", 132, 136], ["IL-6", "GENE_OR_GENE_PRODUCT", 138, 142], ["IL-8", "GENE_OR_GENE_PRODUCT", 144, 148], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 150, 155], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 161, 166], ["neutrophils", "CELL", 225, 236], ["lymphocytes", "CELL", 238, 249], ["macrophages", "CELL", 255, 266], ["transcription factors", "PROTEIN", 27, 48], ["inflammatory cytokines", "PROTEIN", 108, 130], ["IL-2, IL-6, IL-8", "PROTEIN", 132, 148], ["TNF", "PROTEIN", 150, 153], ["\u03b1", "PROTEIN", 154, 155], ["IFN", "PROTEIN", 161, 164], ["neutrophils", "CELL_TYPE", 225, 236], ["lymphocytes", "CELL_TYPE", 238, 249], ["macrophages", "CELL_TYPE", 255, 266], ["crucial transcription factors", "PROBLEM", 19, 48], ["inflammatory cytokines", "TEST", 108, 130], ["IL", "TEST", 132, 134], ["IL", "TEST", 138, 140], ["IL", "TEST", 144, 146], ["TNF", "TEST", 150, 153], ["the inflammation", "PROBLEM", 186, 202], ["the neutrophils", "TEST", 221, 236], ["lymphocytes", "TEST", 238, 249], ["macrophages", "PROBLEM", 255, 266], ["phagocytosis", "PROBLEM", 290, 302], ["infection", "PROBLEM", 312, 321], ["inflammation", "OBSERVATION", 190, 202], ["infection", "OBSERVATION", 312, 321]]], ["This property of ozone would allow acting in the viral response phase (state 1 and state 2) of the viral infection (Table 1, Fig. 2).Property 3 ::: Potential Properties of Ozone on SARS-COV-2Ozone at therapeutic doses modulates erythroid nuclear factor type 2 (Nrf2) and NF-\u041a\u03b2 and induces the rebalancing of the antioxidant environment [40\u201344].", [["ozone", "CHEMICAL", 17, 22], ["viral infection", "DISEASE", 99, 114], ["Ozone", "CHEMICAL", 172, 177], ["SARS-COV-2Ozone", "CHEMICAL", 181, 196], ["ozone", "CHEMICAL", 17, 22], ["Ozone", "CHEMICAL", 172, 177], ["ozone", "SIMPLE_CHEMICAL", 17, 22], ["Ozone", "SIMPLE_CHEMICAL", 172, 177], ["SARS-COV-2Ozone", "SIMPLE_CHEMICAL", 181, 196], ["erythroid nuclear factor type 2", "GENE_OR_GENE_PRODUCT", 228, 259], ["Nrf2", "GENE_OR_GENE_PRODUCT", 261, 265], ["NF-\u041a\u03b2", "GENE_OR_GENE_PRODUCT", 271, 276], ["erythroid nuclear factor type 2", "PROTEIN", 228, 259], ["Nrf2", "PROTEIN", 261, 265], ["NF-\u041a\u03b2", "PROTEIN", 271, 276], ["the viral infection", "PROBLEM", 95, 114], ["SARS", "PROBLEM", 181, 185], ["COV", "TEST", 186, 189], ["2Ozone", "TREATMENT", 190, 196], ["ozone", "OBSERVATION", 17, 22], ["viral", "OBSERVATION_MODIFIER", 99, 104], ["infection", "OBSERVATION", 105, 114], ["Ozone", "OBSERVATION_MODIFIER", 172, 177]]], ["Nrf2 is the key transcriptionist that controls various aspects related to cellular homeostasis in response to toxic or oxidizing agents.", [["cellular", "ANATOMY", 74, 82], ["Nrf2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cellular", "CELL", 74, 82], ["Nrf2", "PROTEIN", 0, 4], ["cellular homeostasis", "PROBLEM", 74, 94], ["oxidizing agents", "TREATMENT", 119, 135], ["cellular homeostasis", "OBSERVATION", 74, 94]]], ["In particular, the effects of Nrf2 mediate basal or induced transcription of phase II antioxidant enzymes (it produces the enzymes catalase, glutathione peroxidase, and superoxide dismutase), which are the enzymes responsible for the elimination of ROS.", [["glutathione", "CHEMICAL", 141, 152], ["superoxide", "CHEMICAL", 169, 179], ["ROS", "CHEMICAL", 249, 252], ["glutathione", "CHEMICAL", 141, 152], ["superoxide", "CHEMICAL", 169, 179], ["Nrf2", "GENE_OR_GENE_PRODUCT", 30, 34], ["catalase", "GENE_OR_GENE_PRODUCT", 131, 139], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 141, 163], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 169, 189], ["ROS", "SIMPLE_CHEMICAL", 249, 252], ["Nrf2", "PROTEIN", 30, 34], ["phase II antioxidant enzymes", "PROTEIN", 77, 105], ["catalase", "PROTEIN", 131, 139], ["glutathione peroxidase", "PROTEIN", 141, 163], ["superoxide dismutase", "PROTEIN", 169, 189], ["phase II antioxidant enzymes", "TEST", 77, 105], ["the enzymes catalase", "TEST", 119, 139], ["glutathione peroxidase", "TREATMENT", 141, 163], ["superoxide dismutase", "TEST", 169, 189], ["the enzymes", "TEST", 202, 213]]], ["During acute inflammatory processes, to increase the magnitude of the response, NF-kB promotes increased activity of mitochondrial NADPH oxidase, the main source of endogenous superoxide anion radical.", [["mitochondrial", "ANATOMY", 117, 130], ["NADPH", "CHEMICAL", 131, 136], ["superoxide", "CHEMICAL", 176, 186], ["NADPH", "CHEMICAL", 131, 136], ["superoxide", "CHEMICAL", 176, 186], ["NF-kB", "GENE_OR_GENE_PRODUCT", 80, 85], ["mitochondrial", "CELLULAR_COMPONENT", 117, 130], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 131, 144], ["superoxide anion radical", "SIMPLE_CHEMICAL", 176, 200], ["NF-kB", "PROTEIN", 80, 85], ["mitochondrial NADPH oxidase", "PROTEIN", 117, 144], ["acute inflammatory processes", "PROBLEM", 7, 35], ["mitochondrial NADPH oxidase", "TREATMENT", 117, 144], ["endogenous superoxide anion radical", "TREATMENT", 165, 200], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["inflammatory", "OBSERVATION", 13, 25], ["NADPH oxidase", "OBSERVATION", 131, 144], ["endogenous superoxide", "OBSERVATION", 165, 186], ["anion radical", "OBSERVATION", 187, 200]]], ["It is now clear that there are strong links between the coordinated activity of gene activation by both transcription factors (NF-kB and Nrf2) to solve inflammatory processes at the cellular and tissue level.", [["cellular", "ANATOMY", 182, 190], ["tissue", "ANATOMY", 195, 201], ["NF-kB", "GENE_OR_GENE_PRODUCT", 127, 132], ["Nrf2", "GENE_OR_GENE_PRODUCT", 137, 141], ["cellular", "CELL", 182, 190], ["tissue", "TISSUE", 195, 201], ["transcription factors", "PROTEIN", 104, 125], ["NF-kB", "PROTEIN", 127, 132], ["Nrf2", "PROTEIN", 137, 141], ["solve inflammatory processes", "PROBLEM", 146, 174], ["clear", "OBSERVATION", 10, 15], ["strong", "OBSERVATION_MODIFIER", 31, 37], ["coordinated", "OBSERVATION_MODIFIER", 56, 67], ["activity", "OBSERVATION_MODIFIER", 68, 76], ["inflammatory", "OBSERVATION", 152, 164], ["tissue", "ANATOMY", 195, 201]]], ["An imbalance between the NF-kB and Nrf2 routes is associated with a large number of diseases, as is the case of COVID-19 complications [43, 44].", [["NF-kB", "GENE_OR_GENE_PRODUCT", 25, 30], ["Nrf2", "GENE_OR_GENE_PRODUCT", 35, 39], ["NF-kB", "PROTEIN", 25, 30], ["Nrf2", "PROTEIN", 35, 39], ["An imbalance", "PROBLEM", 0, 12], ["Nrf2 routes", "TREATMENT", 35, 46], ["a large number of diseases", "PROBLEM", 66, 92], ["COVID", "TEST", 112, 117], ["imbalance", "OBSERVATION", 3, 12], ["large", "OBSERVATION_MODIFIER", 68, 73], ["number", "OBSERVATION_MODIFIER", 74, 80], ["diseases", "OBSERVATION", 84, 92]]], ["Fern\u00e1ndez-Cuadros has stated that ozone is capable of blocking the NF-\u041a\u03b2 pathway, decreasing proinflammatory cytokines IL-1, IL-6, TNF-\u03b1, and stimulating anti-inflammatory cytokines IL-4 and IL-10 [45, 46].", [["ozone", "CHEMICAL", 34, 39], ["ozone", "CHEMICAL", 34, 39], ["ozone", "SIMPLE_CHEMICAL", 34, 39], ["NF-\u041a\u03b2", "GENE_OR_GENE_PRODUCT", 67, 72], ["IL-1", "GENE_OR_GENE_PRODUCT", 119, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 125, 129], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 131, 136], ["IL-4", "GENE_OR_GENE_PRODUCT", 182, 186], ["IL-10", "GENE_OR_GENE_PRODUCT", 191, 196], ["NF-\u041a\u03b2", "PROTEIN", 67, 72], ["proinflammatory cytokines", "PROTEIN", 93, 118], ["IL", "PROTEIN", 119, 121], ["IL-6", "PROTEIN", 125, 129], ["TNF", "PROTEIN", 131, 134], ["anti-inflammatory cytokines", "PROTEIN", 154, 181], ["IL", "PROTEIN", 182, 184], ["IL", "PROTEIN", 191, 193], ["decreasing proinflammatory cytokines IL", "TREATMENT", 82, 121], ["IL", "TEST", 125, 127], ["TNF", "TEST", 131, 134], ["stimulating anti-inflammatory cytokines IL", "TREATMENT", 142, 184]]], ["Furthermore, in a recent study, Fern\u00e1ndez-Cuadros has observed that ozone is capable of modulating inflammation, decreasing inflammation markers such as CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate) [16].", [["erythrocyte", "ANATOMY", 187, 198], ["ozone", "CHEMICAL", 68, 73], ["inflammation", "DISEASE", 99, 111], ["inflammation", "DISEASE", 124, 136], ["ozone", "CHEMICAL", 68, 73], ["ozone", "SIMPLE_CHEMICAL", 68, 73], ["CRP", "GENE_OR_GENE_PRODUCT", 153, 156], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 158, 176], ["erythrocyte sedimentation", "GENE_OR_GENE_PRODUCT", 187, 212], ["inflammation markers", "PROTEIN", 124, 144], ["CRP", "PROTEIN", 153, 156], ["C-reactive protein", "PROTEIN", 158, 176], ["ESR", "PROTEIN", 182, 185], ["a recent study", "TEST", 16, 30], ["modulating inflammation", "PROBLEM", 88, 111], ["decreasing inflammation markers", "PROBLEM", 113, 144], ["CRP", "TEST", 153, 156], ["C-reactive protein", "TEST", 158, 176], ["ESR", "TEST", 182, 185], ["erythrocyte sedimentation rate", "TEST", 187, 217], ["inflammation", "OBSERVATION", 99, 111], ["decreasing", "OBSERVATION_MODIFIER", 113, 123], ["inflammation", "OBSERVATION", 124, 136]]], ["Due to these characteristics, we believe that ozone could modulate inflammation and have a therapeutic role in the hyper inflammation phase, acting on the \u201ccytokine storm\u201d (Table 1, Fig. 2).Property 4 ::: Potential Properties of Ozone on SARS-COV-2Ozone could improve the circulation and perfusion of the lung and of all the organs in a state of hypoxia.", [["lung", "ANATOMY", 305, 309], ["organs", "ANATOMY", 325, 331], ["ozone", "CHEMICAL", 46, 51], ["inflammation", "DISEASE", 67, 79], ["inflammation", "DISEASE", 121, 133], ["Ozone", "CHEMICAL", 229, 234], ["SARS-COV-2Ozone", "CHEMICAL", 238, 253], ["hypoxia", "DISEASE", 346, 353], ["ozone", "CHEMICAL", 46, 51], ["Ozone", "CHEMICAL", 229, 234], ["ozone", "SIMPLE_CHEMICAL", 46, 51], ["Ozone", "SIMPLE_CHEMICAL", 229, 234], ["SARS-COV-2Ozone", "SIMPLE_CHEMICAL", 238, 253], ["lung", "ORGAN", 305, 309], ["organs", "ORGAN", 325, 331], ["cytokine", "PROTEIN", 156, 164], ["modulate inflammation", "PROBLEM", 58, 79], ["the hyper inflammation phase", "PROBLEM", 111, 139], ["SARS", "PROBLEM", 238, 242], ["2Ozone", "TREATMENT", 247, 253], ["hypoxia", "PROBLEM", 346, 353], ["inflammation", "OBSERVATION", 67, 79], ["therapeutic", "OBSERVATION_MODIFIER", 91, 102], ["hyper", "OBSERVATION_MODIFIER", 115, 120], ["inflammation", "OBSERVATION", 121, 133], ["Ozone", "OBSERVATION_MODIFIER", 229, 234], ["lung", "ANATOMY", 305, 309], ["organs", "ANATOMY", 325, 331], ["hypoxia", "OBSERVATION", 346, 353]]], ["Ozone improves the metabolism of oxygen [15, 26].", [["Ozone", "CHEMICAL", 0, 5], ["oxygen", "CHEMICAL", 33, 39], ["Ozone", "CHEMICAL", 0, 5], ["oxygen", "CHEMICAL", 33, 39], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["oxygen", "SIMPLE_CHEMICAL", 33, 39], ["metabolism", "OBSERVATION_MODIFIER", 19, 29]]], ["Ozonized erythrocytes show improved glycolysis with increased levels of ATP and 2,3-DPG (diphosphoglycerate), which can shift the HbO2 dissociation curve to the right, increase arterial PO2, and decrease venous PO2 (Bhor effect), improving oxygen supply to ischemic tissues [15, 26].", [["erythrocytes", "ANATOMY", 9, 21], ["arterial", "ANATOMY", 177, 185], ["venous", "ANATOMY", 204, 210], ["tissues", "ANATOMY", 266, 273], ["ATP", "CHEMICAL", 72, 75], ["2,3-DPG", "CHEMICAL", 80, 87], ["diphosphoglycerate", "CHEMICAL", 89, 107], ["PO2", "CHEMICAL", 186, 189], ["PO2", "CHEMICAL", 211, 214], ["oxygen", "CHEMICAL", 240, 246], ["ATP", "CHEMICAL", 72, 75], ["2,3-DPG", "CHEMICAL", 80, 87], ["diphosphoglycerate", "CHEMICAL", 89, 107], ["PO2", "CHEMICAL", 211, 214], ["oxygen", "CHEMICAL", 240, 246], ["erythrocytes", "CELL", 9, 21], ["ATP", "SIMPLE_CHEMICAL", 72, 75], ["2,3-DPG", "SIMPLE_CHEMICAL", 80, 87], ["diphosphoglycerate", "SIMPLE_CHEMICAL", 89, 107], ["HbO2", "SIMPLE_CHEMICAL", 130, 134], ["arterial", "MULTI-TISSUE_STRUCTURE", 177, 185], ["PO2", "SIMPLE_CHEMICAL", 186, 189], ["venous", "MULTI-TISSUE_STRUCTURE", 204, 210], ["PO2", "SIMPLE_CHEMICAL", 211, 214], ["oxygen", "SIMPLE_CHEMICAL", 240, 246], ["tissues", "TISSUE", 266, 273], ["Ozonized erythrocytes", "CELL_TYPE", 0, 21], ["Ozonized erythrocytes", "TEST", 0, 21], ["improved glycolysis", "PROBLEM", 27, 46], ["increased levels of ATP", "PROBLEM", 52, 75], ["DPG (diphosphoglycerate", "TREATMENT", 84, 107], ["the HbO2 dissociation curve", "TEST", 126, 153], ["arterial PO2", "TEST", 177, 189], ["decrease venous PO2", "PROBLEM", 195, 214], ["ischemic tissues", "PROBLEM", 257, 273], ["improved glycolysis", "OBSERVATION", 27, 46], ["right", "ANATOMY_MODIFIER", 161, 166], ["increase", "OBSERVATION_MODIFIER", 168, 176], ["arterial PO2", "OBSERVATION", 177, 189], ["decrease", "OBSERVATION_MODIFIER", 195, 203], ["venous", "ANATOMY", 204, 210], ["ischemic tissues", "OBSERVATION", 257, 273]]], ["Continuous applications of ozone stimulate the bone marrow and induce it to generate new \u201cgifted erythrocytes\u201d with an increase in the content of 2,3-DPG, as well as an elevation of glucose 6-phosphate dehydrogenase (G6PD); this may allow a profound modification of functional activities leading tissues and organs from a hypoxic to a normoxic state [15, 26].", [["bone marrow", "ANATOMY", 47, 58], ["erythrocytes", "ANATOMY", 97, 109], ["tissues", "ANATOMY", 296, 303], ["organs", "ANATOMY", 308, 314], ["ozone", "CHEMICAL", 27, 32], ["2,3-DPG", "CHEMICAL", 146, 153], ["glucose 6-phosphate", "CHEMICAL", 182, 201], ["ozone", "CHEMICAL", 27, 32], ["2,3-DPG", "CHEMICAL", 146, 153], ["glucose 6-phosphate", "CHEMICAL", 182, 201], ["ozone", "SIMPLE_CHEMICAL", 27, 32], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 47, 58], ["erythrocytes", "CELL", 97, 109], ["2,3-DPG", "SIMPLE_CHEMICAL", 146, 153], ["glucose 6-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 182, 215], ["G6PD", "GENE_OR_GENE_PRODUCT", 217, 221], ["tissues", "TISSUE", 296, 303], ["organs", "ORGAN", 308, 314], ["\u201cgifted erythrocytes", "CELL_TYPE", 89, 109], ["glucose 6-phosphate dehydrogenase", "PROTEIN", 182, 215], ["G6PD", "PROTEIN", 217, 221], ["ozone stimulate the bone marrow", "TREATMENT", 27, 58], ["new \u201cgifted erythrocytes", "PROBLEM", 85, 109], ["DPG", "TREATMENT", 150, 153], ["an elevation of glucose", "PROBLEM", 166, 189], ["phosphate dehydrogenase (G6PD)", "PROBLEM", 192, 222], ["a hypoxic to a normoxic state", "PROBLEM", 320, 349], ["bone marrow", "ANATOMY", 47, 58], ["increase", "OBSERVATION_MODIFIER", 119, 127], ["elevation", "OBSERVATION", 169, 178], ["hypoxic", "OBSERVATION_MODIFIER", 322, 329]]], ["Patients with SARS-CoV-2 are likely to have mild non-specific hepatitis, pulmonary fibrosis, and renal failure [47].", [["pulmonary", "ANATOMY", 73, 82], ["renal", "ANATOMY", 97, 102], ["SARS", "DISEASE", 14, 18], ["hepatitis", "DISEASE", 62, 71], ["pulmonary fibrosis", "DISEASE", 73, 91], ["renal failure", "DISEASE", 97, 110], ["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 14, 24], ["pulmonary", "ORGAN", 73, 82], ["renal", "ORGAN", 97, 102], ["Patients", "SPECIES", 0, 8], ["SARS", "PROBLEM", 14, 18], ["mild non-specific hepatitis", "PROBLEM", 44, 71], ["pulmonary fibrosis", "PROBLEM", 73, 91], ["renal failure", "PROBLEM", 97, 110], ["mild", "OBSERVATION_MODIFIER", 44, 48], ["non-specific", "OBSERVATION_MODIFIER", 49, 61], ["hepatitis", "OBSERVATION", 62, 71], ["pulmonary", "ANATOMY", 73, 82], ["fibrosis", "OBSERVATION", 83, 91], ["renal", "ANATOMY", 97, 102], ["failure", "OBSERVATION", 103, 110]]], ["Ozone therapy stabilizes liver metabolism and plasma fibrinogen and prothrombin levels tend to normalize in infected patients, suggesting an improvement in the synthesis of liver proteins [47].", [["liver", "ANATOMY", 25, 30], ["plasma", "ANATOMY", 46, 52], ["liver", "ANATOMY", 173, 178], ["Ozone", "CHEMICAL", 0, 5], ["Ozone", "CHEMICAL", 0, 5], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["liver", "ORGAN", 25, 30], ["plasma", "ORGANISM_SUBSTANCE", 46, 52], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 53, 63], ["prothrombin", "GENE_OR_GENE_PRODUCT", 68, 79], ["patients", "ORGANISM", 117, 125], ["liver", "ORGAN", 173, 178], ["plasma fibrinogen", "PROTEIN", 46, 63], ["prothrombin", "PROTEIN", 68, 79], ["liver proteins", "PROTEIN", 173, 187], ["patients", "SPECIES", 117, 125], ["Ozone therapy", "TREATMENT", 0, 13], ["liver metabolism", "TEST", 25, 41], ["plasma fibrinogen", "TEST", 46, 63], ["prothrombin levels", "TEST", 68, 86], ["the synthesis of liver proteins", "PROBLEM", 156, 187], ["liver", "ANATOMY", 25, 30], ["improvement", "OBSERVATION_MODIFIER", 141, 152], ["liver", "ANATOMY", 173, 178]]], ["There is enough research showing the protective effect of ozone to prevent oxidative damage to the heart, liver, lung, and kidney tissues [47].", [["heart", "ANATOMY", 99, 104], ["liver", "ANATOMY", 106, 111], ["lung", "ANATOMY", 113, 117], ["kidney tissues", "ANATOMY", 123, 137], ["ozone", "CHEMICAL", 58, 63], ["ozone", "CHEMICAL", 58, 63], ["ozone", "SIMPLE_CHEMICAL", 58, 63], ["heart", "ORGAN", 99, 104], ["liver", "ORGAN", 106, 111], ["lung", "ORGAN", 113, 117], ["kidney tissues", "TISSUE", 123, 137], ["ozone", "TREATMENT", 58, 63], ["oxidative damage to the heart, liver, lung, and kidney tissues", "PROBLEM", 75, 137], ["oxidative", "OBSERVATION_MODIFIER", 75, 84], ["damage", "OBSERVATION", 85, 91], ["heart", "ANATOMY", 99, 104], ["liver", "ANATOMY", 106, 111], ["lung", "ANATOMY", 113, 117], ["kidney", "ANATOMY", 123, 129]]], ["For these reasons, we believe that ozone would be useful in the phase of hyper inflammation and multi-organ failure, restoring hypoxemia (Table 1, Fig. 2).Method of AdministrationOzone can be administered by different routes, by the systemic (major autohemotherapy, saturated saline solution, rectal and vaginal insufflation) or non-systemic technique (minor autohemotherapy and bag ozone therapy) [26, 31].", [["multi-organ", "ANATOMY", 96, 107], ["rectal", "ANATOMY", 293, 299], ["vaginal", "ANATOMY", 304, 311], ["ozone", "CHEMICAL", 35, 40], ["inflammation", "DISEASE", 79, 91], ["multi-organ failure", "DISEASE", 96, 115], ["hypoxemia", "DISEASE", 127, 136], ["AdministrationOzone", "CHEMICAL", 165, 184], ["ozone", "CHEMICAL", 383, 388], ["ozone", "CHEMICAL", 35, 40], ["ozone", "CHEMICAL", 383, 388], ["ozone", "SIMPLE_CHEMICAL", 35, 40], ["multi-organ", "ORGAN", 96, 107], ["AdministrationOzone", "SIMPLE_CHEMICAL", 165, 184], ["saline", "SIMPLE_CHEMICAL", 276, 282], ["rectal", "ORGANISM_SUBDIVISION", 293, 299], ["vaginal", "ORGANISM_SUBDIVISION", 304, 311], ["hyper inflammation", "PROBLEM", 73, 91], ["multi-organ failure", "PROBLEM", 96, 115], ["restoring hypoxemia", "PROBLEM", 117, 136], ["AdministrationOzone", "TREATMENT", 165, 184], ["the systemic (major autohemotherapy, saturated saline solution", "TREATMENT", 229, 291], ["rectal and vaginal insufflation", "TREATMENT", 293, 324], ["non-systemic technique", "TREATMENT", 329, 351], ["minor autohemotherapy", "TREATMENT", 353, 374], ["bag ozone therapy", "TREATMENT", 379, 396], ["hyper", "OBSERVATION_MODIFIER", 73, 78], ["inflammation", "OBSERVATION", 79, 91], ["multi-organ", "ANATOMY", 96, 107], ["failure", "OBSERVATION", 108, 115], ["hypoxemia", "OBSERVATION", 127, 136], ["rectal", "ANATOMY", 293, 299], ["vaginal", "ANATOMY", 304, 311]]], ["There are currently three clinical trials that are being carried out in China and seek to assess the effectiveness of major autohemotherapy on SARS-CoV-2 [4].", [["SARS", "DISEASE", 143, 147], ["SARS-CoV", "SPECIES", 143, 151]]], ["There is no experimental study that is assessing the administration of systemic ozone by rectal insufflation technique.", [["rectal", "ANATOMY", 89, 95], ["ozone", "CHEMICAL", 80, 85], ["ozone", "CHEMICAL", 80, 85], ["ozone", "SIMPLE_CHEMICAL", 80, 85], ["rectal", "ORGAN", 89, 95], ["experimental study", "TEST", 12, 30], ["systemic ozone", "TREATMENT", 71, 85], ["rectal insufflation technique", "TREATMENT", 89, 118], ["no", "UNCERTAINTY", 9, 11], ["rectal", "ANATOMY", 89, 95], ["insufflation", "OBSERVATION", 96, 108]]], ["In this review, we propose that a systemic route, easy to carry out, for the administration of ozone, is the rectal route.", [["rectal", "ANATOMY", 109, 115], ["ozone", "CHEMICAL", 95, 100], ["ozone", "CHEMICAL", 95, 100], ["ozone", "SIMPLE_CHEMICAL", 95, 100], ["rectal", "ORGANISM_SUBDIVISION", 109, 115], ["a systemic route", "TREATMENT", 32, 48], ["ozone", "TREATMENT", 95, 100], ["the rectal route", "TREATMENT", 105, 121], ["rectal", "ANATOMY", 109, 115]]], ["The Ethical Committee at our Hospital has authorized the use of this technique for compassionate management of SARS-CoV-2 infection, considering the four biological ozone properties exposed previously.Method of AdministrationThe rectal insufflation method is a technique of systemic application of ozone that delivers 95\u201396% of ozone compared to the major autohemotherapy route (100% delivery of ozone), but without the risks or technical difficulties involved in venous extraction, venous oxygenation, and reinfusion.", [["rectal", "ANATOMY", 229, 235], ["venous", "ANATOMY", 464, 470], ["venous", "ANATOMY", 483, 489], ["SARS-CoV-2 infection", "DISEASE", 111, 131], ["ozone", "CHEMICAL", 165, 170], ["ozone", "CHEMICAL", 298, 303], ["ozone", "CHEMICAL", 328, 333], ["ozone", "CHEMICAL", 396, 401], ["ozone", "CHEMICAL", 165, 170], ["ozone", "CHEMICAL", 298, 303], ["ozone", "CHEMICAL", 328, 333], ["ozone", "CHEMICAL", 396, 401], ["SARS-CoV-2", "ORGANISM", 111, 121], ["rectal", "ORGAN", 229, 235], ["ozone", "SIMPLE_CHEMICAL", 298, 303], ["ozone", "SIMPLE_CHEMICAL", 328, 333], ["ozone", "SIMPLE_CHEMICAL", 396, 401], ["venous", "MULTI-TISSUE_STRUCTURE", 464, 470], ["venous", "MULTI-TISSUE_STRUCTURE", 483, 489], ["SARS-CoV-2", "SPECIES", 111, 121], ["this technique", "TREATMENT", 64, 78], ["compassionate management", "TREATMENT", 83, 107], ["SARS", "PROBLEM", 111, 115], ["CoV-2 infection", "PROBLEM", 116, 131], ["Method of Administration", "TREATMENT", 201, 225], ["The rectal insufflation method", "TREATMENT", 225, 255], ["systemic application of ozone", "TREATMENT", 274, 303], ["technical difficulties", "PROBLEM", 429, 451], ["venous extraction", "TREATMENT", 464, 481], ["venous oxygenation", "TEST", 483, 501], ["reinfusion", "TREATMENT", 507, 517], ["infection", "OBSERVATION", 122, 131], ["rectal", "ANATOMY", 229, 235], ["insufflation", "OBSERVATION", 236, 248], ["venous", "ANATOMY", 464, 470], ["venous", "ANATOMY", 483, 489], ["oxygenation", "OBSERVATION", 490, 501]]], ["The proposed technique, according to the International Declaration of Ozone Therapy in Madrid, is to administer a volume of between 100 and 300 cc of rectal ozone at a concentration of 25 \u03bcg/ml, to gradually increase every 3 days, until reaching a maximum concentration of 35\u201339 \u03bcg/ml, in an expected time of 10 daily sessions [48].Method of AdministrationRowen, with the same administration technique (rectal ozone), applied to five patients with Ebola (disease that presents a mortality of 60%), has reported a success rate of 100%.", [["rectal", "ANATOMY", 150, 156], ["rectal", "ANATOMY", 403, 409], ["Ozone", "CHEMICAL", 70, 75], ["ozone", "CHEMICAL", 157, 162], ["ozone", "CHEMICAL", 410, 415], ["Ebola", "DISEASE", 448, 453], ["Ozone", "CHEMICAL", 70, 75], ["ozone", "CHEMICAL", 157, 162], ["ozone", "CHEMICAL", 410, 415], ["Ozone", "SIMPLE_CHEMICAL", 70, 75], ["rectal", "ORGAN", 150, 156], ["rectal", "ORGANISM_SUBDIVISION", 403, 409], ["patients", "ORGANISM", 434, 442], ["Ebola", "ORGANISM", 448, 453], ["patients", "SPECIES", 434, 442], ["Ozone Therapy", "TREATMENT", 70, 83], ["rectal ozone", "TREATMENT", 150, 162], ["AdministrationRowen", "TREATMENT", 342, 361], ["the same administration technique", "TREATMENT", 368, 401], ["rectal ozone)", "TREATMENT", 403, 416], ["Ebola (disease", "PROBLEM", 448, 462], ["Ebola", "OBSERVATION", 448, 453]]], ["Rowen noted improvement from the first insufflation, although he completed up to five treatment sessions.", [["improvement", "OBSERVATION_MODIFIER", 12, 23]]], ["With this encouraging report, we believe that this experience can be extended to the management of SARS-Cov-2 [49].ConclusionsTo date, there is no definitive treatment for the new SARS-CoV-2 pandemic.", [["SARS", "DISEASE", 99, 103], ["SARS-CoV-2 pandemic", "DISEASE", 180, 199], ["SARS-CoV-2", "ORGANISM", 180, 190], ["SARS", "PROBLEM", 99, 103], ["definitive treatment", "TREATMENT", 147, 167], ["the new SARS", "PROBLEM", 172, 184], ["CoV", "TEST", 185, 188], ["pandemic", "PROBLEM", 191, 199], ["no definitive", "UNCERTAINTY", 144, 157], ["new", "OBSERVATION_MODIFIER", 176, 179], ["SARS", "OBSERVATION", 180, 184]]], ["There are 80 international experimental trials underway seeking effective treatment for the COVID-19 pandemic.", [["effective treatment", "TREATMENT", 64, 83], ["the COVID", "TEST", 88, 97], ["pandemic", "PROBLEM", 101, 109]]], ["Of these, there are only three that they consider as alternatives to ozone therapy (major autohemotherapy).", [["ozone", "CHEMICAL", 69, 74], ["ozone", "CHEMICAL", 69, 74], ["ozone", "SIMPLE_CHEMICAL", 69, 74], ["ozone therapy", "TREATMENT", 69, 82]]], ["There is no study evaluating rectal ozone insufflation, despite being a safe, inexpensive, risk-free technique that is a systemic route of administration (ozone 95\u201396%) and that could be extrapolated to the use of SARS-CoV-2, given the excellent results observed in the management of Ebola.ConclusionsOzone has four proven biological properties that could allow its use as an alternative therapy in the different phases of SARS-CoV-2 infection.", [["rectal", "ANATOMY", 29, 35], ["ozone", "CHEMICAL", 36, 41], ["ozone", "CHEMICAL", 155, 160], ["SARS", "DISEASE", 214, 218], ["Ebola", "DISEASE", 284, 289], ["Ozone", "CHEMICAL", 301, 306], ["SARS-CoV-2 infection", "DISEASE", 423, 443], ["ozone", "CHEMICAL", 36, 41], ["ozone", "CHEMICAL", 155, 160], ["Ozone", "CHEMICAL", 301, 306], ["rectal", "ORGAN", 29, 35], ["ozone", "SIMPLE_CHEMICAL", 155, 160], ["Ebola", "ORGANISM", 284, 289], ["Ozone", "SIMPLE_CHEMICAL", 301, 306], ["SARS-CoV-2", "ORGANISM", 423, 433], ["SARS-CoV", "SPECIES", 214, 222], ["SARS-CoV-2", "SPECIES", 423, 433], ["study", "TEST", 12, 17], ["rectal ozone insufflation", "TREATMENT", 29, 54], ["Ebola", "PROBLEM", 284, 289], ["an alternative therapy", "TREATMENT", 373, 395], ["SARS", "PROBLEM", 423, 427], ["CoV-2 infection", "PROBLEM", 428, 443], ["no", "UNCERTAINTY", 9, 11], ["rectal", "ANATOMY", 29, 35], ["ozone insufflation", "OBSERVATION", 36, 54], ["Ebola", "OBSERVATION", 284, 289], ["infection", "OBSERVATION", 434, 443]]], ["Ozone could inactivate the virus by direct (O3) or indirect oxidation (ROS and LOPs) and could stimulate the cellular and humoral immune systems, being useful in the early COVID-19 infection phase (states 1 and 2a).", [["cellular", "ANATOMY", 109, 117], ["Ozone", "CHEMICAL", 0, 5], ["O3", "CHEMICAL", 44, 46], ["ROS", "CHEMICAL", 71, 74], ["infection", "DISEASE", 181, 190], ["Ozone", "CHEMICAL", 0, 5], ["O3", "CHEMICAL", 44, 46], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["O3", "SIMPLE_CHEMICAL", 44, 46], ["ROS", "SIMPLE_CHEMICAL", 71, 74], ["LOPs", "SIMPLE_CHEMICAL", 79, 83], ["cellular", "CELL", 109, 117], ["Ozone", "TREATMENT", 0, 5], ["the virus", "PROBLEM", 23, 32], ["indirect oxidation (ROS and LOPs", "TEST", 51, 83], ["the early COVID", "TEST", 162, 177]]], ["Ozone improves gas exchange, reduces inflammation, and modulates the antioxidant system, so it would be useful in the hyper inflammation or cytokine storm phase, and in the hypoxemia and/or multi-organ failure phase (state 2b and state 3).ConclusionsGiven the current pandemic, it is urgent to carry out an experimental study that confirms or rules out the biological properties of ozone and thus allows it to be an alternative or compassionate therapy for the effective management of SARS-Cov-2 infection.", [["multi-organ", "ANATOMY", 190, 201], ["Ozone", "CHEMICAL", 0, 5], ["inflammation", "DISEASE", 37, 49], ["inflammation", "DISEASE", 124, 136], ["hypoxemia", "DISEASE", 173, 182], ["multi-organ failure", "DISEASE", 190, 209], ["ozone", "CHEMICAL", 382, 387], ["SARS", "DISEASE", 485, 489], ["infection", "DISEASE", 496, 505], ["Ozone", "CHEMICAL", 0, 5], ["ozone", "CHEMICAL", 382, 387], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["ozone", "SIMPLE_CHEMICAL", 382, 387], ["Cov-2", "ORGANISM", 490, 495], ["cytokine", "PROTEIN", 140, 148], ["inflammation", "PROBLEM", 37, 49], ["the hyper inflammation", "PROBLEM", 114, 136], ["the hypoxemia", "PROBLEM", 169, 182], ["multi-organ failure phase", "PROBLEM", 190, 215], ["an experimental study", "TEST", 304, 325], ["compassionate therapy", "TREATMENT", 431, 452], ["the effective management", "TREATMENT", 457, 481], ["SARS", "PROBLEM", 485, 489], ["Cov-2 infection", "PROBLEM", 490, 505], ["gas exchange", "OBSERVATION", 15, 27], ["reduces", "OBSERVATION_MODIFIER", 29, 36], ["inflammation", "OBSERVATION", 37, 49], ["inflammation", "OBSERVATION", 124, 136], ["hypoxemia", "OBSERVATION", 173, 182], ["multi-organ", "ANATOMY", 190, 201], ["failure", "OBSERVATION", 202, 209], ["infection", "OBSERVATION", 496, 505]]]], "6426b4a29be4f73f35f303b01c270e2fb4142029": [["IntroductionMathematical models allow us to simulate the spread of diseases through different kinds of settings, model the possible interventions, and provide useful information to policymakers to quick response to curb the disease spread.", [["diseases", "PROBLEM", 67, 75], ["interventions", "TREATMENT", 132, 145], ["the disease spread", "PROBLEM", 220, 238], ["disease", "OBSERVATION", 224, 231]]], ["There is a number of evidence showing that mathematical models play an essential role in investigating disease spread and identifying the key factors that significantly affect outbreaks [1] [2] [3] [4] [5] [6] [7] .", [["[1] [2] [3] [4] [5] [6]", "CHEMICAL", 186, 209], ["[1] [2] [3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 186, 213], ["investigating disease spread", "PROBLEM", 89, 117]]], ["It is well known that mathematical models have successfully helped understand and predict the trend of spread of diseases during the 2003 outbreak of Severe Acute Respiratory Syndrome (SARS) [8] [9] [10] [11] and the 2009 novel A/H1N1 pandemic influenza [12] [13] [14] .", [["Acute Respiratory Syndrome", "DISEASE", 157, 183], ["SARS", "DISEASE", 185, 189], ["influenza", "DISEASE", 244, 253], ["H1N1 pandemic influenza", "SPECIES", 230, 253], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 150, 190], ["A/H1N1 pandemic influenza", "SPECIES", 228, 253], ["diseases", "PROBLEM", 113, 121], ["Severe Acute Respiratory Syndrome", "PROBLEM", 150, 183], ["A/H1N1 pandemic influenza", "PROBLEM", 228, 253], ["Severe", "OBSERVATION_MODIFIER", 150, 156], ["Acute", "OBSERVATION_MODIFIER", 157, 162], ["Respiratory Syndrome", "OBSERVATION", 163, 183]]], ["In fact, the modeling processes are usually the approximation to the real world, and modelers have been looking for the balance between the formulation of sufficiently fine/realistic models and feasibly manipulated models.IntroductionInterventions are usually modeled by continuous processes and disease spread with interventions are often described by the ordinary differential equations.", [["IntroductionInterventions", "TREATMENT", 222, 247], ["disease spread", "PROBLEM", 296, 310], ["interventions", "TREATMENT", 316, 329]]], ["A common assumption for the existing models is that human exploitative activities occur continuously [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .", [["[15] [16] [17] [18] [19] [20] [21] [22] [23]", "CHEMICAL", 101, 145], ["human", "ORGANISM", 52, 57], ["[15] [16] [17] [18] [19] [20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 101, 150], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["human exploitative activities", "PROBLEM", 52, 81]]], ["Mostly, in the early stages of the outbreak of emergent infectious diseases, the public is less aware of information on the disease itself, the degree of crisis or the necessary measures to protection and control, the disease spreads very quickly.", [["infectious diseases", "DISEASE", 56, 75], ["emergent infectious diseases", "PROBLEM", 47, 75], ["the disease itself", "PROBLEM", 120, 138], ["crisis", "PROBLEM", 154, 160], ["the disease spreads", "PROBLEM", 214, 233], ["infectious", "OBSERVATION", 56, 66], ["crisis", "OBSERVATION", 154, 160], ["disease", "OBSERVATION", 218, 225]]], ["As the disease further spreads or the number of infected individuals exceeds a certain number, the public then begin to implement some strategies to protect or control.", [["the disease further spreads", "PROBLEM", 3, 30], ["infected individuals", "PROBLEM", 48, 68], ["some strategies", "TREATMENT", 130, 145], ["disease", "OBSERVATION", 7, 14], ["infected", "OBSERVATION", 48, 56]]], ["Consequently, the threshold policy (TP) provides a natural description of such systems [7, 25] , and consequently Filippov systems become more realistic ones to represent density-dependent control strategies.", [["density-dependent control strategies", "PROBLEM", 171, 207], ["density", "OBSERVATION", 171, 178], ["dependent", "OBSERVATION_MODIFIER", 179, 188]]], ["These systems appear in almost every domain of applied sciences [26] [27] [28] [29] [30] , and in particular, in population dynamics [31] [32] [33] and epidemiology [34] [35] [36] [37] [38] .IntroductionRecently, a number of mathematical models have been proposed to investigate the effect of threshold policy on disease dynamics [31, [34] [35] [36] [37] [39] [40] [41] [42] .", [["[26] [27] [28] [29] [30]", "SIMPLE_CHEMICAL", 64, 88], ["[31] [32] [33]", "SIMPLE_CHEMICAL", 133, 147], ["[34] [35] [36] [37] [38]", "SIMPLE_CHEMICAL", 165, 189], ["[34] [35] [36] [37] [39] [40] [41] [42]", "SIMPLE_CHEMICAL", 335, 374], ["disease dynamics", "TEST", 313, 329]]], ["Existing approaches to model the impact of threshold policy have assumed that the threshold policy only influences on a certain type of population such that they implement control measures or change their behaviors.", [["threshold policy", "TREATMENT", 43, 59], ["control measures", "TREATMENT", 172, 188]]], ["For example, only susceptible individuals enhance the protection strategies to let the incidence rate be reduced by a rate once the number of infected individuals exceeds a threshold level [35, 36] .", [["individuals", "ORGANISM", 30, 41], ["susceptible individuals", "PROBLEM", 18, 41], ["infected individuals", "PROBLEM", 142, 162], ["susceptible", "OBSERVATION_MODIFIER", 18, 29], ["reduced", "OBSERVATION_MODIFIER", 105, 112], ["infected", "OBSERVATION", 142, 150]]], ["However, not only susceptible but also (imperfect) vaccinated individuals enhance protection and control measures to avoid to be infected.", [["individuals", "ORGANISM", 62, 73], ["control measures", "TREATMENT", 97, 113], ["infected", "PROBLEM", 129, 137], ["not only", "UNCERTAINTY", 9, 17], ["infected", "OBSERVATION", 129, 137]]], ["How effective the threshold policy implemented by not only one compartment remains, is therefore an issue of great importance for epidemics control, and quantifying this policy through a mathematical modeling framework falls within the scope of this study.IntroductionThe purpose of this paper is to investigate the effect of threshold policy on disease dynamics, and further to study what particular threshold level can be used to guide to eradicate the infectious disease.", [["infectious disease", "DISEASE", 455, 473], ["epidemics control", "TREATMENT", 130, 147], ["this study", "TEST", 245, 255], ["disease dynamics", "TEST", 346, 362], ["the infectious disease", "PROBLEM", 451, 473], ["infectious", "OBSERVATION", 455, 465]]], ["We formulate a general piecewise susceptible-infectious-vaccinated (SIV) type of model with nonlinear incidence to investigate the effects of TP implemented by both susceptible and vaccinated individuals.", [["TP", "CHEMICAL", 142, 144], ["SIV", "ORGANISM", 68, 71], ["TP", "GENE_OR_GENE_PRODUCT", 142, 144], ["SIV", "SPECIES", 68, 71], ["TP", "TREATMENT", 142, 144]]], ["In the following section, the sliding mode dynamics is proposed to find out the pseudo-equilibrium.", [["the sliding mode dynamics", "TEST", 26, 51], ["the pseudo-equilibrium", "PROBLEM", 76, 98]]], ["We prove that the pseudo-equilibrium is stable when it is feasible.", [["the pseudo-equilibrium", "PROBLEM", 14, 36], ["stable", "OBSERVATION_MODIFIER", 40, 46]]], ["In Section 4, we investigate the types and stability of all possible equilibria, and global dynamic behaviors by considering several scenarios.", [["global dynamic behaviors", "PROBLEM", 85, 109], ["possible", "UNCERTAINTY", 60, 68], ["equilibria", "OBSERVATION", 69, 79]]], ["Further, the boundary equilibrium bifurcation is examined in Section 5.", [["boundary", "OBSERVATION_MODIFIER", 13, 21], ["equilibrium bifurcation", "OBSERVATION", 22, 45]]], ["Finally concluding marks are given in the last section.The SIV model with threshold policyFirst we divide the total population N into three compartments: susceptible (S), infected (I) and vaccinated (V ) to establish the SIV model with threshold policy.", [["SIV", "ORGANISM", 59, 62], ["SIV", "ORGANISM", 221, 224], ["SIV", "SPECIES", 221, 224], ["The SIV model with threshold policy", "TREATMENT", 55, 90], ["the SIV model with threshold policy", "TREATMENT", 217, 252], ["SIV model", "OBSERVATION", 59, 68], ["total", "OBSERVATION_MODIFIER", 110, 115]]], ["Although vaccination can reduce the infection by protecting susceptibles, it may not be completely effective.", [["infection", "DISEASE", 36, 45], ["vaccination", "TREATMENT", 9, 20], ["the infection", "PROBLEM", 32, 45], ["infection", "OBSERVATION", 36, 45], ["may not be", "UNCERTAINTY", 77, 87]]], ["We let a factor of parameter \u03c3 (0 < \u03c3 < 1) to measure the efficiency of the vaccine as a multiplier to the infection rate, here \u03c3 = 0 means that the vaccine is perfectly effective, while \u03c3 = 1 means the vaccine has no effect at all.", [["infection", "DISEASE", 107, 116], ["the vaccine", "TREATMENT", 72, 83], ["the infection rate", "PROBLEM", 103, 121], ["the vaccine", "TREATMENT", 145, 156], ["the vaccine", "TREATMENT", 199, 210], ["infection", "OBSERVATION", 107, 116]]], ["Given that the vaccination is not permanent we let \u03b8 be the rate of loss of immunity, then 1 \u03b8 is the immunity period after an effective vaccination.", [["loss of immunity", "DISEASE", 68, 84], ["an effective vaccination", "TREATMENT", 124, 148]]], ["We divide each variable by N to normalize the variables, and hence in the following S, I, and V represent the proportions of three compartments, then we getThe SIV model with threshold policyhere H(I) is a given threshold function which may depend on the number of infected individuals, \u03f5(t) is a piecewise function which is dependent on the sign of H(I).", [["H(I)", "CHEMICAL", 350, 354], ["SIV", "ORGANISM", 160, 163], ["The SIV model", "TREATMENT", 156, 169]]], ["Constant \u00b5 is the natural birth (death) rate of population, \u03b2 is the basic transmission coefficient, and \u03b3 represents the rate of recovery/remove from infected class.", [["death", "DISEASE", 33, 38]]], ["All the parameters are assumed to be positive constants.", [["positive constants", "PROBLEM", 37, 55], ["assumed to be", "UNCERTAINTY", 23, 36], ["positive constants", "OBSERVATION", 37, 55]]], ["We denote the structure without intervention (\u03f5(t) = 0) by the free system (S 1 ) and the structure with intervention (\u03f5(t) = 1) by the control system (S 2 ).", [["intervention", "TREATMENT", 32, 44], ["intervention", "TREATMENT", 105, 117]]], ["Here \u03f5(t) = 1 means that when the number of infected individuals exceeds a certain number (I(t) > I c ), people begin to enhance some precaution and control measures such as wearing face masks, hand-washing and avoiding crowded places, and consequently the baseline transmission rate \u03b2 is then reduced to be \u03b2(1 \u2212 f ).", [["hand", "ANATOMY", 194, 198], ["people", "ORGANISM", 105, 111], ["people", "SPECIES", 105, 111], ["infected individuals", "PROBLEM", 44, 64], ["some precaution", "TREATMENT", 129, 144], ["control measures", "TREATMENT", 149, 165], ["face masks", "TREATMENT", 182, 192], ["hand-washing", "TREATMENT", 194, 206], ["the baseline transmission rate", "TEST", 253, 283], ["infected", "OBSERVATION", 44, 52]]], ["Positive constant f represents the intensity level of the implemented precaution and control strategies.The SIV model with threshold policyThere is a variable structure with two distinct structures with their own equilibrium points due to the threshold policy.The SIV model with threshold policyThe total population is supposed to be constant here, so we have (S + I + V ) \u2032 = 0.", [["SIV", "ORGANISM", 108, 111], ["SIV", "ORGANISM", 264, 267], ["the implemented precaution", "TREATMENT", 54, 80], ["control strategies", "TREATMENT", 85, 103], ["The SIV model with threshold policy", "TREATMENT", 104, 139], ["a variable structure", "PROBLEM", 148, 168], ["the threshold policy", "TREATMENT", 239, 259], ["The SIV model with threshold policy", "TREATMENT", 260, 295], ["constant f", "OBSERVATION_MODIFIER", 9, 19], ["SIV model", "OBSERVATION", 108, 117], ["variable", "OBSERVATION_MODIFIER", 150, 158], ["structure", "OBSERVATION", 159, 168], ["two", "OBSERVATION_MODIFIER", 174, 177], ["distinct", "OBSERVATION_MODIFIER", 178, 186], ["structures", "OBSERVATION", 187, 197], ["SIV model", "OBSERVATION", 264, 273], ["total", "OBSERVATION_MODIFIER", 299, 304], ["supposed to be", "UNCERTAINTY", 319, 333]]], ["Substituting the variable 1 \u2212 I \u2212 V for S to yield the following two dimensional systemThe SIV model with threshold policyIt is easy to get the invariant region by using the similar method in [43]The SIV model with threshold policyLet H(U) = I \u2212 I c with the vector U = (V , I) for convenience.", [["SIV", "ORGANISM", 91, 94], ["SIV", "ORGANISM", 200, 203], ["I c", "PROTEIN", 246, 249], ["The SIV model with threshold policy", "TREATMENT", 87, 122], ["The SIV model", "TREATMENT", 196, 209], ["SIV model", "OBSERVATION", 91, 100]]], ["Then the discontinuous switching surface \u03a3 can be definedThe SIV model with threshold policywhich divides the plane R 2 + into two separate partsThe SIV model with threshold policyHere we characterize the right side of the equation in G i (i = 1, 2) to the form of column vector F i (U) with the elements F ij for convenient, thereforeThe SIV model with threshold policyso we can formulate the Filippov system by the following for\u1e41The SIV model with threshold policyFirstly, we will do the preliminary work to show the respective dynamics behavior for two subsystems.The SIV model with threshold policyFree system S 1 gives the following model equationsThe SIV model with threshold policyBy employing the well-known next generation method in [44] , we can derive the basic reproduction numberThe SIV model with threshold policyIt is easy to get the disease-free equilibrium E 1 0 = ( \u03c6 \u00b5+\u03b8 +\u03c6 , 0).", [["surface", "ANATOMY", 33, 40], ["SIV", "ORGANISM", 149, 152], ["SIV", "ORGANISM", 339, 342], ["SIV", "ORGANISM", 435, 438], ["SIV", "ORGANISM", 571, 574], ["SIV", "ORGANISM", 657, 660], ["SIV", "ORGANISM", 796, 799], ["the discontinuous switching surface \u03a3", "TREATMENT", 5, 42], ["The SIV model", "TREATMENT", 57, 70], ["The SIV model with threshold policy", "TREATMENT", 145, 180], ["the elements F ij", "TREATMENT", 292, 309], ["The SIV model with threshold policyso", "TREATMENT", 335, 372], ["The SIV model with threshold policy", "TREATMENT", 567, 602], ["The SIV model", "TREATMENT", 653, 666], ["The SIV model with threshold policy", "TREATMENT", 792, 827], ["the disease", "TEST", 845, 856], ["free equilibrium E", "TEST", 857, 875], ["SIV model", "OBSERVATION", 149, 158], ["right", "ANATOMY_MODIFIER", 205, 210], ["ij", "ANATOMY", 307, 309], ["SIV model", "OBSERVATION", 571, 580], ["SIV model", "OBSERVATION", 796, 805]]], ["The endemic equilibria are solutions of the algebraicThe SIV model with threshold policyOne can get the quadratic equation for IThe SIV model with threshold policywithThe SIV model with threshold policy, we can easily obtain I 1 1 > 0 and I 1 2 < 0.", [["SIV", "ORGANISM", 57, 60], ["SIV", "ORGANISM", 171, 174], ["the algebraicThe SIV model with threshold policy", "TREATMENT", 40, 88], ["the quadratic equation", "TREATMENT", 100, 122], ["IThe SIV model", "TREATMENT", 127, 141], ["I", "TEST", 225, 226], ["endemic equilibria", "OBSERVATION", 4, 22]]], ["When R 1 0 < 1 and B 1 < 0, we have I 1 1 > I 1 2 > 0.", [["I", "TEST", 36, 37]]], ["Then the second equation of (7) givesThe SIV model with threshold policyIn fact, system S 1 has been carefully studied in [43] , and here we only introduce main results without giving detailed calculations.", [["SIV", "ORGANISM", 41, 44], ["The SIV model with threshold policy", "TREATMENT", 37, 72]]], ["We easily know that there is a backward bifurcation at R 1 0 = 1 when the conditions B 1 < 0 and B 2 1 > 4A 1 C 1 are satisfied.", [["the conditions B", "TEST", 70, 86]]], ["There are two positive endemic equilibria when the parameter \u03b2 changes from \u03b2 c to \u03b2 1 , which are corresponding to B 1 = \u22122 \u221a A 1 C 1 and R 1 0 = 1 respectively.", [["\u03b2 c", "PROTEIN", 76, 79], ["\u03b2 1", "PROTEIN", 83, 86], ["two positive endemic equilibria", "PROBLEM", 10, 41], ["the parameter", "TEST", 47, 60], ["B", "TEST", 116, 117], ["two", "OBSERVATION_MODIFIER", 10, 13], ["positive", "OBSERVATION_MODIFIER", 14, 22], ["endemic", "OBSERVATION_MODIFIER", 23, 30], ["equilibria", "OBSERVATION", 31, 41]]], ["By computing the equationThe SIV model with threshold policyThe disease-free equilibrium is E 2The SIV model with threshold policyThe basic reproduction number for control system S 2 isThe SIV model with threshold policyUsing the same method as free system S 1 , we can derive the following quadratic equation for IThe SIV model with threshold policywithThe SIV model with threshold policyIt follows thatThe SIV model with threshold policyHence, for subsystem S 2 , we get the two equilibria E 2 1 (V 2The SIV model with threshold policyand only one feasible equilibrium E 2 1 when \u2206 2 > 0 and R 2 0 > 1 hold.", [["SIV", "ORGANISM", 99, 102], ["SIV", "ORGANISM", 189, 192], ["SIV", "ORGANISM", 358, 361], ["SIV", "ORGANISM", 408, 411], ["The disease", "PROBLEM", 60, 71], ["The SIV model with threshold policy", "TREATMENT", 185, 220], ["IThe SIV model", "TREATMENT", 314, 328], ["The SIV model with threshold policy", "TREATMENT", 354, 389], ["The SIV model with threshold policy", "TREATMENT", 404, 439], ["the two equilibria E", "TREATMENT", 473, 493], ["The SIV model with threshold policyand", "TREATMENT", 502, 540], ["disease", "OBSERVATION", 64, 71], ["SIV model", "OBSERVATION", 358, 367]]], ["The disease-free equilibrium E 2 0 is a LAS node when R 2 0 < 1 and unstable when R 2 0 > 1, while the endemicThe SIV model with threshold policythere are precisely two endemic equilibria for subsystem (6) provided B 2 < 0 and \u2206 2 > 0, then we conclude that E 2 1 is a locally stable node, while E 2 2 is an unstable saddle point.", [["node", "ANATOMY", 284, 288], ["SIV", "ORGANISM", 114, 117], ["node", "MULTI-TISSUE_STRUCTURE", 284, 288], ["The disease", "PROBLEM", 0, 11], ["a LAS node", "PROBLEM", 38, 48], ["a locally stable node", "PROBLEM", 267, 288], ["disease", "OBSERVATION", 4, 11], ["free", "OBSERVATION_MODIFIER", 12, 16], ["node", "OBSERVATION", 44, 48], ["stable", "OBSERVATION_MODIFIER", 277, 283], ["node", "OBSERVATION", 284, 288], ["unstable", "OBSERVATION_MODIFIER", 308, 316], ["saddle point", "OBSERVATION", 317, 329]]], ["When R 2 0 < R 1 c , the disease-free equilibrium E 2 0 is GAS.", [["GAS", "DNA", 59, 62], ["the disease", "PROBLEM", 21, 32], ["disease", "OBSERVATION", 25, 32]]], ["It is worth noting that both the two subsystems may have two positive equilibria, we can order them by the elementary of variable I as I 1 2 < I 2 2 < I 2 1 < I 1 1 , provided they are feasible (see detailed calculation in Appendix).", [["positive", "OBSERVATION_MODIFIER", 61, 69], ["equilibria", "OBSERVATION", 70, 80], ["Appendix", "ANATOMY", 223, 231]]], ["Further, we note that R 2 c and R 1 c , which are independent of transmission coefficient \u03b2, are the same, so we denote them by R c , that is, we useSliding mode dynamicsNow we briefly recall the definitions of sliding segment and crossing segment, then calculate the pseudo-equilibrium and give the sufficient conditions for existence of the pseudo-equilibrium.", [["R 2 c", "GENE_OR_GENE_PRODUCT", 22, 27], ["R 1 c", "GENE_OR_GENE_PRODUCT", 32, 37], ["R c", "GENE_OR_GENE_PRODUCT", 128, 131], ["sliding segment and crossing segment", "PROBLEM", 211, 247], ["the pseudo-equilibrium", "PROBLEM", 264, 286], ["the pseudo-equilibrium", "PROBLEM", 339, 361], ["pseudo-equilibrium", "OBSERVATION", 343, 361]]], ["By using the Filippov convex method [45] , we letSliding mode dynamicswhere \u27e8\u00b7, \u00b7\u27e9 denotes the standard scalar product, H U (U) = ( \u2202H \u2202V , \u2202H \u2202I ) is the nonvanishing gradient on the discontinuity boundary \u03a3.", [["H", "CHEMICAL", 133, 134], ["H", "CHEMICAL", 141, 142], ["I", "PROTEIN", 144, 145], ["V", "TEST", 136, 137], ["the nonvanishing gradient", "TEST", 151, 176]]], ["It is well-known that the crossing segment \u03a3 c \u2282 \u03a3 is defined asSliding mode dynamicswhich means that the vectors F 1 (U) and F 2 (U) have the same sign with nontrivial normal components [45] .", [["F 1", "GENE_OR_GENE_PRODUCT", 114, 117], ["F 2", "GENE_OR_GENE_PRODUCT", 126, 129], ["\u03a3", "PROTEIN", 49, 50], ["nontrivial normal", "OBSERVATION", 158, 175]]], ["A sliding mode ensures that both trajectories in the vicinity of vector fields along I c are directing toward each other.Sliding mode dynamicsWhen there are some subregions of the line \u03a3 such that both vectors of two subsystems S 1 and S 2 are directed towards each other, then the sliding segment appears on the boundary.", [["I c", "GENE_OR_GENE_PRODUCT", 85, 88], ["S 2", "GENE_OR_GENE_PRODUCT", 236, 239], ["I c", "PROTEIN", 85, 88], ["sliding segment", "DNA", 282, 297], ["A sliding mode ensures", "TREATMENT", 0, 22], ["the line", "TREATMENT", 176, 184], ["sliding mode", "OBSERVATION_MODIFIER", 2, 14], ["some", "OBSERVATION_MODIFIER", 157, 161], ["subregions", "OBSERVATION_MODIFIER", 162, 172], ["line", "OBSERVATION", 180, 184], ["sliding segment", "OBSERVATION", 282, 297]]], ["We employ the equivalent control method as in [26] to examine the sliding domain and sliding mode dynamics of Filippov system (3) .", [["the sliding domain", "TREATMENT", 62, 80]]], ["So the sliding domain can be defined asSliding mode dynamicsHere H = I \u2212 I c , which means H U (U) = (0, 1) T .", [["I c", "PROTEIN", 73, 76], ["the sliding domain", "TREATMENT", 3, 21]]], ["When h(U) = \u27e8H U (U), F 1 (U)\u27e9\u27e8H U (U), F 2 (U)\u27e9 = F 12 (U)F 22 (U) \u2264 0, note that F 12 (U) > F 22 (U) for any f > 0, it is impossible to be F 12 \u2264 0 and F 22 \u2265 0.", [["U", "TEST", 100, 101], ["any f", "TEST", 107, 112]]], ["Therefore, (11) is equivalent to the followingSliding mode dynamics) denote the endpoints of the sliding segment.", [["Sliding mode dynamics", "TREATMENT", 46, 67], ["the sliding segment", "TREATMENT", 93, 112], ["sliding segment", "OBSERVATION", 97, 112]]], ["So we have the sliding domain of the Filippov system as followsSliding mode dynamicswithSliding mode dynamicsHence, there are two real roots for Eq.", [["roots", "ANATOMY", 135, 140], ["roots", "ORGAN", 135, 140], ["roots", "OBSERVATION_MODIFIER", 135, 140]]], ["(12):Sliding mode dynamicsWe now claim V 2Sliding mode dynamicsThen, the right hand side of (13)Sliding mode dynamicsSecondly, we want to find the sufficient conditions under which V 1Sliding mode dynamicsAs A 2 > 0, the parabolic curve of G 2 is opening upward, then whenSliding mode dynamicswe have G 2 (I c ) > 0, and hence \u03c8(Sliding mode dynamicsAs A 1 > 0, then whenSliding mode dynamicsit follows that G 1 (I c ) < 0, and consequently we have \u03c8(V R ) < 0.Sliding mode dynamicsIn order to make sure V 1Sliding mode dynamics, we need the sufficient condition to get \u03c8(V L ) > 0 and \u03c8(V R ) < 0.", [["right hand", "ANATOMY", 73, 83], ["G 2", "GENE_OR_GENE_PRODUCT", 240, 243], ["the parabolic curve", "TEST", 217, 236], ["Sliding mode dynamicsAs", "TEST", 329, 352], ["right", "ANATOMY_MODIFIER", 73, 78]]], ["Therefore, when I c satisfies (14) and (15), i.e., I 1 2 < I c < I 2 2 or I 2Sliding mode dynamics, then we getSliding mode dynamicswhich means that E 1 p is LAS, that is to say, the pseudo-equilibrium is locally stable when it is feasible.", [["locally", "OBSERVATION_MODIFIER", 205, 212], ["stable", "OBSERVATION", 213, 219]]], ["As E 2 p does not locate in the sliding segment, may not be named as a pseudo-equilibrium, we now use E p to denote the only possible pseudo-equilibrium (when it exist) in the following (i.e., E p = E 1 p ).Global dynamics of the switching systemIn this section, we examine the global dynamics of the piecewise system.", [["E 2 p", "DNA", 3, 8], ["a pseudo-equilibrium", "PROBLEM", 69, 89], ["pseudo-equilibrium", "PROBLEM", 134, 152]]], ["We initially analyze the nonexistence of all possible limit cycles, that is, we exclude the existence of three possible limit cycles, the canard limit cycles, which contain part of the sliding segment, the limit cycles that totally in the region G i (i = 1, 2) and the limit cycles that surround the sliding segment.", [["the sliding segment", "TREATMENT", 181, 200], ["possible limit cycles", "OBSERVATION_MODIFIER", 45, 66], ["possible limit cycles", "OBSERVATION_MODIFIER", 111, 132], ["sliding segment", "OBSERVATION", 185, 200], ["limit cycles", "OBSERVATION_MODIFIER", 206, 218], ["limit cycles", "OBSERVATION", 269, 281], ["sliding segment", "OBSERVATION", 300, 315]]], ["By combining the type (i.e., regular/sliding equilibria) and local stability of equilibria, we can obtain the reachability of orbits theoretically and numerically.", [["regular/sliding equilibria", "TREATMENT", 29, 55]]], ["Then we can conclude the global stability of the equilibria.", [["global", "OBSERVATION_MODIFIER", 25, 31], ["stability", "OBSERVATION_MODIFIER", 32, 41], ["equilibria", "OBSERVATION", 49, 59]]], ["To the end, we classify all the types of equilibria, and discuss the global dynamics of the proposed system in terms of relations of R 1 0 , R 2 0 , R c and 1.", [["R c", "GENE_OR_GENE_PRODUCT", 149, 152]]], ["According to the previous conclusion, we get R 1Global dynamics of the switching systemIn such case we easily know that the endemic equilibria E 1 1 and E 2 1 are GAS for subsystem S 1 and S 2 according to Lemmas 1 and 2, respectively.", [["GAS", "DNA", 163, 166], ["the endemic equilibria E", "TEST", 120, 144], ["GAS", "TEST", 163, 166], ["subsystem S", "TEST", 171, 182], ["Lemmas", "TEST", 206, 212]]], ["In this case, I i 1 (i = 1, 2) is monotonously increase with \u03b2 (the detailed proof is given in Appendix A.1), so we have I 1 Fig. A.1(A) ).", [["\u03b2", "PROTEIN", 61, 62]]], ["According to Section 3, when the threshold value I c is between I 2 1 and I 1 1 , the sliding mode with a pseudo-equilibrium appears.", [["I c", "PROTEIN", 49, 52]]], ["In the following, we will examine the global analysis of the switching system (3) with (2).", [["the global analysis", "TEST", 34, 53]]], ["Here we take case (a) as an example to show non-existence of limit cycle.Global dynamics of the switching systemNote that the existence of limit cycle of other cases are similar to do, hence we omit the detailed proof for other cases.Nonexistence of limit cycleBy using the method in Lemma 1 [25] , we conclude that there is no limit cycle totally located in G 1 for the subsystem S 1 when R 1 0 > 1.", [["the subsystem S", "TEST", 367, 382], ["limit cycleBy", "OBSERVATION_MODIFIER", 250, 263]]], ["Similarly, we get that no limit cycle for subsystem S 2 exists in region G 2 for R 2 0 > 1.", [["subsystem S", "TEST", 42, 53]]], ["Therefore, we have the following Lemma 3.Lemma 3.There is no closed orbit which is totally located in the region G i (i = 1, 2) for Case (a).Lemma 3.We now examine the limit cycle which contains part of the sliding segment or surround the sliding domain, and have the following two Lemmas.Lemma 4.There is no limit cycle which contains part of the sliding segment AB for Case (a).Lemma 4.Proof.", [["orbit", "ORGAN", 68, 73], ["closed orbit", "PROBLEM", 61, 73], ["the sliding segment", "TREATMENT", 203, 222], ["limit cycle", "PROBLEM", 309, 320], ["no", "UNCERTAINTY", 58, 60], ["closed", "OBSERVATION_MODIFIER", 61, 67], ["orbit", "ANATOMY", 68, 73], ["sliding segment", "OBSERVATION_MODIFIER", 207, 222], ["sliding domain", "OBSERVATION", 239, 253], ["no", "UNCERTAINTY", 306, 308], ["limit cycle", "OBSERVATION_MODIFIER", 309, 320]]], ["By Section 3, we know that the sliding mode does exist for I 2 1 < I c < I 1 1 and the pseudo-equilibrium E p is feasible and LAS.", [["the sliding mode", "TEST", 27, 43]]], ["This implies that trajectories which hit the sliding line will tend to the pseudo-equilibrium E p , hence there is no limit cycle containing part of the sliding line for I 2Lemma 4.We now need to prove this Lemma for the case I c < I 2 1 or I c > I 1 1 .", [["I 2Lemma 4", "PROTEIN", 170, 180], ["the sliding line", "TREATMENT", 41, 57], ["the sliding line", "TREATMENT", 149, 165], ["sliding line", "OBSERVATION", 45, 57]]], ["Without loss of generality, we only prove the former.Lemma 4.on the sliding segment.", [["loss of generality", "PROBLEM", 8, 26], ["the sliding segment", "TREATMENT", 64, 83], ["sliding segment", "OBSERVATION_MODIFIER", 68, 83]]], ["So the trajectories move from the right to the left along the sliding line.", [["the sliding line", "TREATMENT", 58, 74], ["right", "ANATOMY_MODIFIER", 34, 39], ["left", "ANATOMY_MODIFIER", 47, 51], ["sliding line", "OBSERVATION", 62, 74]]], ["Note that four isoclinic lines and the switching line I = I c divide the whole region into seven parts, in which the general trend of trajectories are identified (shown in Fig. 1(A) ).", [["isoclinic lines", "CELL_LINE", 15, 30], ["I c", "PROTEIN", 58, 61], ["four isoclinic lines", "TREATMENT", 10, 30], ["the switching line I = I c divide the whole region", "TREATMENT", 35, 85]]], ["Trajectories hitting the sliding line will move from right to left and pass through the left endpoint A, as E 2 1 is the only real stable node in G 2 and A is a visible tangent point (see the definition in Section 5), so they move towards up and left in the domain delimited by the horizontal isocline g 2 I (red line), the vertical isocline g 2 V (green line) and the switching line I = I c (black dashed line), without hitting the switching line again.", [["node", "ANATOMY", 138, 142], ["E 2 1", "DNA", 108, 113], ["switching line I = I c (black dashed line", "CELL_LINE", 369, 410], ["the sliding line", "TREATMENT", 21, 37], ["the horizontal isocline g 2 I (red line", "TREATMENT", 278, 317], ["the vertical isocline g 2 V (green line", "TREATMENT", 320, 359], ["the switching line", "TREATMENT", 365, 383], ["black dashed line", "TREATMENT", 393, 410], ["sliding line", "OBSERVATION", 25, 37], ["right", "ANATOMY_MODIFIER", 53, 58], ["left", "ANATOMY_MODIFIER", 62, 66], ["left", "ANATOMY_MODIFIER", 88, 92], ["stable", "OBSERVATION_MODIFIER", 131, 137], ["node", "OBSERVATION", 138, 142]]], ["Then we know that no closed orbit containing part of the sliding segment exists for I c < I 2 1 .", [["I c", "PROTEIN", 84, 87], ["I 2 1", "PROTEIN", 90, 95], ["closed orbit", "PROBLEM", 21, 33], ["orbit", "ANATOMY", 28, 33]]], ["We can also use the similar method to prove the non-existence of limit cycle for I c > I 1 1 .Lemma 5.There is no closed orbit surrounding the sliding segment AB in Case (a).Lemma 5.Proof.", [["orbit", "ANATOMY", 121, 126], ["orbit", "ORGAN", 121, 126], ["closed orbit", "PROBLEM", 114, 126], ["no", "UNCERTAINTY", 111, 113], ["closed", "OBSERVATION_MODIFIER", 114, 120], ["orbit", "ANATOMY", 121, 126], ["sliding segment", "OBSERVATION_MODIFIER", 143, 158]]], ["Suppose there is a limit cycle L = L 1 + L 2 surrounding AB, which intersects with switching line I = I c at point P and Q , as shown in Fig. 1(B) .", [["I c", "PROTEIN", 102, 105]]], ["We add two auxiliary lines I = I c \u2212 \u03f5 and I = I c + \u03f5 in the form of a dotted line (\u2200\u03f5 > 0).", [["c + \u03f5", "GENE_OR_GENE_PRODUCT", 49, 54], ["I c", "PROTEIN", 31, 34], ["I c", "PROTEIN", 47, 50], ["\u03f5", "PROTEIN", 53, 54], ["dotted line", "CELL_LINE", 72, 83], ["a dotted line", "TREATMENT", 70, 83], ["dotted line", "OBSERVATION", 72, 83]]], ["The two lines intersect with L at points P 1 , Q 1 and P 2 , Q 2 respectively.", [["P", "TEST", 41, 42], ["two", "OBSERVATION_MODIFIER", 4, 7], ["lines", "OBSERVATION", 8, 13], ["L", "ANATOMY_MODIFIER", 29, 30]]], ["Denote the region delimited by L 1 and P 1 Q 1 by K 1 in the lower part, while the region delimited by L 2 and P 2 Q 2 by K 2 in the higher part.", [["K", "CHEMICAL", 50, 51], ["K", "CHEMICAL", 122, 123], ["K 1", "GENE_OR_GENE_PRODUCT", 50, 53], ["K 2", "GENE_OR_GENE_PRODUCT", 122, 125], ["L 1 and P 1 Q 1", "DNA", 31, 46], ["K 1", "DNA", 50, 53], ["P 2 Q 2", "DNA", 111, 118], ["K 2", "DNA", 122, 125], ["K", "TEST", 122, 123], ["region", "ANATOMY_MODIFIER", 11, 17], ["L", "ANATOMY_MODIFIER", 31, 32], ["lower", "ANATOMY_MODIFIER", 61, 66]]], ["Let the Dulac function be B = 1 VI , we can get the following results by the Green's theorem.\u222b\u222bSum up the both sides of the two equations above, we obtain the following\u222b\u222bOn the switching line, we have I = I c and dI dt = 0, which mean\u222b\u222bTherefore, we have\u222b\u222bOn the other hand, \u2212 \u03b2 V \u2212 \u03c6(1\u2212I)\u222b\u222bThis is an obvious contradiction with Eq.", [["B = 1 VI", "GENE_OR_GENE_PRODUCT", 26, 34], ["1\u2212I", "SIMPLE_CHEMICAL", 285, 288], ["the switching line", "TREATMENT", 173, 191]]], ["So we have the conclusion that there is no limit cycle surrounding the sliding segment AB, the proof is then completed.Global stability of the endemic equilibriumIn the following, we will investigate the global stability of endemic equilibria in terms of relationship of I 1 1 , I 2 1 and I c .", [["I c", "GENE_OR_GENE_PRODUCT", 289, 292], ["I 2 1 and I c", "PROTEIN", 279, 292], ["the sliding segment AB", "TREATMENT", 67, 89], ["endemic equilibria", "PROBLEM", 224, 242], ["no", "UNCERTAINTY", 40, 42], ["sliding segment", "OBSERVATION_MODIFIER", 71, 86], ["stability", "OBSERVATION_MODIFIER", 126, 135], ["endemic", "OBSERVATION_MODIFIER", 143, 150], ["global", "OBSERVATION_MODIFIER", 204, 210], ["stability", "OBSERVATION_MODIFIER", 211, 220], ["endemic equilibria", "OBSERVATION", 224, 242]]], ["In such subcase, the endemic equilibrium E 1 1 is real, while E 2 1 is virtual.", [["E 2 1", "DNA", 62, 67], ["the endemic equilibrium E", "TEST", 17, 42], ["endemic", "OBSERVATION_MODIFIER", 21, 28]]], ["We know that the sliding mode does exist but there is not a pseudo-equilibrium according to the previous derivation.", [["a pseudo-equilibrium", "PROBLEM", 58, 78]]], ["We conclude that E 1 1 is GAS in the following.", [["E 1 1", "GENE_OR_GENE_PRODUCT", 17, 22], ["GAS", "GENE_OR_GENE_PRODUCT", 26, 29], ["E 1 1", "DNA", 17, 22], ["GAS", "DNA", 26, 29]]], ["According to Lemma 1, the endemic equilibrium E 1 1 is real and is a LAS node for subsystem S 1 .", [["the endemic equilibrium E", "TEST", 22, 47], ["node", "OBSERVATION", 73, 77]]], ["And we know that any trajectory, once touching the sliding mode, moves from the left to the right along the sliding segment AB by the procedure of proof of Lemma 4.", [["the sliding mode", "TREATMENT", 47, 63], ["the procedure", "TREATMENT", 130, 143], ["left", "ANATOMY_MODIFIER", 80, 84], ["right", "ANATOMY_MODIFIER", 92, 97], ["sliding segment", "OBSERVATION_MODIFIER", 108, 123]]], ["Note that there is no limit cycle totally located in the region G 1 or G 2 according to Lemma 3.", [["G 2", "GENE_OR_GENE_PRODUCT", 71, 74], ["region G 1", "DNA", 57, 67], ["no", "UNCERTAINTY", 19, 21], ["limit cycle", "OBSERVATION_MODIFIER", 22, 33]]], ["Moreover, we know that there is no limit cycle which contains part of the sliding line or surrounding the sliding line AB by Lemmas 4 and 5.", [["sliding line AB", "CELL_LINE", 106, 121], ["the sliding line", "TREATMENT", 70, 86], ["the sliding line AB", "TREATMENT", 102, 121], ["no", "UNCERTAINTY", 32, 34], ["limit cycle", "OBSERVATION_MODIFIER", 35, 46], ["sliding line", "OBSERVATION", 74, 86], ["sliding line", "OBSERVATION", 106, 118]]], ["Hence, trajectories initiating from region G 1 will either go toward E 1 1 directly or hit the sliding line and slide along this line from the left side to the right endpoint B, then go toward E 1 1 ultimately.", [["E 1 1", "DNA", 69, 74], ["the sliding line", "TREATMENT", 91, 107], ["sliding line", "OBSERVATION", 95, 107], ["left", "ANATOMY_MODIFIER", 143, 147], ["right", "ANATOMY_MODIFIER", 160, 165]]], ["Trajectories starting from region G 2 will either cross over the switching line to get into the region G 1 or touch the sliding domain and then move along this line from left side to right in order to approach E 1 1 (shown in Fig. 2(B) ).", [["G 1", "GENE_OR_GENE_PRODUCT", 103, 106], ["region G 1", "DNA", 96, 106], ["sliding domain", "DNA", 120, 134], ["E 1 1", "DNA", 210, 215], ["the switching line", "TREATMENT", 61, 79], ["the sliding domain", "TREATMENT", 116, 134], ["left", "ANATOMY_MODIFIER", 170, 174], ["right", "ANATOMY_MODIFIER", 183, 188]]], ["So the endemic equilibrium E 1 1 is GAS.", [["GAS", "DNA", 36, 39], ["E 1 1", "SPECIES", 27, 32]]], ["This completes the proof.Global stability of the endemic equilibriumSubcase (a2): assume I 2 1 < I c < I 1 1 .", [["I 1 1", "PROTEIN", 103, 108], ["stability", "OBSERVATION_MODIFIER", 32, 41], ["endemic", "OBSERVATION_MODIFIER", 49, 56]]], ["In such subcase both E 1 1 and E 2 1 are virtual, the sliding mode does exist, and the pseudo-equilibrium E p does exist and is LAS.", [["E 2 1", "GENE_OR_GENE_PRODUCT", 31, 36], ["E 1 1 and E 2 1", "DNA", 21, 36]]], ["Now we want to show that E p is GAS in the following.Global stability of the endemic equilibriumProof.", [["E p", "GENE_OR_GENE_PRODUCT", 25, 28], ["GAS", "DNA", 32, 35], ["stability", "OBSERVATION_MODIFIER", 60, 69], ["endemic", "OBSERVATION_MODIFIER", 77, 84]]], ["In such case we easily know that the virtual equilibrium E 1 1 is in region G 2 while E 2 1 is in region G 1 .", [["E 2 1", "GENE_OR_GENE_PRODUCT", 86, 91], ["region G 1", "GENE_OR_GENE_PRODUCT", 98, 108], ["E 1 1", "DNA", 57, 62], ["E 2 1", "DNA", 86, 91], ["region G 1", "DNA", 98, 108], ["the virtual equilibrium E", "TEST", 33, 58]]], ["Consequently, all the trajectories collide with the switching line.", [["the switching line", "TREATMENT", 48, 66]]], ["In view of Section 3, E p is locally stable.", [["locally", "OBSERVATION_MODIFIER", 29, 36], ["stable", "OBSERVATION_MODIFIER", 37, 43]]], ["Hence, some trajectories which intersect with the switching line at the sliding segment move to the pseudo-equilibrium E p along the switching line, while others which intersect with the switching line at the crossing segment enter into the opposite region.", [["E p", "DNA", 119, 122], ["some trajectories", "PROBLEM", 7, 24], ["the switching line", "TREATMENT", 46, 64], ["the switching line", "TREATMENT", 129, 147], ["the switching line", "TREATMENT", 183, 201], ["switching line", "OBSERVATION", 133, 147], ["switching line", "OBSERVATION", 187, 201], ["opposite", "ANATOMY_MODIFIER", 241, 249], ["region", "ANATOMY_MODIFIER", 250, 256]]], ["Further, there is no limit cycle according to Lemmas 3-5, thus all the trajectories touch the sliding segment finally (shown in Fig. 2(C) ).", [["Lemmas", "TEST", 46, 52], ["no", "UNCERTAINTY", 18, 20], ["limit cycle", "OBSERVATION_MODIFIER", 21, 32]]], ["Hence, we obtain that the pseudo-equilibrium E p is GAS.", [["GAS", "DNA", 52, 55]]], ["Note that this subcase is opposite of subcase (a1), and in such subcase the endemic equilibrium E 1 1 is virtual while E 2 1 is real, and there is no pseudo-equilibrium here.", [["E 2 1", "DNA", 119, 124], ["pseudo-equilibrium", "PROBLEM", 150, 168], ["opposite", "OBSERVATION_MODIFIER", 26, 34], ["endemic", "OBSERVATION_MODIFIER", 76, 83], ["no", "UNCERTAINTY", 147, 149], ["pseudo-equilibrium", "OBSERVATION", 150, 168]]], ["As there is no limit cycle, while the equilibrium E 2 1 of subsystem S 2 is globally stable in region G 2 (shown in Fig. 2(D) ).", [["subsystem S 2", "GENE_OR_GENE_PRODUCT", 59, 72], ["region G 2", "GENE_OR_GENE_PRODUCT", 95, 105], ["no", "UNCERTAINTY", 12, 14], ["limit cycle", "OBSERVATION_MODIFIER", 15, 26], ["globally", "OBSERVATION_MODIFIER", 76, 84], ["stable", "OBSERVATION", 85, 91]]], ["The endemic equilibrium E 2 1 = (V 2 1 , I 2 1 ) is a GAS node if 1 < R 2 0 < R 1 0 and I c < I 2 1 .CaseIn such case, there is only one globally stable endemic equilibrium E 1 1 for free subsystem S 1 , while there are two endemic equilibria E 1 2 and E 2 2 for control subsystem S 2 .", [["The endemic equilibrium E", "TEST", 0, 25], ["a GAS node", "TEST", 52, 62], ["GAS", "ANATOMY", 54, 57], ["node", "OBSERVATION", 58, 62], ["stable", "OBSERVATION_MODIFIER", 146, 152]]], ["In view of Lemmas 1 and 2, E 1 1 and E 2 1 are LAS nodes, while E 2 2 is a unstable saddle point, and the disease-free equilibrium E 0 is unstable for subsystem S 1 as R 1 0 > 1.", [["E 2 1", "GENE_OR_GENE_PRODUCT", 37, 42], ["E 1 1 and E 2 1", "DNA", 27, 42], ["E 2 2", "DNA", 64, 69], ["E 0", "DNA", 131, 134], ["Lemmas", "TEST", 11, 17], ["LAS nodes", "TEST", 47, 56], ["a unstable saddle point", "PROBLEM", 73, 96], ["the disease", "PROBLEM", 102, 113], ["subsystem S", "TEST", 151, 162], ["Lemmas", "OBSERVATION", 11, 17], ["nodes", "OBSERVATION", 51, 56], ["unstable", "OBSERVATION_MODIFIER", 75, 83], ["saddle point", "OBSERVATION", 84, 96], ["disease", "OBSERVATION", 106, 113]]], ["There is a backward bifurcation at R 2 0 = 1 (i.e., C 2 = 0) for control system S 2 , then we have the order I 2 2 < I 2 1 < I 1 1 according to Fig. A.1(B) , and see detailed calculation in the Appendix.", [["backward", "OBSERVATION_MODIFIER", 11, 19], ["bifurcation", "OBSERVATION_MODIFIER", 20, 31], ["Appendix", "ANATOMY", 194, 202]]], ["Again, we discuss the asymptotic behavior in terms of order of I 1 1 , I 2 1 , I 2 2 and I c .CaseSubcase (b1): assume I c > I 1 1 .", [["I c", "PROTEIN", 89, 92], ["b1", "PROTEIN", 107, 109], ["I c", "PROTEIN", 119, 122], ["I 1 1", "PROTEIN", 125, 130]]], ["The equilibrium E 1 1 is real and LAS, while E 2 1 is virtual but stable in this subcase.", [["E 2 1", "GENE_OR_GENE_PRODUCT", 45, 50], ["E 1 1", "DNA", 16, 21], ["E 2 1", "DNA", 45, 50], ["The equilibrium E", "TEST", 0, 17], ["stable", "OBSERVATION_MODIFIER", 66, 72]]], ["It is mentionable that the sliding mode exist but there is no pseudo-equilibrium.", [["pseudo-equilibrium", "PROBLEM", 62, 80], ["no", "UNCERTAINTY", 59, 61], ["pseudo-equilibrium", "OBSERVATION", 62, 80]]], ["As we can preclude the existence of limit cycle using the same method as case (a), by analyzing the trend of any trajectory (similar to case (a)) we can obtain that E 1 1 is GAS (shown in Fig. 3(A) ).CaseSubcase (b2): assume I 2 1 < I c < I 1 1 .", [["GAS", "DNA", 174, 177], ["GAS", "TEST", 174, 177]]], ["All the equilibria E 1 1 , E 2 1 and E 2 2 are virtual.", [["E 2 2", "GENE_OR_GENE_PRODUCT", 37, 42], ["E 2 1", "DNA", 27, 32], ["E 2 2", "DNA", 37, 42], ["All the equilibria E", "TEST", 0, 20], ["equilibria", "OBSERVATION", 8, 18]]], ["As there is no limit cycle, the sliding mode happens and the pseudo-equilibrium appears (shown in Fig. 3(B) ), then the pseudo-equilibrium E p is GAS.", [["GAS", "DNA", 146, 149], ["no", "UNCERTAINTY", 12, 14], ["limit cycle", "OBSERVATION_MODIFIER", 15, 26]]], ["In this subcase, E 2 1 is a real and a stable equilibrium, while E 1 1 and E 2 2 are virtual.", [["E 1 1", "GENE_OR_GENE_PRODUCT", 65, 70], ["E 2 2", "GENE_OR_GENE_PRODUCT", 75, 80], ["E 1 1 and E 2 2", "DNA", 65, 80], ["stable", "OBSERVATION_MODIFIER", 39, 45], ["equilibrium", "OBSERVATION", 46, 57]]], ["On the basis of non-existence of limit cycle for the whole system, we can confirm that E 2 1 is the only GAS equilibrium (shown in Fig. 3(C) ).Case.", [["E 2 1", "GENE_OR_GENE_PRODUCT", 87, 92], ["the whole system", "TEST", 49, 65], ["GAS equilibrium", "TEST", 105, 120]]], ["Both E 2 1 and E 2 2 are real equilibria, while E 1 1 is virtual.", [["E 2 2", "GENE_OR_GENE_PRODUCT", 15, 20], ["E 1 1", "GENE_OR_GENE_PRODUCT", 48, 53], ["E 2 1 and E 2 2", "DNA", 5, 20], ["E 1 1", "DNA", 48, 53], ["equilibria", "OBSERVATION", 30, 40]]], ["Trajectories starting above \u0393 2 (the stable manifold of E 2 2 , the pink line in Fig. 3(D) ) in region G 2 tend to equilibrium E 2 1 , while trajectories initiating below \u0393 2 in G 2 will tend to equilibrium E 0 .", [["Trajectories", "TEST", 0, 12], ["stable", "OBSERVATION_MODIFIER", 37, 43], ["pink line", "OBSERVATION", 68, 77]]], ["Further, when trajectories starting from G 1 intent do go upward to approach the equilibrium E 1 1 , they collide with the switching line, and consequently the locally stable pseudo-equilibrium E p appears.", [["the switching line", "TREATMENT", 119, 137], ["locally", "OBSERVATION_MODIFIER", 160, 167], ["stable", "OBSERVATION_MODIFIER", 168, 174], ["pseudo", "OBSERVATION", 175, 181]]], ["Hence, both E 2 1 and E p are bi-stable (shown in Fig. 3(D) ).", [["E 2 1", "GENE_OR_GENE_PRODUCT", 12, 17], ["E p", "GENE_OR_GENE_PRODUCT", 22, 25], ["E 2 1 and E p", "DNA", 12, 25]]], ["We summarize the above conclusion as the following:Theorem 4.Suppose R c < R 2 0 < 1 < R 1 0 , we conclude that the endemic equilibrium E 1 1 is GAS for I c > I 1 1 ; the pseudo-equilibrium E p is GAS for I 2 1 < I c < I 1 1 ; E 2 1 is GAS for I 2 2 < I c < I 2 1 ; and both E 2 1 and E p are bi-stable for I c < I 2 2 .Case (c):In such case endemic equilibrium E 1 1 of system S 1 is GAS in G 1 , while system S 2 has no positive equilibrium.", [["G 1", "GENE_OR_GENE_PRODUCT", 392, 395], ["I c", "PROTEIN", 307, 310], ["the endemic equilibrium E", "TEST", 112, 137], ["GAS", "TEST", 145, 148], ["the pseudo", "TEST", 167, 177], ["GAS", "TEST", 197, 200], ["I", "TEST", 205, 206], ["I c", "TEST", 213, 216], ["I", "TEST", 219, 220], ["E", "TEST", 227, 228], ["GAS", "TEST", 236, 239], ["I", "TEST", 244, 245], ["I c", "TEST", 252, 255], ["I", "TEST", 258, 259], ["E", "TEST", 275, 276], ["E p", "TEST", 285, 288], ["I c", "TEST", 307, 310], ["system S", "TEST", 371, 379], ["GAS in G", "TEST", 385, 393], ["positive equilibrium", "PROBLEM", 422, 442], ["no", "UNCERTAINTY", 419, 421], ["positive equilibrium", "OBSERVATION", 422, 442]]], ["We consider the following two subcases in terms of relations of I c and I 1 1 .Case (c):Subcase (c1): assume I c > I 1 1 .", [["I c", "PROTEIN", 64, 67], ["I 1 1", "PROTEIN", 72, 77], ["I 1 1", "PROTEIN", 115, 120]]], ["In such subcase, E 1 1 is a real equilibrium and is stable in G 1 , while the disease-free equilibrium E 1 0 is unstable for subsystem S 1 .", [["E 1 1", "GENE_OR_GENE_PRODUCT", 17, 22], ["G 1", "GENE_OR_GENE_PRODUCT", 62, 65], ["E 1 1", "DNA", 17, 22], ["stable", "OBSERVATION_MODIFIER", 52, 58], ["disease", "OBSERVATION", 78, 85]]], ["Since subsystem S 2 has no endemic states, its disease-free equilibrium E 2 0 is stable in G 2 .", [["G 2", "GENE_OR_GENE_PRODUCT", 91, 94], ["endemic states", "PROBLEM", 27, 41], ["its disease", "PROBLEM", 43, 54], ["no", "UNCERTAINTY", 24, 26], ["endemic", "OBSERVATION_MODIFIER", 27, 34], ["stable", "OBSERVATION_MODIFIER", 81, 87]]], ["Any trajectory initiating from G 2 intends to approach to the disease-free equilibrium, and then go down to the region G 1 by crossing switching line I = I c .", [["G 1", "PROTEIN", 119, 122], ["I c", "PROTEIN", 154, 157], ["the disease", "PROBLEM", 58, 69], ["disease", "OBSERVATION", 62, 69]]], ["As the limit cycles are ruled out, we can derive that the equilibrium E 1 1 is GAS (shown in Fig. 4(A) ).", [["GAS", "DNA", 79, 82], ["GAS", "TEST", 79, 82]]], ["In this subcase, E 1 1 is in G 2 and is virtual.", [["E 1 1", "GENE_OR_GENE_PRODUCT", 17, 22], ["G 2", "GENE_OR_GENE_PRODUCT", 29, 32], ["E 1 1", "DNA", 17, 22]]], ["Then two types of trajectories collide at the switching line, the sliding mode with a pseudo-equilibrium appears.", [["the switching line", "TREATMENT", 42, 60], ["the sliding mode", "TREATMENT", 62, 78]]], ["Using the same method as before we rule out the existence of limit cycles, we can easily derive that the pseudo-equilibrium E p is GAS (shown in Fig. 4(B) ).", [["GAS", "DNA", 131, 134]]], ["Then we have the following conclusion:Case (c):0 , we conclude that the endemic equilibrium E 1 1 is GAS for I c > I 1 1 ; while the pseudo-equilibrium E p is GAS for I c < I 1 1 .CaseIn such case, both the two subsystems have backward bifurcations for R i 0 = 1(i = 1, 2), respectively.", [["GAS", "DNA", 159, 162], ["I 1 1", "PROTEIN", 173, 178]]], ["As the order of the four biological roots are determined (see Fig. A.1(C) ), that is, I 1 2 < I 2 2 < I 2 1 < I 1 1 , we can classify all the types of phase portraits in term of the relation of I 1 1 , I 1 2 , I 2 1 , I 2 2 and I c .CaseSubcase (d1): assume I c > I 1 1 .", [["roots", "ANATOMY", 36, 41], ["roots", "ORGAN", 36, 41], ["I c", "PROTEIN", 228, 231], ["CaseSubcase (d1)", "PROTEIN", 233, 249], ["I c", "PROTEIN", 258, 261], ["I 1 1", "PROTEIN", 264, 269]]], ["In such subcase, the switching line I = I c is higher than all the endemic equilibria, E 1 1 and E 1 2 are real, while E 2 1 and E 2 2 are virtual.", [["E 2 2", "GENE_OR_GENE_PRODUCT", 129, 134], ["I c", "PROTEIN", 40, 43], ["higher", "OBSERVATION_MODIFIER", 47, 53], ["endemic", "OBSERVATION_MODIFIER", 67, 74], ["equilibria", "OBSERVATION", 75, 85]]], ["When trajectories starting from G 2 intend to go downward to approach E 2 1 , they touch the switching line, and either slide along the switching line or enter the region G 1 .", [["G 1", "GENE_OR_GENE_PRODUCT", 171, 174], ["region G 1", "DNA", 164, 174]]], ["In particular, when the starting point is above the stable manifold of E 1 2 (the pink line \u0393 1 in Fig. 5(A) ), the trajectories move upward to tend to E 1 1 , when the starting point is below the stable manifold of E 1 2 , the trajectories go downward to E 0 .", [["the pink line", "TREATMENT", 78, 91], ["stable", "OBSERVATION", 52, 58], ["pink line", "OBSERVATION", 82, 91], ["stable", "OBSERVATION", 197, 203]]], ["Hence both E 1 1 and E 0 are LAS in their own attraction domain (shown in Fig. 5(A) ), and then they are bi-stable in this subcase.", [["E 1 1", "GENE_OR_GENE_PRODUCT", 11, 16], ["E 0", "GENE_OR_GENE_PRODUCT", 21, 24], ["E 1 1 and E 0", "DNA", 11, 24]]], ["Here we know E 1 2 is real, while E 1 1 , E 2 1 and E 2 2 are virtual.", [["E 2 2", "GENE_OR_GENE_PRODUCT", 52, 57], ["E 1 1 , E 2 1 and E 2 2", "DNA", 34, 57]]], ["Trajectories starting from G 2 intend to go downward to approach E 2 1 , after a slide or refraction, then enter into the region G 1 .", [["G 1", "GENE_OR_GENE_PRODUCT", 129, 132], ["E 2 1", "DNA", 65, 70], ["region G 1", "DNA", 122, 132], ["a slide or refraction", "TREATMENT", 79, 100]]], ["While the trajectories initiating above the stable manifold of E 1 2 in G 1 intend to go upward to approach to E 1 1 .", [["G 1", "GENE_OR_GENE_PRODUCT", 72, 75], ["E 1 1", "GENE_OR_GENE_PRODUCT", 111, 116], ["E 1 2", "DNA", 63, 68], ["E 1 1", "DNA", 111, 116], ["stable", "OBSERVATION_MODIFIER", 44, 50]]], ["Then two types of trajectories touch the switching line, and slide to the pseudo-equilibrium.", [["the switching line", "TREATMENT", 37, 55], ["switching line", "OBSERVATION", 41, 55]]], ["The trajectories initiating below the stable manifold \u0393 1 of E 1 2 in region G 1 intend to go downward to tend to E 0 locally.", [["E 1 2", "DNA", 61, 66], ["region G 1", "DNA", 70, 80], ["stable", "OBSERVATION_MODIFIER", 38, 44]]], ["Hence, both E p and E 0 are bi-stable (shown in Fig. 5(B) ).CaseSubcase (d3): assume I 2 2 < I c < I 2 1 .", [["E p and E 0", "DNA", 12, 23], ["both E p and E 0", "TEST", 7, 23]]], ["The endemic equilibriums E 1 1 and E 2 2 are virtual, while E 2 1 and E 1 2 are real.", [["E 1 2", "GENE_OR_GENE_PRODUCT", 70, 75], ["E 2 1", "DNA", 60, 65], ["E 1 2", "DNA", 70, 75], ["The endemic equilibriums E", "TEST", 0, 26], ["endemic", "OBSERVATION_MODIFIER", 4, 11]]], ["Then trajectories starting from G 2 intend to tend to E 2 1 , while the trajectories starting from the region above \u0393 1 (the stable manifold of E 1 2 ) in G 1 intend to go upward to tend to E 1 1 , after a slide or refraction at the switching line, move upward to E 2 1 following the vector field for S 2 system.", [["E 1 1", "DNA", 190, 195], ["E 2 1", "DNA", 264, 269], ["a slide or refraction at the switching line", "TREATMENT", 204, 247], ["region", "ANATOMY_MODIFIER", 103, 109], ["stable", "OBSERVATION_MODIFIER", 125, 131]]], ["Trajectories starting from the region below the stable manifold \u0393 1 of E 1 2 in G 1 go downward to approach E 0 locally (shown in Fig. 5(C) ).", [["E 1 2", "DNA", 71, 76], ["stable", "OBSERVATION_MODIFIER", 48, 54]]], ["Therefore, the real equilibrium E 2 1 and the disease-free equilibrium E 0 are bi-stable in this subcase.Case.", [["E 2 1", "GENE_OR_GENE_PRODUCT", 32, 37], ["E 0", "DNA", 71, 74], ["the real equilibrium E", "TEST", 11, 33], ["the disease", "PROBLEM", 42, 53], ["disease", "OBSERVATION", 46, 53]]], ["Then we get E 1 1 is virtual, while E 1 2 , E 2 2 and E 2 1 are real.", [["E 2 1", "GENE_OR_GENE_PRODUCT", 54, 59], ["E 1 1", "DNA", 12, 17], ["E 2 2", "DNA", 44, 49], ["E 2 1", "DNA", 54, 59]]], ["We divide the whole region into four parts according to the attraction domain separatrix and the switching line.", [["attraction domain separatrix", "PROTEIN", 60, 88], ["the switching line", "TREATMENT", 93, 111], ["whole", "ANATOMY_MODIFIER", 14, 19], ["region", "ANATOMY_MODIFIER", 20, 26], ["four parts", "ANATOMY_MODIFIER", 32, 42], ["switching line", "OBSERVATION", 97, 111]]], ["The trajectories starting above \u0393 2 (the stable manifold of E 2 2 ) in G 2 of subsystem 2 intend to tend to E 2 1 as the real equilibrium E 2 1 is locally stable, while trajectories starting below the stable manifold of E 2 2 in G 2 intend to go downward to E 0 .", [["The trajectories", "TEST", 0, 16], ["stable", "OBSERVATION_MODIFIER", 41, 47], ["locally", "OBSERVATION_MODIFIER", 147, 154], ["stable", "OBSERVATION_MODIFIER", 155, 161], ["stable", "OBSERVATION_MODIFIER", 201, 207]]], ["When these two types of trajectories touch the switching line, the sliding mode with locally stable pseudo-equilibrium appears.", [["the switching line", "TREATMENT", 43, 61], ["the sliding mode", "TREATMENT", 63, 79], ["stable", "OBSERVATION_MODIFIER", 93, 99], ["pseudo", "OBSERVATION", 100, 106]]], ["Trajectories initiating from the region below \u0393 1 in G 1 intend to go downward to E 0 , then E 0 is locally stable in this situation.", [["\u0393 1", "DNA", 46, 49], ["region", "ANATOMY_MODIFIER", 33, 39], ["locally", "OBSERVATION_MODIFIER", 100, 107], ["stable", "OBSERVATION", 108, 114]]], ["As is shown in Fig. 5(D) , the real equilibrium E 2 1 , the pseudo-equilibrium E p and the disease-free equilibrium E 0 are locally stable.", [["the real equilibrium E", "TEST", 27, 49], ["the disease", "PROBLEM", 87, 98], ["disease", "OBSERVATION", 91, 98], ["locally", "OBSERVATION_MODIFIER", 124, 131], ["stable", "OBSERVATION_MODIFIER", 132, 138]]], ["Hence three equilibria are tri-stable in such subcase.CaseHere we get that E 1 1 and E 1 2 are virtual, while E 2 1 and E 2 2 are real.", [["E 2 2", "GENE_OR_GENE_PRODUCT", 120, 125], ["E 1 2", "DNA", 85, 90], ["E 2 1 and E 2 2", "DNA", 110, 125], ["three", "OBSERVATION_MODIFIER", 6, 11], ["equilibria", "OBSERVATION", 12, 22], ["tri-stable", "OBSERVATION_MODIFIER", 27, 37]]], ["Trajectories starting above \u0393 2 (the stable manifold of E 2 2 ) in G 2 intend to tend to equilibrium E 2 1 .", [["G 2", "GENE_OR_GENE_PRODUCT", 67, 70], ["Trajectories", "TEST", 0, 12], ["stable", "OBSERVATION_MODIFIER", 37, 43]]], ["Trajectories initiating below \u0393 2 in G 2 will tend to E 0 , and it is notable that when they go across the switching line, there is a slide or refraction on this line, and then these trajectories move to E 0 according to the vector field for subsystem S 1 .", [["E 0", "DNA", 204, 207], ["this line", "TREATMENT", 157, 166]]], ["Meanwhile, it is obviously that trajectories starting from G 1 tend to E 0 directly.", [["G 1", "GENE_OR_GENE_PRODUCT", 59, 62]]], ["Hence, both E 2 1 and E 0 are bi-stable (shown in Fig. 5(E) ).", [["E 2 1", "GENE_OR_GENE_PRODUCT", 12, 17], ["E 0", "GENE_OR_GENE_PRODUCT", 22, 25], ["E 2 1 and E 0", "DNA", 12, 25], ["both E 2 1 and E 0", "TEST", 7, 25]]], ["Then we conclude the following:CaseIn such case, subsystem S 1 has two endemic equilibria, while subsystem S 2 have no biological equilibrium.", [["biological equilibrium", "PROBLEM", 119, 141]]], ["So we consider the following three subcases in term of the relation of I 1 1 , I 1 2 and I c .CaseSubcase (e1): assume I c > I 1 1 .", [["CaseSubcase (e1)", "PROTEIN", 94, 110], ["I c", "PROTEIN", 119, 122], ["I 1 1", "PROTEIN", 125, 130]]], ["Under this condition, both E 1 1 and E 1 2 are real, E 0 is real too.", [["E 1 1 and E 1 2", "DNA", 27, 42]]], ["All trajectories initiating above the stable manifold \u0393 1 of E 1 2 in G 1 intend to go upward to E 1 1 , while trajectories initiating below \u0393 1 in G 1 go downward to E 0 .", [["G 1", "GENE_OR_GENE_PRODUCT", 70, 73], ["E 1 2", "DNA", 61, 66], ["\u0393 1", "DNA", 141, 144], ["E 0", "DNA", 167, 170], ["stable", "OBSERVATION_MODIFIER", 38, 44]]], ["And trajectories starting from G 2 intend to go downward to approach E 0 , then they collide at the switching line.CaseAs there is no closed orbit, these trajectories will either slide along the switching line or refract at this line, and then continue to move according to vector field of system S 1 .", [["orbit", "MULTI-TISSUE_STRUCTURE", 141, 146], ["closed orbit", "PROBLEM", 134, 146], ["no", "UNCERTAINTY", 131, 133], ["closed", "OBSERVATION_MODIFIER", 134, 140], ["orbit", "ANATOMY", 141, 146]]], ["Therefore, both E 1 1 and E 0 are bi-stable (shown in Fig. 6(A) ).CaseSubcase (e2): assume I 1 2 < I c < I 1 1 .", [["E 1 1", "GENE_OR_GENE_PRODUCT", 16, 21], ["E 0", "GENE_OR_GENE_PRODUCT", 26, 29], ["E 1 1 and E 0", "DNA", 16, 29]]], ["All trajectories starting from G 2 intend to go downward to approach E 0 , trajectories initiating above the stable manifold \u0393 1 of E 1 2 in G 1 go upward to approach E 1 1 .", [["All trajectories", "PROBLEM", 0, 16], ["stable", "OBSERVATION", 109, 115]]], ["These two types of trajectories then collide at the switching line, the sliding mode with pseudo-equilibrium appears.", [["the switching line", "TREATMENT", 48, 66]]], ["Hence equilibria E 0 and E p are bi-stable (shown in Fig. 6(B) ).", [["E p", "GENE_OR_GENE_PRODUCT", 25, 28]]], ["Both E 1 1 and E 1 2 are virtual, while E 0 is real.", [["E 1 2", "GENE_OR_GENE_PRODUCT", 15, 20], ["E 1 1 and E 1 2", "DNA", 5, 20], ["E 0", "DNA", 40, 43]]], ["It is obviously that all the trajectories intend to go downward to tend to E 0 , and moreover we note that trajectories initiating from G 2 slide from left to right side along the switching line, or refract at the line.", [["left", "ANATOMY_MODIFIER", 151, 155], ["right", "ANATOMY_MODIFIER", 159, 164], ["switching line", "OBSERVATION", 180, 194], ["line", "OBSERVATION", 214, 218]]], ["Therefore, E 0 is GAS (shown in Fig. 6(C) ).", [["E 0", "DNA", 11, 14], ["GAS", "DNA", 18, 21], ["GAS", "TEST", 18, 21]]], ["Then we conclude the following:CaseIn such case, there is no biological endemic state for subsystem S 1 or S 2 , the disease-free equilibrium E 0 = E 1 0 = E 2 0 is the only equilibrium for two subsystems.", [["subsystem S", "TEST", 90, 101], ["the disease", "TEST", 113, 124], ["free equilibrium E", "TEST", 125, 143], ["no", "UNCERTAINTY", 58, 60], ["disease", "OBSERVATION", 117, 124]]], ["It is obvious that E 0 is always located in the G 1 region.", [["E 0", "GENE_OR_GENE_PRODUCT", 19, 22], ["G 1", "GENE_OR_GENE_PRODUCT", 48, 51], ["E 0", "DNA", 19, 22], ["G 1 region", "DNA", 48, 58], ["G 1", "ANATOMY_MODIFIER", 48, 51], ["region", "ANATOMY_MODIFIER", 52, 58]]], ["As there is no other locally stable equilibrium or limit cycle, simply analyzing the trend of orbits can yield that the disease-free equilibrium is GAS for this scenario (shown in Fig. 6(D) ).", [["GAS", "DNA", 148, 151], ["the disease", "PROBLEM", 116, 127], ["no other", "UNCERTAINTY", 12, 20], ["locally", "OBSERVATION_MODIFIER", 21, 28], ["stable", "OBSERVATION_MODIFIER", 29, 35], ["equilibrium", "OBSERVATION", 36, 47], ["limit cycle", "OBSERVATION_MODIFIER", 51, 62], ["orbits", "ANATOMY", 94, 100], ["disease", "OBSERVATION", 120, 127]]], ["In summary, we discuss the types and stability of all possible equilibria for Filippov system (3) , and obtain the global asymptotic behavior for all cases.", [["Filippov system", "TREATMENT", 78, 93]]], ["It is worth noting that the idea of proving global stability of Filippov system (3) is based on the local stability of equilibria, reachability of orbits (i.e., regular/sliding equilibria) and nonexistence of limit cycles.", [["reachability of orbits", "PROBLEM", 131, 153], ["regular/sliding equilibria)", "TREATMENT", 161, 188], ["global", "OBSERVATION_MODIFIER", 44, 50], ["stability", "OBSERVATION", 51, 60], ["equilibria", "OBSERVATION", 119, 129], ["orbits", "ANATOMY", 147, 153], ["limit cycles", "OBSERVATION_MODIFIER", 209, 221]]], ["For this purpose we carefully analyze the types of various equilibria and trend of orbits in phase plane under different cases.Boundary equilibrium bifurcation analysisNow we investigate the boundary equilibrium bifurcation of the switching system.", [["various equilibria", "PROBLEM", 51, 69], ["Boundary equilibrium bifurcation analysis", "TEST", 127, 168], ["orbits", "ANATOMY", 83, 89], ["equilibrium bifurcation", "OBSERVATION", 136, 159], ["bifurcation", "OBSERVATION_MODIFIER", 212, 223]]], ["The readers can find the detailed definitions for the boundary equilibrium and the tangent point in Appendix.Boundary equilibrium bifurcation analysisLet E B be a boundary equilibrium, namely, E B satisfies the following equations:Boundary equilibrium bifurcation analysisSo we can get two possible boundary equilibria by solving the above equations in (17)Boundary equilibrium bifurcation analysisThe equilibrium does not exist; GAS: globally asymptotically stable.Boundary equilibrium bifurcation analysiswhich are corresponding to \u03f5 = 0 or \u03f5 = 1, respectively.", [["Let E B", "GENE_OR_GENE_PRODUCT", 150, 157], ["E B", "GENE_OR_GENE_PRODUCT", 193, 196], ["E B", "DNA", 154, 157], ["E B", "DNA", 193, 196], ["GAS", "DNA", 430, 433], ["the boundary equilibrium", "PROBLEM", 50, 74], ["Boundary equilibrium bifurcation analysis", "TEST", 109, 150], ["Boundary equilibrium bifurcation analysis", "TEST", 231, 272], ["boundary equilibria", "PROBLEM", 299, 318], ["Boundary equilibrium bifurcation analysis", "TEST", 357, 398], ["Appendix", "ANATOMY", 100, 108], ["equilibrium bifurcation", "OBSERVATION", 118, 141], ["stable", "OBSERVATION_MODIFIER", 459, 465], ["equilibrium bifurcation", "OBSERVATION", 475, 498]]], ["Here I c satisfies G 1 (I c ) = 0 or G 2 (I c ) = 0, so we have I c = I 1 1 or I 1 2 for G 1 (I c ) = 0, and I c = I 2 1 or I 2 2 for G 2 (I c ) = 0.", [["I c", "PROTEIN", 5, 8], ["G", "TEST", 89, 90], ["G", "TEST", 134, 135], ["I c", "TEST", 139, 142]]], ["Then we get four possible boundary equilibria.Boundary equilibrium bifurcation analysisLet T be a tangent point, according to the definition we can get the following equations:Boundary equilibrium bifurcation analysisIt follows that the possible tangent points areBoundary equilibrium bifurcation analysiswhich are the solutions of Eq.", [["Let T", "GENE_OR_GENE_PRODUCT", 87, 92], ["boundary equilibria", "PROBLEM", 26, 45], ["Boundary equilibrium bifurcation analysis", "TEST", 46, 87], ["Boundary equilibrium bifurcation analysis", "TEST", 176, 217], ["equilibria", "OBSERVATION", 35, 45], ["bifurcation", "OBSERVATION_MODIFIER", 67, 78], ["equilibrium bifurcation", "OBSERVATION", 185, 208], ["Boundary", "OBSERVATION_MODIFIER", 264, 272], ["equilibrium bifurcation", "OBSERVATION", 273, 296]]], ["With the variation of the threshold value I c , the boundary equilibrium bifurcation occurs when the regular equilibrium collides with the tangent point and the boundary equilibrium.", [["I c", "PROTEIN", 42, 45], ["variation", "OBSERVATION_MODIFIER", 9, 18], ["equilibrium bifurcation", "OBSERVATION", 61, 84], ["boundary equilibrium", "OBSERVATION", 161, 181]]], ["Fig. 7 illustrates a series of the boundary equilibrium bifurcations for case (d), in which each subsystem has two positive equilibria: a stable node and a saddle point.", [["node", "ANATOMY", 145, 149], ["node", "MULTI-TISSUE_STRUCTURE", 145, 149], ["positive equilibria", "OBSERVATION", 115, 134], ["stable", "OBSERVATION_MODIFIER", 138, 144], ["node", "OBSERVATION", 145, 149], ["saddle", "ANATOMY_MODIFIER", 156, 162]]], ["The real and stable node E 1 1 coexists with the visible tangent point T 2 for I c > I 1 1 (shown in Fig. 7(A) ).", [["node", "ANATOMY", 20, 24], ["E 1 1", "DNA", 25, 30], ["stable", "OBSERVATION_MODIFIER", 13, 19], ["node", "OBSERVATION", 20, 24]]], ["As I c decreases from I c > I 1 1 to I 1 1 , E 1 1 collides with T 2 (shown in Fig. 7(B) ).", [["T 2", "GENE_OR_GENE_PRODUCT", 65, 68], ["I c", "PROTEIN", 3, 6]]], ["As threshold I c continues to decrease to I 2 1 < I c < I 1 1 , the stable pseudo-equilibrium E p appears and T 2 becomes an invisible tangent point (shown in Fig. 7(C) ).", [["T 2", "GENE_OR_GENE_PRODUCT", 110, 113], ["I c", "PROTEIN", 13, 16], ["stable", "OBSERVATION_MODIFIER", 68, 74], ["pseudo", "OBSERVATION", 75, 81]]], ["This bifurcation shows how a stable pseudo-equilibrium appears.", [["stable", "OBSERVATION_MODIFIER", 29, 35], ["pseudo", "OBSERVATION", 36, 42]]], ["Moreover, another boundary bifurcation occurs when I c passes through the critical value I 2 1 .", [["I c", "PROTEIN", 51, 54], ["bifurcation", "OBSERVATION_MODIFIER", 27, 38]]], ["The tangent point T 1 , the real node E 2 1 and the pseudo-equilibrium collide when I c = I 2 1 (shown in Fig. 7(D) ), then the pseudo-equilibrium E p disappears, and stable node E 2 1 becomes the locally attractor (shown in Fig. 7(E) ).", [["E 2 1", "DNA", 38, 43], ["The tangent point T", "TEST", 0, 19], ["the real node E", "TEST", 24, 39], ["tangent", "OBSERVATION_MODIFIER", 4, 11], ["node", "OBSERVATION", 33, 37], ["stable", "OBSERVATION_MODIFIER", 167, 173], ["node", "OBSERVATION", 174, 178]]], ["When I c continuously decreases to I 2 2 , the third boundary bifurcation occurs, the visible tangent point T 1 collides with the saddle point E 2 2 (shown in Fig. 7(F) ).", [["I c", "PROTEIN", 5, 8], ["bifurcation", "OBSERVATION_MODIFIER", 62, 73], ["saddle", "ANATOMY_MODIFIER", 130, 136]]], ["When I c further passes through I 2 2 to I 1 2 < I c < I 2 2 , the locally stable pseudo-equilibrium E p appears (Fig. 7(G) ), and the tri-stable phenomenon (E p , the disease-free equilibrium E 0 and real node E 2 1 ) emerges.", [["I c", "PROTEIN", 5, 8], ["the tri-stable phenomenon", "PROBLEM", 131, 156], ["the disease", "PROBLEM", 164, 175], ["stable", "OBSERVATION_MODIFIER", 75, 81], ["pseudo", "OBSERVATION", 82, 88]]], ["The fourth boundary equilibrium occurs when I c passes through I 1 2 , the tangent point T 2 collides with saddle point E 2 2 and the pseudo-equilibrium E p for I c = I 2 2 (Fig. 7(H) ).", [["I c", "PROTEIN", 44, 47], ["I 1 2", "PROTEIN", 63, 68], ["I c", "PROTEIN", 161, 164], ["I 2 2", "PROTEIN", 167, 172], ["saddle point E", "TEST", 107, 121], ["the pseudo", "TEST", 130, 140]]], ["When the threshold continues to decrease to be lower than I 1 2 , the pseudo-equilibrium E p disappears and tangent point T 2 becomes invisible ( Fig. 7(I)) , and consequently the disease-free equilibrium E 0 and the node point E 2 1 are bi-stable in this situation.", [["the disease", "PROBLEM", 176, 187], ["disease", "OBSERVATION", 180, 187], ["node", "OBSERVATION", 217, 221]]], ["Moreover, it is notable that the first two boundary equilibrium bifurcations are boundary node bifurcations, while the last two are boundary saddle bifurcations.Discussion and conclusionIt has been observed that interventions, such as quarantine, isolation, treatment and vaccination, play a significant role in controlling the emerging and reemerging infectious diseases.", [["boundary node", "ANATOMY", 81, 94], ["infectious diseases", "DISEASE", 352, 371], ["node bifurcations", "MULTI-TISSUE_STRUCTURE", 90, 107], ["interventions", "TREATMENT", 212, 225], ["quarantine", "TREATMENT", 235, 245], ["isolation", "TREATMENT", 247, 256], ["treatment", "TREATMENT", 258, 267], ["vaccination", "TREATMENT", 272, 283], ["notable", "OBSERVATION_MODIFIER", 16, 23], ["boundary", "OBSERVATION_MODIFIER", 43, 51], ["equilibrium", "OBSERVATION_MODIFIER", 52, 63], ["bifurcations", "OBSERVATION_MODIFIER", 64, 76], ["boundary", "OBSERVATION_MODIFIER", 81, 89], ["node", "OBSERVATION", 90, 94], ["bifurcations", "OBSERVATION_MODIFIER", 95, 107], ["boundary", "OBSERVATION_MODIFIER", 132, 140], ["saddle bifurcations", "OBSERVATION", 141, 160]]], ["However, not all interventions are implemented from the beginning of the outbreak or during the entire outbreak.", [["all interventions", "TREATMENT", 13, 30]]], ["In this study, we extend the existing SIV-type model by including the extra control strategies once the number of infected individuals exceeds a certain level.", [["SIV", "ORGANISM", 38, 41], ["this study", "TEST", 3, 13], ["the existing SIV-type model", "TREATMENT", 25, 52], ["the extra control strategies", "TREATMENT", 66, 94], ["infected individuals", "PROBLEM", 114, 134], ["infected", "OBSERVATION", 114, 122]]], ["In particular, based on the SIV-type model we consider susceptible and imperfect vaccinated individuals to enhance protection and control measures conditional upon relatively high prevalence.Discussion and conclusionThe global dynamics of the Filippov system is fully investigated for different cases.", [["SIV", "ORGANISM", 28, 31], ["susceptible and imperfect vaccinated individuals", "PROBLEM", 55, 103], ["global", "OBSERVATION_MODIFIER", 220, 226]]], ["It is interesting to note that two subsystems can undergo backward bifurcations, and consequently one endemic state and disease-free equilibrium for free or control system may be bistable when its specific reproduction number is less than one.", [["disease", "PROBLEM", 120, 127]]], ["The switching system may stabilize at regular equilibrium E 1 1 or E 2 1 , or the pseudo-equilibrium E p , which depends on the threshold value I c .", [["I c", "PROTEIN", 144, 147]]], ["The global stability of the pseudo-equilibrium indicates that when we choose the threshold value properly, the number of infected individuals can stabilize at a previously given value.", [["infected individuals", "PROBLEM", 121, 141], ["global", "OBSERVATION_MODIFIER", 4, 10], ["stability", "OBSERVATION_MODIFIER", 11, 20], ["pseudo-equilibrium", "OBSERVATION", 28, 46], ["infected", "OBSERVATION", 121, 129]]], ["For cases (a), (b) and (c), we observed some new phenomena.", [["some new phenomena", "PROBLEM", 40, 58], ["new", "OBSERVATION_MODIFIER", 45, 48], ["phenomena", "OBSERVATION", 49, 58]]], ["The disease-free equilibrium E 0 and E 1 1 , or E 0 and E 2 1 , or E 0 and E p may be bistable (as shown in Fig. 5(B,C,D) ).", [["E 1 1", "GENE_OR_GENE_PRODUCT", 37, 42], ["E 2 1", "GENE_OR_GENE_PRODUCT", 56, 61], ["E 0", "GENE_OR_GENE_PRODUCT", 67, 70], ["E p", "GENE_OR_GENE_PRODUCT", 75, 78], ["B,C,D", "SIMPLE_CHEMICAL", 115, 120], ["E 1 1", "DNA", 37, 42], ["E 0", "DNA", 48, 51], ["E 2 1", "DNA", 56, 61], ["E 0", "DNA", 67, 70], ["E p", "DNA", 75, 78], ["The disease", "TEST", 0, 11], ["free equilibrium E", "TEST", 12, 30], ["disease", "OBSERVATION", 4, 11], ["free", "OBSERVATION_MODIFIER", 12, 16]]], ["Especially, the disease-free equilibrium E 0 , E p and E 2 1 may be tri-stable, and the disease-free equilibrium E 0 may be GAS.", [["E 2 1", "GENE_OR_GENE_PRODUCT", 55, 60], ["GAS", "DNA", 124, 127], ["the disease", "PROBLEM", 12, 23], ["free equilibrium E", "TEST", 24, 42], ["the disease", "PROBLEM", 84, 95], ["disease", "OBSERVATION", 16, 23], ["disease", "OBSERVATION", 88, 95], ["GAS", "OBSERVATION", 124, 127]]], ["Moreover, the threshold policy makes the whole system show more complex dynamical behaviors.", [["complex", "OBSERVATION_MODIFIER", 64, 71], ["dynamical behaviors", "OBSERVATION", 72, 91]]], ["The four boundary bifurcations are illustrated with the variation of threshold value I c .", [["I c", "PROTEIN", 85, 88], ["four", "OBSERVATION_MODIFIER", 4, 8], ["boundary", "OBSERVATION_MODIFIER", 9, 17], ["bifurcations", "OBSERVATION_MODIFIER", 18, 30]]], ["All the evolutionary processes are displayed when I c passes across the four particular values I 1 1 , I 2 1 , I 2 2 and I 1 2 .", [["I c", "PROTEIN", 50, 53]]], ["It is worth noticing that the idea of proving global stability of the Filippov system (3) is based on the local stability of equilibria, reachability of orbits (i.e., regular/sliding equilibria) and nonexistence of limit cycles.", [["reachability of orbits", "PROBLEM", 137, 159], ["regular/sliding equilibria)", "TREATMENT", 167, 194], ["global", "OBSERVATION_MODIFIER", 46, 52], ["stability", "OBSERVATION", 53, 62], ["equilibria", "OBSERVATION", 125, 135], ["orbits", "ANATOMY", 153, 159], ["limit cycles", "OBSERVATION_MODIFIER", 215, 227]]], ["For this purpose, we carefully analyze the types of various equilibria and trend of orbits in phase plane under different cases.", [["various equilibria", "PROBLEM", 52, 70], ["orbits", "ANATOMY", 84, 90]]], ["Consequently, the proof of the global stability is a bit descriptive instead of using mathematical notations, which has also been intensely applied to investigating the global dynamics for other Filippov systems [27, 37, 38, 42] .", [["global", "OBSERVATION_MODIFIER", 31, 37], ["stability", "OBSERVATION", 38, 47]]], ["Note that the proof of global stability can also be given by using mathematical notations like attractor, limit set and etc. We choose this way of description seems more readable and simple.", [["global", "OBSERVATION_MODIFIER", 23, 29], ["stability", "OBSERVATION", 30, 39]]], ["The proposed switching system exhibits rich dynamics, implying that three equilibria including pseudo-equilibrium may be tri-stable or bi-stable.", [["bi-stable", "PROBLEM", 135, 144], ["rich dynamics", "OBSERVATION", 39, 52]]], ["In particular, the pseudo-equilibrium or disease-free equilibrium may be GAS for particular conditions and suitable threshold level I c , which means that the disease can be eradicated or stabilize to a previously given level.", [["I c", "PROTEIN", 132, 135], ["the pseudo-equilibrium", "PROBLEM", 15, 37], ["disease", "PROBLEM", 41, 48], ["particular conditions", "PROBLEM", 81, 102], ["the disease", "PROBLEM", 155, 166], ["disease", "OBSERVATION", 41, 48], ["disease", "OBSERVATION", 159, 166]]], ["Hence the modeling approach and main results give us a new understanding to realize the disease eradication and epidemic control.", [["the disease eradication", "PROBLEM", 84, 107], ["epidemic control", "TREATMENT", 112, 128]]], ["The tangent point T , which refers to the point at which F i (T ) \u0338 = 0(i = 1, 2), and the trajectory of S i (i = 1, 2) tangents to the switching line \u03a3.", [["the switching line", "TREATMENT", 132, 150], ["tangent", "OBSERVATION_MODIFIER", 4, 11]]], ["That is to say, the tangent points satisfy \u27e8F 1 (T ), H U (T )\u27e9 = 0 or \u27e8F 2 (T ), H U (T )\u27e9 = 0.Discussion and conclusionDefinition 5 (Visible (Invisible) Tangent Point).", [["the tangent points satisfy", "TEST", 16, 42], ["U", "TEST", 56, 57], ["\u27e9", "TEST", 90, 91]]], ["If the orbit ofU = F 1 (U) starting at T belongs to S 1 for all sufficiently small |t| \u0338 = 0, we say that this tangent point is visible.", [["orbit", "ANATOMY", 7, 12]]], ["While if this orbit belongs to S 2 , this tangent point is invisible.", [["S 2", "GENE_OR_GENE_PRODUCT", 31, 34], ["orbit", "ANATOMY", 14, 19]]], ["Our purpose is to show the order of the four biological roots are determined when all the four or two or three of them are feasible.Discussion and conclusionFirstly, we want to show G 2 (I 1 1 ) > 0 when R 1 0 > 1.Discussion and conclusionTo simplify the expression, let M = (\u00b5 + \u03b8 + \u03c3 \u03c6) + \u03c3 (\u00b5 + \u03b3 ), N = (\u00b5 + \u03b3 )(\u00b5 + \u03b8 + \u03c6), K = \u00b5 + \u03b8 + \u03c3 \u03c6, then we need to show G 2 (I 1Discussion and conclusionThe both two sides of the inequation are multiplied byDiscussion and conclusiondivided by \u03c3 2 N 2 at each side of the inequation, one obtainsDiscussion and conclusionThe left side is negative, while the right side is positive, the inequality is evidently valid so that (A.1) holds.", [["roots", "ANATOMY", 56, 61], ["left side", "ANATOMY", 569, 578], ["roots", "ORGAN", 56, 61], ["\u03b8", "PROTEIN", 320, 321], ["\u03c6", "PROTEIN", 324, 325], ["\u03b8", "PROTEIN", 336, 337], ["\u03c3 \u03c6", "CELL_LINE", 340, 343], ["the expression", "TEST", 251, 265], ["\u00b5", "TEST", 308, 309], ["\u00b5", "TEST", 316, 317], ["\u03b8", "TEST", 320, 321], ["K", "TEST", 328, 329], ["\u00b5", "TEST", 332, 333], ["\u03b8", "TEST", 336, 337], ["\u03c6", "TEST", 342, 343], ["G", "TEST", 366, 367], ["left", "ANATOMY_MODIFIER", 569, 573], ["negative", "OBSERVATION", 582, 590], ["right", "ANATOMY_MODIFIER", 602, 607], ["positive", "OBSERVATION", 616, 624]]], ["R 1Discussion and conclusionSecondly, when R 2 0 < 1, C 2 > 0, so I 2 2 > 0.", [["conclusionSecondly", "TEST", 18, 36], ["C", "TEST", 54, 55]]], ["We want to prove the inequality G 1 (I 2 1 ) < 0 holds when R 1 0 > 1 > R 2 0 .", [["the inequality G", "TEST", 17, 33]]], ["Combine these two inequalities with G 1 (I 1 1 ) = 0, we have the relation I 1 1 > I 2 1 > I 2 2 (see Fig. A.1(B) ).", [["G", "TEST", 36, 37]]]]}